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Rheumatoid arthritis (RA) and periodontitis (PID) are two chronic inflammatory 
diseases associated with the modification of self-proteins by citrullinating peptidyl 
arginine deiminase (PAD) enzymes, leading to a loss of tolerance by the immune 
system. The main goal of this study was to explore the action of PAD enzyme-
mediated citrullination on T cell membrane proteins and gene expression in relation to 
the T cell phenotype in PID. Effects on cells of the adaptive immune system have been 
less well studied in PID and the data obtained here shows that citrullination of 
peripheral blood mononuclear cells (PBMC) by PAD enzymes impairs T cell activation. 
Microarray studies showed that PAD enzyme treatment led to the dysregulation of 
genes involved in glucose and amino acid metabolism in PBMC. Real time quantitative 
polymerase chain reaction (RT-QPCR) in CD4 and CD8 T cells from PID patients 
showed a trend towards down-regulation of hexokinase 3 and up-regulation of 
argininosuccinate synthase1. Also, proteomic and genomic studies in PBMC implicated 
the involvement of the complement system in the impairment of the T cell response by 
PAD enzymes. Taken together, the results obtained here support a potential link 
between T cell surface citrullination and metabolic asynchrony in T cells and may offer 
an explanation for the lack of immune suppression in PID. 
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1.1. Inflammation and immunity 
Inflammation is the biological response to internal or external harmful stimuli. As 
described by the four Latin words calor, dolor, rubor and tumor; inflammation is 
characterized by heat, pain, redness and swelling. These characteristics result from 
cytokines and other inflammatory mediators acting on specific receptors on circulating 
cells and endothelial cells in the local blood vessels in response to internal or external 
stimuli [1]. The immune system is responsible for this inflammatory response and can 
be separated into innate and adaptive immunity. The fine crosstalk between these two 
systems is crucial for the development of an effective immune response and cytokines 
have a key role in this modulation [1-3].  
1.1.1. Innate immunity 
When pathogens invade the human body, cells of the immune system initiate an innate 
immune response. The innate immune system comprises natural killer (NK) cells, 
macrophages, neutrophils, dendritic cells (DC), mast cells, eosinophils, basophils and 
complement factors, which account for the first, rapid and non-specific response to 
pathogens and damaged, injured or stressed cells [3]. The first cells to respond to an 
inflammatory stimulus are phagocytic macrophages and neutrophils. The activation of 
macrophages by bacteria and their component molecules in the site of inflammation 
triggers the release of cytokines and chemokines. Cytokines, such as tumour necrosis 
factor (TNF)-α, interferon (IFN)-Ȗ, interleukins (IL)-1ȕ, IL-4, IL-6, IL-10, IL-12, IL-18 and 
chemokine (C-C motif) ligand 4 (CCL4) are small soluble mediators, that mediate 
signalling processes and promote the extravasation of other immune cells to the 
inflammatory site [4]. Chemokines have a major role in the attraction of other cells, 
such as monocytes, to the site of inflammation. This inflammatory process can also be 
initiated by activation of the complement system by bacterial cell surface antigens 
(described in section 1.1.3). Bacterial elimination via the complement system is based 
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on the coating of bacterial surfaces with soluble complement proteins that are then 
recognised and internalised by phagocytic cells [1].  
1.1.2. Adaptive immunity 
When the innate immune system is not sufficient for the elimination of pathogens, an 
adaptive immune response is mounted. Adaptive immunity is slower, but targeted to a 
specific antigen and results in the generation of immunological memory. The adaptive 
immune system involves T and B lymphocytes, but the initiation of this response 
depends on cells of the innate immune system [1, 3]. For example, antigen presenting 
cells (APC) in the infected tissues, internalise pathogens by macropinocytosis and 
receptor-mediated phagocytosis and present the pathogen antigens to naïve T cells in 
the lymph nodes [1, 3]. T cells are responsible for the cell-mediated immune 
responses. T cells that hold a T cell receptor (TCR) on the surface for the specific 
antigen presented by APC become activated and differentiate into effector T cells that 
will then induce B cells to expand and differentiate into antibody producing cells. B cells 
are involved in the humoral immune response but can also act as APC and activate 
specific T cells. [3, 5]. The B cell antibody response will target specific antigens and 
lead to the elimination of the pathogen [3, 5]. Once the immune response is resolved, 
most of the activated T and B cells die [1]. However, some of these cells differentiate 
into memory cells and after a second exposure to the antigen they are able to trigger a 
faster and stronger secondary immune response, known as immunological memory [3]. 
1.1.3. The complement system 
The complement system consists of plasma proteins able to interact within themselves 
promoting the opsonisation of pathogens and the activation of inflammatory responses. 
Depending on the molecules involved in the activation of the complement system, this 
can be divided into three major pathways: classical, lectin and alternative (Figure 1.1).  
The classical pathway is initiated via the binding of the C1 complex (C1q in 
complex with C1r and C1s serine proteases) to the Fc region of complement-fixing 
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antibodies attached to the surface of pathogens. The activation of C1r and C1s leads 
to the cleavage of C4 and C2 into C4b and C4a and C2b and C2a fragments, 
respectively. The fragments C4b and C2a associate and form the C4bC2a complex 
(C3 convertase) on the pathogen surface that is able to convert C3 into C3a and C3b, 
converging to the common point between all the complement activation cascades.  
 The lectin pathway depends on the recognition of pathogen-associated 
molecular patterns (PAMP) on the surface of pathogens by pattern-recognition 
receptors (PRR), such as mannose-binding lectin (MBL). The binding of MBL 
complexed with MBL-associated serine proteases (MASP)-1, MASP-2 and MASP-3 to 
the pathogen surface triggers the activation of MASP, the cleavage of C4 and C2 and 
consequent formation of the C3 convertase, as in the classical pathway. 
 The alternative pathway is activated by the hydrolysis of C3 into C3b and C3a 
by components present on the pathogens’ cell surface. The fragment C3b promotes 
the cleavage of Factor B into Bb and Ba by Factor D, allowing the formation of the 
C3bBb complex (C3 convertase). This C3 convertase is analogue to the one produced 
via the classical and lectin pathways and is able to convert C3 into C3b and C3a. 
 The conversion of C3 into C3b, common to the three pathways, exposes an 
internal thioester bond that identifies pathogens as non-self to the host, triggering 
further complement activation via the binding of C3b to the C3 convertase, forming the 
C5 convertase. The conversion of C5 into C5a and C5b, via C5 convertase, leads to 
the formation of the membrane-attack complex (MAC) through the binding of C5b to 
terminal complement components (C6-C9).  
 The success of the complement system in the elimination of pathogens is 
based on different mechanisms: production of fragments, such as C3b and C4b, that 
opsonise the pathogen targeting it to phagocytosis; production of fragments, such as 
C5a and C3a, that act as chemoattractants and activators to phagocytes; formation of 
the terminal complement component MAC that creates pores in the bacterial 
membrane, leading to cell lysis [1, 6].  
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In addition to its roles in the innate immune system, the complement system 
has also been related with the modulation of adaptive immunity, in particular with T cell 
responses. Complement factors produced upon T cell contact with APC are involved in 
the co-stimulation of the TCR and are also associated in the maintenance of naïve T 
cells’ viability [7]. To date, the mechanism involved in the modulation of T cell 
responses by the complement system is not fully understood. However, it was 
suggested that C3a and C5a receptors are upregulated in the surface of T cells and 
APC during contact at the immunological synapse. The signalling induced by the 
binding of C3a and C5a to their respective receptors activates phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI-3K) and Akt intracellular signalling pathways, which leads to 
enhanced T cell proliferation and reduced T cell apoptosis [7-9]. 
 
 
Figure 1.1 Schematic representation of the activation of the complement system through the three 
different pathways: classical, lectin and alternative. Adapted from periobasics.com. 
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1.1.4. Cell surface proteins and inflammatory response 
The inflammatory response combines the action of immune cells, blood vessels and 
molecular mediators in a regulated orchestration of events. These events involve: 
leakage of water, salt and proteins from the vascular compartment; activation of 
endothelial cells; adhesive interactions between leukocytes and the vascular 
endothelium; recruitment of leukocytes; activation of tissue macrophages; activation 
and aggregation of platelets; activation of complement, clotting and fibrinolytic systems; 
and release of proteases and production of free radical species via nicotinamide 
adenine dinucleotide phosphatase (NADPH) oxidases and nitric oxide synthases from 
phagocytic cells, like neutrophils, monocytes/macrophages and resident tissue 
macrophages with concomitant activation of nuclear factor-κB (NF-κB) and pro-
inflammatory gene expression [10, 11]. Proteins present at the surface of cells are key 
players on the complex cascade of events involved in the inflammatory response.  
Cell surface proteins are components of the cellular membrane consisting of 
hydrophobic and hydrophilic regions. Hydrophobic residues are often buried within the 
lipid bilayer while hydrophilic residues are located at the membrane surface (intra- or 
extracellular) [12]. Cell surface proteins can be classified according to their topology as 
integral membrane proteins, peripheral membrane proteins or polypeptide toxins 
(Figure 1.2). Integral membrane proteins are permanent constituents of the cellular 
membrane and can be classified into polytopic (if they span across the membrane) or 
monotopic (attached to only one side of the membrane) proteins. Peripheral membrane 
proteins can be attached to the lipid components of the membrane or to integral 
proteins. Polypeptide toxins can associate with the lipid bilayer and be membrane-
associated proteins [13].  
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Figure 1.2 Schematic representation of the different categories of cell surface proteins according 
with their topology and interactions. a) Bitopic transmembrane α-helical protein; b) Polytopic 
transmembrane α-helical protein; c) Polytopic transmembrane ȕ-sheet protein; d) Parallel monotopic α-
helical protein; e) Interaction of a cell surface protein via a hydrophobic loop; f) Interaction of a cell surface 
protein via a membrane lipid; g) Interaction of a cell surface protein via electrostatic or ionic interactions 
with membrane lipids. Yellow rectangle represents the cell membrane. EC – Extracellular side. IC – 
Intracellular side. Adapted from https://en.wikipedia.org/wiki. 
 
Cell surface proteins can also be classified according to their functions as membrane 
receptor proteins, transport proteins, membrane enzymes and cell adhesion molecules 
(CAM) (Figure 1.3). Membrane receptor proteins are mainly involved in cell signalling 
[12]. Cell surface receptors have been categorised to several classes, where G protein-
coupled receptors (GPCR), receptors protein-tyrosine kinases (RTK) and cytokine 
receptors are the main classes (Table 1.1). GPCR, the largest family of cell surface 
receptors, consists of seven membrane spanning α-helices and includes ȕ-adrenergic 
receptors, prostaglandin E2 receptors and rhodopsin. The interaction of these 
receptors (extracellular domain) with ligands induces a conformational change that 
enables the receptor (intracellular domain) to bind and activate a G protein (guanine 
nucleotide-binding protein) associated with the inner face of the plasma membrane. 
The activated G protein further dissociates from the receptor and transmits the 
intracellular signal to enzymes, ion channels or second messengers, such as cyclic 
adenosine monophosphate (cAMP), diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3) [12, 14]. RTK are directly linked to intracellular enzymes and are 
responsible for the phosphorylation of tyrosine residues on their target proteins. 
Structurally these receptors consist of an N-terminal extracellular ligand-binding 
domain, a single transmembrane α-helix and a cytosolic C-terminal domain containing 
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the protein-tyrosine kinase activity. Intracellular signalling by protein-tyrosine kinases is 
accomplished by the binding of ligands to the N-terminal extracellular domain. This 
binding induces receptor dimerisation, auto-phosphorylation of the receptor itself and 
phosphorylation of intracellular target proteins that propagate the initial signal [12, 15]. 
Cytokine receptors consist of interleukin receptors, chemokine receptors and 
granulocyte macrophage colony stimulating factor (GM-CSF) receptor, amongst others. 
These receptors contain an N-terminal extracellular ligand-binding domain, a single 
transmembrane α-helix and a cytosolic C-terminal domain that is associated with non-
receptor protein-tyrosine kinases (nRTK). Intracellular signalling through cytokine 
receptors is initiated by the binding of ligands to the extracellular domain, leading to 
receptor dimerisation and cross-phosphorylation of the associated nRTK. 
Subsequently, the receptor is phosphorylated by the activated kinases and recruits 
signalling molecules containing Src homology 2 (SH2) domains that propagate the 
signal [12, 16]. Receptors on the surface of cells of the immune system are involved in 
the phagocytosis of recognised pathogens, in the chemotaxis of neutrophils mediated 
by bacterial components and in the induction of effector molecules, triggering the 
adaptive immune system [1].  
 
Table 1.1 Summary of the main classes of cell surface receptors. 
Category Structure Mechanism Examples 
GPCR Seven TM 
domains 
Ligand binding to the extracellular domain; 
Conformational change; 
Intracellular binding and activation of G protein; 
Signal transduction through cAMP, DAG and IP3. 
 
ȕ-adrenergic receptor; 
Prostaglandin E2 receptor; 
Rhodopsin. 
RTK Single TM 
α-helix 
Ligand binding to the extracellular domain; 
Receptor dimerization and auto-phosphorylation; 
Intracellular phosphorylation of target protein. 
 
Epidermal growth factor 
receptor; 
Fibroblast growth factor 
receptor; 
Vascular endothelial 
growth factor receptor. 
 
Cytokine Single TM 
α-helix 
Ligand binding to the extracellular domain; 
Receptor dimerization; 
Cross-phosphorylation by activate kinases; 
Recruitment of intracellular signalling molecules. 
 
GM-CSF receptor; 
Interleukin receptors. 
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CAM are involved in cell growth, differentiation, embryogenesis, immune cell 
transmigration and response and cancer metastasis. CAM consist of an extracellular 
domain that interacts with other CAM or the extracellular matrix, a transmembrane 
domain and an intracellular domain. CAM can be grouped in four classes: Ig 
superfamily, integrins, cadherins and selectins [17-20]. The Ig superfamily consists in 
calcium-independent transmembrane glycoproteins, like intracellular adhesion 
molecule (ICAM), vascular-cell adhesion molecule (VCAM-1), platelet-endothelial-cell 
adhesion molecule (PECAM-1) and neural-cell adhesion molecule (NCAM). Integrins 
are non-covalently linked heterodimers of α and ȕ dimer CAM that need activation to 
bind to their ligand [17, 19-21]. Cadherins are calcium-dependent CAM. The classical 
cadherin subfamily include cadherins such as neural (N)-cadherin, placental (P)-
cadherin and epithelial (E)-cadherin [17, 19, 22, 23]. Selectins are carbohydrate-
binding proteins that depend on divalent cations. Selectins can be grouped in 
endothelial (E)-selectin, leukocyte (L)-selectin and platelet (P)-selectin [17, 19-21]. 
CAM are also important players in the progress of an immune response. The 
recruitment of lymphocytes to inflammation depends on their passage from the blood 
stream to the specific tissue and this process is determined by the expression of CAM. 
The up-regulation of endothelial CAM promotes leukocyte adhesion to and rolling on 
the endothelial surface and the production of VCAM-1, which can bind to adhesion 
molecules on the leukocytes, consolidating the interaction between the vascular 
endothelium and leukocytes and allowing the leukocytes to infiltrate the tissue. 
Additionally to a general function of CAM in the recruitment of leukocytes to the 
inflammation site, CAM are also involved in the T cell response. Naïve T cells in the 
periphery are recruited into the lymph nodes through the interaction between ICAM-1 
and ICAM-2 and lymphocyte function-associated antigen 1 (LFA 1) expressed on the 
surface of T cells. Furthermore, the homing of effector T cells to the inflamed site is 
also mediated by specific CAM, like integrin α4:ȕ1, at the surface of T cells, that binds 
VCAM-1, promoting the extravasation of effector T cells [1].  
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Transport proteins include channel and carrier proteins. While channel proteins 
form pores in the membrane that allow free diffusion of molecules of an appropriate 
size, carrier proteins selectively bind and transport specific small molecules across the 
membrane in a conformational dependent manner [12]. Membrane enzymes are those 
involved in the metabolism of different membrane components. Examples of these cell 
surface proteins include phospholipases, cholesterol oxidases, glycosyltransferase, 
transglycosidases, signal peptidase, palmitoyl protein thioesterases and lipases [12]. 
 
 
Figure 1.3 Schematic representation of the different categories of cell surface proteins according 
with their functions. a) Transport protein; b) Membrane receptor protein; c) Membrane enzyme; d) Cell 
adhesion molecule. Yellow rectangle represents the cell membrane. EC – Extracellular side. IC – 
Intracellular side. Adapted from [24]. 
 
 
1.2. T cell biology 
1.2.1. T cell maturation  
T cells derive from hematopoietic stem cell precursors that migrate from the bone 
marrow to the thymus. The thymus is localised in the upper anterior thorax and 
comprises several lobules that can be divided into peripheral cortex and central 
medulla. In the thymus, T cell precursors undertake different maturation steps that 
drive commitment to the T cell lineage and differentiation into the alternative T cell 
lineages.  
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The first development step involves the activation of the Notch signalling 
pathway and is the basis of the differentiation of hematopoietic precursors to the T cell 
lineage rather than the B cell lineage.  
Developing thymocytes then undertake several maturation processes that 
involve the rearrangement of the TCR genes and the expression of different molecules 
at the surface of the cell, like cluster of differentiation (CD) 3 complex and co-receptor 
proteins CD4 and CD8. The changes at the thymocytes’ surface are characteristic for 
each stage of maturation. Initially, thymocytes do not express any of the surface 
markers of mature T cells and the TCR genes are not rearranged. The first stage of 
differentiation involves cell proliferation and the expression of c-Kit, a stem cell growth 
factor receptor, CD44, an adhesion molecule, and CD25, α-chain of the IL-2 receptor 
(IL-2R). After this, TCR genes start rearranging, originating T cells bearing αȕ or Ȗį 
TCR. At this point, the thymocytes do not express CD4 or CD8 T cell surface markers 
and are denominated double negative (DN) [25-27]. Ȗį thymocytes represent 10% of T 
lymphocytes of healthy adults and can be divided into three main populations based on 
the į chain expression: Vį1, Vį2 and Vį3. The initiation of the immune response in Ȗį 
T cells relies on cell-cell contact with APC. Ȗį T cells can recognise a variety of 
different ligands, including non-peptidic antigens, MHC and non-MHC cell surface 
molecules and soluble proteins. The thymocytes expressing αȕ TCR differentiate into 
the CD4CD8 double positive (DP) stage, where both CD4 and CD8 co-receptors are 
expressed at the cell surface. At this phase, negative selection processes eliminate DP 
thymocytes that have a TCR incapable of binding MHC-I or MHC-II. Then, the DP 
thymocytes maturate into CD4 or CD8 single positive (SP) T cells. Thymocytes that 
recognise self-peptides complexed with MHC class I (MHC-I) become CD8 or cytotoxic 
T (Tc) cells, whereas thymocytes that recognise antigens presented via MHC-II 
become CD4 or T helper (Th) cells [2, 28-30]. Besides CD4 and CD8 T cells, other 
non-conventional lineages are also produced during the maturation process in the 
thymus. These include: natural regulatory T (Treg) cells, expressing FOXP3CD4CD25; 
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natural killer T (NKT) cells, reactive to CD1d; MHC1b CD8 T cells; and major 
histocompatibility molecule-related 1 (MR1)-restricted mucosa associated invariant T 
cells [31, 32]. 
Processes of negative and positive selection are again initiated. Mature T cells 
with TCR that strongly interact with self-MHC molecules are negatively selected and 
eliminated to prevent autoimmune reactions. Mature T cells that react too little to self-
peptides are also eliminated. The T cells that bear αȕ TCR capable of recognising self-
peptides on thymic epithelial cells with intermediate level of TCR signalling are 
positively selected and leave the thymus to the periphery as mature naïve T cells [29]. 
1.2.2. T cell activation and T cell receptor signalling  
Naïve T cells circulate in the periphery until they become activated through the 
presentation of antigens by APC. The contact between T cells and APC is highly 
specific. The TCR at the surface of T cells recognises a specific antigen bound to MHC 
molecules at the surface of the APC [3, 33]. The interface between APC and T cell, 
where the MHC molecules in APC interact with the TCR in T cells, is denoted as the 
immunological synapse. Additional to the binding between TCR and MHC, T cell 
activation depends on co-stimulatory molecules and chemical mediators expressed by 
APC. Co-stimulatory molecules, such as CD80 (or B7-1) and CD86 (or B7-2), engage 
with counter-receptors on the surface of T cells and transmit important signals for T cell 
proliferation and survival. Chemical mediators, like interleukins, act on T cells 
promoting their differentiation into effector cells [33].  
The TCR, as outlined in the schematic in figure 1.4, is a transmembrane protein 
and consists of a peptide-MHC recognition unit (α and ȕ chains) and a signal 
transduction unit (Ȗ, į, İ and ζ chains, or CD3 complex) [34]. When the antigen 
presented by MHC binds to the TCR at the immunological synapse, intracellular protein 
tyrosine kinases (PTK) of the Src, Syk and Tec families are recruited and activated. 
Lymphocyte-specific protein tyrosine kinase (LCK), a Src family PTK member, 
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phosphorylates ITAM on the Ȗ-, į-, İ- and ζ-CD3 chains, leading to the recruitment and 
activation of the Syk family PTK zeta-chain-associated protein kinase 70 (ZAP70). 
Phosphorylated and activated ZAP70, in turn, phosphorylate the adaptors linker of 
activated T cells (LAT) and SH2 domain containing lymphocyte protein of 76 kDa 
molecules (SLP-76). LAT and SLP-76 form platforms that allow signal transduction 
molecules to arrange in the correct intracellular location and execute their functions. 
LAT recruits signalling molecules that include phospholipase CȖ1 (PLCȖ1), growth 
factor receptor-bound protein 2 (GRB2), GRB2-related adaptor protein (GADS), 
adhesion- and degranulation-promoting adaptor protein (ADAP), interleukin-2-inducible 
T cell kinase (ITK), non-catalytic region of tyrosine kinase adaptor protein 1 (NCK1) 
and guanine nucleotide exchange factor (VAV1). This cascade of events leads to the 
TCR signal propagation and activation of intracellular pathways, like the mitogen-
activated protein kinase (MAPK), the nuclear factor-κB (NF-κB) and the Ras signalling 
pathways, which are involved in cytoskeletal reorganisation, calcium signalling and 
mobilisation of transcription factors [34-36]. The mobilisation of NF-κB, activator protein 
1 (AP1) and nuclear factor of activated T cells (NFAT) to the nucleus, consequently 
promotes the transcription of IL-2, IL-4, GM-CSF and TNF-α genes essential for T cell 
growth and differentiation into effector T cells [37, 38]. 
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Figure 1.4 Schematic representation of TCR signalling. ADAP – adhesion- and degranulation-
promoting adaptor protein; Ca2+ - calcium divalent ion; CD3 – cluster of differentiation 3; GADS – grb2-
related adaptor downstream of Shc; GRB2 – growth factor receptor-bound protein 2; ITK – tyrosine-
protein kinase; LAT – linker of activated T cells; LCK – lymphocyte-specific protein tyrosine kinase; MAPK 
– mitogen-activated protein kinase; NCK1 – non-catalytic region of tyrosine kinase adaptor protein 1; NF-
κB – nuclear factor-kappaB; PLCȖ1 – phospholipase C, gamma 1; SLP76 – SH2 domain containing 
lymphocyte protein of 76 kDa molecules; TCR – T cell receptor; VAV1 – guanine nucleotide exchange 
factor; ZAP70 – zeta-chain-associated protein kinase 70. 
 
1.2.3. Interleukin-2 signalling pathway 
IL-2 is a 15 kDa quaternary α-helical glycoprotein produced mainly by activated CD4 T 
cells, but also by CD8 and NKT cells and NK cells [39]. Besides being recognised as a 
T cell growth factor, IL-2 is also involved in activation-induced cell death (AICD), 
development of Treg and CD8 T cells, secondary expansion of memory CD8 T cells 
and modulation of CD4 T cell differentiation. Depending on the cytokine environment 
following antigen presentation, naïve T cells can differentiate into different T cell 
effector subsets (as detailed in 1.2.4). IL-2 was shown to be involved in the regulation 
of this process by priming cells for differentiation or helping cells to maintain a 
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differentiated state [40]. The production of IL-2 in T cells is potentiated by activation 
through antigen presentation. Secreted IL-2 acts on cells expressing the IL-2R. The IL-
2R consists of three subunits (IL-2Rα or CD25, IL-2Rȕ or CD122 and Ȗc or CD132) 
and three classes of IL-2R exist: low-, intermediate- and high-affinity for IL-2. The 
mechanism of IL-2 interaction with the trimeric high-affinity IL-2R, consisting of 
subunits IL-2Rα, IL-2Rȕ and Ȗc, involves an initial contact between IL-2 and IL-2Rα 
through a large hydrophobic binding surface surrounded by a polar periphery, inducing 
a small conformational change in IL-2 that allows IL-2Rȕ to associate with IL-2 through 
a distinct polar region. The Ȗc unit is then recruited through a weak interaction with IL-2 
and a stronger interaction with IL-2Rȕ, forming the stable quaternary high-affinity IL-2-
IL-2R complex. The dimeric intermediate-affinity IL-2R, consisting of IL-2Rȕ and Ȗc 
subunits, has weak affinity to IL-2 but is able to propagate the signal [41-43]. The 
monomeric IL-2R is formed by the IL-2Rα solely and, although it can bind IL-2 with low 
affinity, it is not competent for signal transduction [43]. The trimeric IL-2R can be found 
in Treg cells or recently antigen-activated T lymphocytes, whereas the dimeric IL-2R is 
almost undetectable on naïve CD4 T cells, but it is expressed at low levels on naïve 
CD8 and memory CD4 T cells and at high levels on memory CD8 T cells and NK cells 
[44]. 
At the cellular level, IL-2R subunits are selectively located in lipid micro 
domains or rafts [45, 46], facilitating the oligomerisation of the receptor and the 
intracellular signalling machinery [47]. Following IL-2-IL-2R complex formation the 
signal transduction process involves the phosphorylation of tyrosine residues on the 
cytoplasmic tail of IL-2Rȕ by tyrosine kinases Jak1 and Jak3, which leads to the 
recruitment of the adaptor Shc [48]. MAPK, PI-3K and signal transducer and activator 
of transcription (STAT) 5 signalling pathways are then activated, leading to STAT5-
dependent gene regulation [43]. The activation of STAT5 is similar in CD4 and CD8 
effector T and Treg cells but the activation of S6 kinase (a downstream target of the PI-
3K-protein kinase B and mammalian target of rapamycin – mTOR – kinase pathways) 
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is distinctive for the cell populations [49]. Furthermore, in Treg cells the expression of 
phosphatase and tensin homolog (PTEN) protein suppresses the activation of PI-3K-
protein kinase B pathway and consequently, IL-2-dependent cell proliferation is not 
observed in vitro [50]. The activation of these signalling pathways promotes T cell 
growth, survival, AICD and differentiation [51, 52]. The signal induced by IL-2 can also 
stimulate the expression of IL-2Rα and IL-2Rȕ, acting as a positive feedback loop [53, 
54]. Following signal transduction, the IL-2-IL-2R complex is internalised, IL-2, IL-2Rȕ 
and Ȗc are rapidly degraded and IL-2Rα is recycled to the cell surface [55, 56]. 
1.2.4. T cell differentiation into different subsets 
The activation of naïve T cells by APC induces T cell proliferation and differentiation 
into specific effector cells.  
CD8 T cells turn into CD8 effector T cells after interaction with APC that present 
antigens via MHC-I molecules. The major transcription factors involved in the 
regulation of CD8 T cell differentiation are T-box transcription factor (T-bet), B 
lymphocyte-induced maturation protein 1 (Blimp1) and inhibitor of DNA binding (ID) 2. 
[57, 58]. CD8 effector T cells act on infected cells by releasing cytotoxins, such as 
perforin, granzymes and granulysin, which can penetrate the lipid bilayer and trigger an 
intrinsic cell death program. Effector cytokines, like IFN-Ȗ and TNF-α, are also released 
by effector CD8 T cells and contribute to infection control [59].  
CD4 T cells that become activated via antigen presentation by MHC-II 
molecules can differentiate into Th1, Th2, Th9, Th17, Th22, follicular helper (Tfh) and 
induced regulatory T (iTreg) cells. The cytokine microenvironment is the major 
contributor for the specific lineage differentiation, but other factors, such as the 
concentration of antigens, type of APC and co-stimulatory molecules, are also involved 
[60, 61] (Figure 1.5 and table 1.2). 
Th1 response is initiated by IL-12 and IFN-Ȗ. IL-12 is secreted by activated APC 
and induces the production of IFN-Ȗ by NK cells. These cytokines are responsible for 
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the activation of several transcription factors, including T-bet, STAT1, STAT4, runt-
related transcription factor (Runx) 3, eomesodermin (Eomes) and H2.0-like homeobox 
(Hlx), where T-bet is the central regulator in the differentiation of Th1 cells. IFN-Ȗ 
released by NK cells activates STAT1 that in turn induces the expression of T-bet. T-
bet further induces the production of more IFN-Ȗ and the suppression of the Th2 and 
Th17 lineages. T-bet suppression of Th2 cells occurs by inhibiting IL-4 gene 
expression and suppressing the functions of Th2 principal transcription factor GATA 
binding protein 3 (GATA3). Th17 cells are inhibited by the suppression of the Th17 
principal transcription factor, retinoic acid receptor-related orphan receptor gamma-T 
(RORȖt). Th1 cells are particularly important against intracellular pathogens and are 
also associated with organ-specific autoimmunity. Th1 cells secrete IFN-Ȗ, lymphotoxin 
α (LTα) and IL-2. IFN-Ȗ increases phagocytic activity by promoting the activation of 
mononuclear phagocytes, like macrophages. LTα, a member of the TNF family, was 
shown to be associated with autoimmunity. IL-2 induces proliferation of CD8 T cells, 
development of CD8 memory T cells, enhancing a secondary immune response, and 
survival and activation of Treg cells.  
The differentiation of Th2 cells depends on IL-4 and IL-2 cytokines. The 
principal transcription factors involved in Th2 response are GATA3, STAT6, STAT5, 
STAT3, growth factor independent 1 transcription repressor (Gfi-1), avian 
musculoaponeurotic fibrosarcoma (c-Maf) and interferon regulatory factor (IRF) 4, 
where GATA3 plays the major role. GATA3 expression, up-regulated by IL-4-induced 
STAT6, induces Th2 cytokine production, selective proliferation of Th2 cells and 
inhibition of Th1 cells differentiation. Th2 cells produce B-cell growth factors and 
interleukins IL-4 and IL-5. The main effector functions of Th2 cells are the induction of 
B cell proliferation, mediation of the immune response against extracellular parasites 
and induction and persistence of allergic inflammation [2, 32, 62, 63].  
Th9 cells are described as a differentiated branch of Th2 cells. Transforming 
growth factor (TGF)-ȕ is the factor responsible for the diversion of the differentiation of 
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Th2 towards the development of Th9 cells. However, the differentiation of Th9 cells can 
be directly induced by TGF-ȕ and IL-4. Th9 cells secrete IL-9 in large quantities and 
are mainly involved in tissue inflammation against helminths and are also associated 
with the pathogenic process of allergy [32, 64, 65].  
Th17 differentiation depends on TGF-ȕ and IL-6 for the differentiation stage; IL-
21 for the self-amplification stage; and IL-23 for the stabilisation stage. The main 
transcription factor affected by these signalling cytokines is RORȖt, which is 
responsible for the production of IL-17A and IL-17F cytokines. Th17 cells are involved 
in the immune response against extracellular bacteria and fungi and are also related to 
the immune response observed in several autoimmune diseases, such as multiple 
sclerosis and rheumatoid arthritis (RA). The main effector cytokines involved in the 
Th17 response are IL-17A, IL-17F, IL-21 and IL-22. [63, 66]. IL-17A and IL-17F 
signalling occurs through the IL-17A receptor and promotes the production of pro-
inflammatory cytokines, including IL-6, IL-1 and TNF-α, and pro-inflammatory 
chemokines, responsible for the chemotaxis of inflammatory cells to the inflammation 
site. IL-21 is essential for the amplification of Th17 development and is also involved in 
the differentiation of B cells into plasmocytes and memory cells and in the activation of 
NK cells. IL-22 promotes mucosal host defence against bacterial pathogens and 
exhibits tissue protective properties [32]. 
Th22 cells differentiate in the presence of TNF-α and IL-6 cytokines but the 
mechanism of signal transduction is not fully understood. The main cytokine expressed 
by these cells is IL-22, which is involved in wound repair and tissue regeneration. Th22 
cells also express chemokine receptors CCR4, CCR6 and CCR10 that promote the 
migration of these cells to particular tissues, such as skin [67]. 
Tfh differentiation occurs in the presence of IL-6 and IL-21 cytokines, which are 
responsible for the induction of STAT3 and B-cell lymphoma (Bcl)-6 transcription 
factors. Inducible co-stimulator (ICOS) is also necessary for Tfh development. Tfh cells 
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participate in the development of B cell response, by regulating the differentiation of B 
cells into plasma cells [32, 65].  
Induced Treg (iTreg) cells differentiate from naïve T cells in the presence of 
TGF-ȕ and IL-2 cytokines. TGF-ȕ and IL-2 signalling promote the activation of FOXP3 
and STAT5 transcription factors, respectively. STAT5 enhances the expression of 
FOXP3 and, consequently, the FOXP3 signalling and iTreg cell differentiation. The 
main function of iTreg cells is to maintain the immune system tolerance to self-
antigens. iTreg cells secrete TGF-ȕ, IL-10 and IL-35, and they also induce immune 
responses through cell-cell interactions [32, 63].  
Once the immune response is resolved, effector T cells are able to generate 
different subsets of memory T cells with diverse phenotypic and functional properties 
and gene expression profiles. 
 
 
Figure 1.5 Schematic representation of T cell maturation and differentiation. 
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Table 1.2 Cytokines and transcription factors involved in the differentiation of the different Th cell 
subsets. The master regulators are highlighted in bold. 
Th Subset Differentiation cytokines Transcription factors Effector cytokines 
Th1 IL-12, IFN-γ T bet, STAT1, STAT4, Runx 
3, Eomes, Hlx 
IFN-Ȗ, LTα, IL-2 
Th2 IL-4, IL-2 
GATA3, STAT6, STAT5, 
STAT3, Gfi-1, c-Maf, IRF4 
IL-4, IL-5 
Th17 IL-6, IL-21, IL-23, TGF-ȕ RORγt, STAT3, RORα, 
Runx1, Batf, IRF4, AHR 
IL-17A, IL-17F, IL-
21, IL-22 
Th22 TNF-α, IL-6 Unknown IL-22 
Tfh IL-6, IL-21 Bcl6, STAT3 IL-21, IL-4 
iTreg TGF-ȕ, IL-2 FOXP3, Smad2, Smad3, 
STAT5, NFAT 
TGF-ȕ, IL-10, IL-35 
Th9 TGF-ȕ, IL-4 IRF4 IL-9 
 
1.2.5. T cell metabolism 
Cellular metabolism plays an important role in the regulation of immune cell functions 
and cell differentiation [68-71]. The regulation of the uptake and utilisation of nutrients, 
such as glucose, fatty acids and amino acids, is crucial for the control of the immune 
cell number and functional activity [72]. 
Glucose is the major energy source for mammalian cells and is also a substrate 
for protein and lipid synthesis (Figure 1.6). Glucose uptake from the extracellular 
medium occurs via two families of structurally related glucose transporters and it is 
metabolised via glycolysis. In glycolytic metabolism, each glucose molecule is 
converted into two molecules of pyruvate with the concomitant production of two 
adenosine triphosphate (ATP) molecules. Pyruvate can be further oxidised via the 
tricarboxylic acid (TCA) cycle to generate nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2) that fuel mitochondrial oxidative 
phosphorylation (OXPHOS) generating thirty-six ATP molecules per glucose molecule. 
Pyruvate can also be converted into lactate by lactate dehydrogenase enzyme, 
regenerating NAD+ that can subsequently participate in glycolysis [73]. The conversion 
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of glucose into lactate is particularly important in hypoxic conditions and when 
mitochondria are damaged and cannot oxidise pyruvate. The conversion of pyruvate 
into lactate in normoxic conditions was first demonstrated by Otto Warburg in cancer 
cells and is described as aerobic glycolysis [74]. In this pathway a high flux of 
glycolysis meets increased cellular energy needs. 
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.  
Figure 1.6 Schematic representation of glucose and glutamine metabolism. ADP – adenosine biphosphate; ATP – adenosine triphosphate; FADH2 – flavin adenine 
dinucleotide; GSH – reduced glutathione; GSSG – oxidised glutathione; NAD+ – nicotinamide adenine dinucleotide ion; NADH – nicotinamide adenine dinucleotide; NADP+ – 
nicotinamide adenine dinucleotide phosphate ion; NADPH – nicotinamide adenine dinucleotide phosphate. 
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T cells alternate through states of metabolic quiescence and activation during their 
development and differentiation. Quiescent T cells require generation of ATP to meet 
their metabolic demands, whereas effector T cells need high metabolic flux 
proliferation-promoting pathways to be activated. The different T cell subsets rely on 
different energetic and biosynthetic pathways to meet their specific functional 
requirements [72]. 
In the thymus, DN thymocytes switch from quiescence to anabolic metabolism 
for the creation of biomass and proliferation. This phase is characterised by high levels 
of expression of glucose transporter 1 (GLUT1) promoting glycolytic metabolism used 
to support cell growth and proliferation. When thymocytes reach DP or SP stages, 
GLUT1 expression is downregulated and the intracellular pool of ATP molecules is 
originated from the breakdown of glucose, lipids and amino acids during OXPHOS [72, 
75, 76].  
Resting naïve T cells in the periphery, as quiescent cells, rely on OXPHOS or 
fatty acid oxidation for the synthesis of ATP [77-81]. Upon activation, T cells start clonal 
expansion and reprogram their metabolic machinery into aerobic glycolysis and 
increased OXPHOS and glutaminolysis for the rapid production of macromolecules 
required for anabolic cell growth [72, 77, 82]. Although glycolysis is less efficient in the 
production of energy-equivalents compared to OXPHOS, activated T cells engage in 
glycolysis since it is a rapid process for the generation of ATP and it also releases 
other metabolites required for productive cell growth [83]. The increase in glycolytic 
flux, observed in activated T cells, depends on the translocation of GLUT1 from the 
cytoplasmic pool to the cell surface in a PI-3K-Akt pathway-dependent process [84]. 
The metabolic reprogramming of T cells following activation is also regulated by mTOR 
pathway [85, 86] and, to a lesser extent, by extracellular signal-related kinase (ERK) 
[87], STAT5 [88], some MAP kinases [89] and hexokinase II [90]. Additionally to 
changes in the ATP source supply, the activation of T cells also induces changes in the 
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localisation of cations, like calcium, from intracellular stores (like endoplasmic reticulum 
– ER) to the cytosol, where they are involved in intracellular signalling [77, 91]. 
Once the immune response is terminated, most of the T cells die. The T cells 
that survive become memory T cells, but for that they need to return to a resting 
metabolic state, where lipid oxidation is the main energy-supply pathway [92]. 
 
1.3. Immune tolerance and autoimmunity 
The immune system has as its main function to protect the organism against internal 
and external harmful stimuli, like bacteria, viruses and damaged cells. Additionally, the 
immune system has to be able to discriminate between self-antigens from foreign-
antigens, in order to prevent inflammatory responses against the host’s own cells and 
tissues [5]. The main tolerance mechanism develops during T cell maturation in the 
thymus, where newly generated T cells whose TCR strongly recognises self-antigens 
are eliminated by negative selection [3]. However, some T cells evade this mechanism 
and are released to the blood stream, where they are reactive to self-antigens. The 
main function of Treg cells is to maintain the organism’s self-tolerance in the periphery 
and consequently Treg cells are able to detect, inhibit the induction of effector function 
and eliminate T cells that escaped the negative selection in the thymus [93, 94]. 
Impaired control of autoreactive T cell responses due to defects in the development, 
stability or function of Treg cells can trigger an immune response against the host 
organism described as autoimmunity [95].  
Autoimmune diseases, resulting from autoimmune responses, affect distinct 
organs and present different clinical manifestations. Examples of autoimmune diseases 
are RA, periodontitis (PID), multiple sclerosis and psoriasis. At cellular level, the 
chronic inflammation and tissue damage observed in autoimmune diseases are due to 
cytokine production, epitope spreading and a disrupted effector T cell/Treg cell balance 
[96].  
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Risk factors for autoimmunity include genetic predisposition and environmental 
triggers combined with impaired immune regulatory functions that enable the escape, 
activation and proliferation of autoreactive lymphocytes. Genome-wide association 
studies (GWAS) focusing on autoimmune diseases have identified a large number of 
disease-associated loci that are usually located in regulatory regions of genes, whose 
products are involved in immunity, like human leukocyte antigen (HLA), 
cytokines/receptors and those involved in central tolerance [97, 98]. The HLA 
corresponds to the human variant of the MHC, which occurs in many species, and is 
responsible for the expression of more than 200 genes. The products of MHC genes 
are highly polymorphic transmembrane glycoproteins expressed at the surface of 
lymphocytes. The products of the HLA/MHC genes can be divided into class I (HLA-A, 
-B and -C) and class II (HLA-DR, -DQ and -DP), according to their structure, tissue 
distribution and characteristics in peptide presentation to T cells. MHC-I genes are 
expressed in all cells but red blood cells; MHC-I protein derived from them are 
responsible for the presentation of intracellular peptides to the immune system. MHC-II 
genes are expressed mainly on APC, such as DC, B cells and macrophages; MHC-II 
proteins usually present exogenous proteins that were taken up by endocytosis and 
fragmented by proteases in an endosome, to other immune cells [99]. MHC-I and -II 
molecules that bind with high affinity to self-peptides are eliminated to prevent 
autoimmunity. However, this is not a faultless process and some HLA alleles have 
different abilities to present auto-antigens to T cells, being associated with the 
breakdown of the immune system observed in autoimmune diseases. Environmental 
triggers for autoimmunity are suggested to include smoking, infections, the microbiome 
and tissue injuries and are responsible for the generation of a pro-inflammatory 
environment that allows the activation of autoreactive lymphocytes [96].  
In addition to the risk factors and the impairment of the regulatory processes of 
the immune system mentioned previously, autoimmunity can be associated with 
modifications on self-antigens presented to the immune system. Post-translational 
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modifications (PTM) occur in proteins during ageing as part of physiological and 
pathological processes and can be responsible for the generation of neo-epitopes from 
self-proteins. In addition, PTM can be catalysed by enzymes or occur by chemical 
reaction and can contribute to alterations in the protein backbone, charge and 
differential three-dimensional folding pattern [100]. Examples of PTM that can affect 
amino acids are described in table 1.3. These modifications can generate neo-self 
epitopes and, consequentely, affect the affinity of MHC molecules or TCR binding or 
the activity of proteolytic enzymes involved in antigen processing [101]. 
 
Table 1.3 Amino acid post-translational modifications. 
Amino acid Modification 
Arginine Citrullination (deimination), methylation 
Asparagine N-linked glycosylation, deamidation (and isomerisation) 
Aspartic acid Isomerisation 
Glutamic acid Methylation 
Glutamine Deamidation 
Histidine Methylation 
Lysine Hydroxylation (and subsequent O-linked glycosylation), methylation 
Proline Hydroxylation 
Serine and threonine Phosphorylation, O-linked glycosylation 
 
1.3.1. Citrullination 
Citrullination (or deimination) is the enzymatic conversion of peptidylarginine into 
peptidylcitrulline mediated by peptidylarginine deiminase (PAD) enzymes (Enzyme 
Commission number 3.5.3.15.) (Figure 1.7). This reaction catalysed by PAD enzymes 
is calcium dependent and involves the hydrolysis of guanidinium groups on arginine 
residues, by a nucleophilic cysteine, to form citrulline. The complete substrate 
guanidinium group hydrolysis is mediated by a second histidine active site, where 
ammonia and water are released [102-107]. PAD enzymes were first described in 1977 
by Rogers [108]. In humans, five isoforms of PAD enzymes (PAD1–4 and PAD6) have 
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been identified in chromosome 1p36 [109]. Additionally, a bacterial PAD enzyme can 
be expressed by Porphyromonas gingivalis (P. gingivalis) [110]. The structure of all 
PAD isoforms have not yet been achieved, but work on PAD2 and PAD4 enzymes 
revealed the presence of several regulatory calcium binding sites that are responsible 
for the correct positioning of the catalytic cysteine residue (Figure 1.8) [111-114]. 
 
 
Figure 1.7 Conversion of protein arginine residues into citrulline by PAD enzymes. PAD – 
peptidylarginine deiminase; Ca2+ – calcium; H2O – water; NH3 – ammonia. 
 
 
Figure 1.8 Schematic representation of PAD2 and PAD4 enzymes structures in the presence and 
absence of calcium. The crystal structures of PAD2 enzyme (Protein data bank – PDB – entity: 4N20, 
4N2B) were determined at 1.6–1.7 Å resolution [113]. The crystal structures of PAD4 enzyme (PDB: 
1WD8, 1WD9) were determined at 2.6–2.8 Å resolution [111]. 
 
Physiologically, citrullination is an essential PTM since citrulline is a non-standard 
amino acid. Human PAD enzyme isoforms are highly conserved (70–95% identical 
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amino acids) amongst themselves. However, factors like the physicochemical features 
(structure, charge, size, flexibility and the amino acids flanking the arginine residues) of 
the target protein, the subcellular localisation of the enzyme and its microenvironment 
influence the susceptibility of arginine residues for citrullination by PAD enzymes [115]. 
PAD1 enzyme is predominantly expressed in the epidermis and uterus [116-119]. The 
citrullination of keratin and keratin-associated protein filaggrin during keratinocyte 
differentiation reduces the flexibility of the keratin cytoskeleton, stimulating the 
cornification of the epidermis and maintaining the physical resistance of the epidermis 
[120-124]. The PAD2 enzyme is the most abundant PAD isoform and is expressed in 
several tissues, like skeletal muscle, brain, spleen and secretory glands [118, 125-
131]. The PAD2 enzyme is regulated at transcriptional and translational levels [132, 
133] and the levels of this enzyme are also under hormonal regulation [119, 125, 134-
136]. In the nervous system, PAD2 is expressed in the grey matter, hypothalamus and 
also in the cerebellum, in oligodendrocytes, astrocytes, microglial cells and Schwann 
cells [137]. The citrullination of filament proteins like myelin basic protein (MBP), the 
major component of the myelin sheath in nerve cells, and glial fibrillary acidic protein 
(GFAP) is associated with the plasticity of the central nervous system [138, 139]. PAD2 
messenger ribonucleic acid (mRNA) is expressed in monocytes and macrophages but 
the protein form is just observed in macrophages [133]. In macrophages, PAD2 mRNA 
expression and protein form of PAD2 enzyme are observed, however, the intracellular 
calcium levels are not sufficient for the enzymatic reaction to occur. So, activation of 
intracellular PAD2 enzyme depends on the increase of cytosolic calcium concentration, 
which is observed in situations of apoptosis and antigen uptake/processing [133, 140]. 
Vimentin, an intermediate filament protein, was found to be citrullinated in apoptotic 
macrophages, suggesting that the citrullination of this protein is involved in the 
disassembly of the vimentin filaments and consequent collapse of the vimentin 
cytoskeleton, observed in apoptotic conditions [141]. PAD3 expression is restricted to 
hair follicles [118, 142-144], where it is able to act on trichohyalin (a structural protein 
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of inner root sheath cells of hair follicles) [108, 144]. Citrullination of trichohyalin opens 
its α-helical structure, allowing the cross-linking of this protein with keratin filaments, 
forming a firm tube to guide the directional growth of the hair fibre [145, 146]. PAD4 
enzyme is expressed by cells of the hematopoietic lineage, in particular granulocytes 
[147-149] and monocytes [133, 150] and can be detected intracellularly at nuclear level 
[149] in different tissues [130, 151]. PAD4 enzyme citrullinates nuclear proteins, such 
as histones and nucleophosmin/B23 [148, 149]. The high content of arginine residues 
in histones renders a strong net positive charge, which is essential for the interaction 
with the negatively charged DNA. Citrullination of histones changes their conformation 
and their net charge, consequently impairing the interaction with deoxyribonucleic acid 
(DNA) and increasing DNA susceptibility to degradation. PAD5 enzyme was initially 
described as a new PAD enzyme isoform but was later confirmed to correspond to 
PAD4 enzyme [147, 149]. PAD6 enzyme is found in early embryos and ovaries, where 
it is responsible for the reorganisation of egg cytoplasmic sheets during early embryo 
development [152] (Table 1.4).  
 
Table 1.4 Tissue distribution, substrates and biological functions of PAD enzyme isoforms. 
Isoform Protein distribution Substrates Biological functions 
PAD1 Epidermis, uterus Keratin K1, filaggrin Cornification of epidermal tissues 
PAD2 
Nervous system, skeletal 
muscle, spleen, uterus, 
pituitary gland 
MBP, vimentin, ȕ and Ȗ-
actins 
Plasticity of the nervous system, 
transcription regulation, innate 
immune defence, female 
reproduction 
PAD3 Epidermis, hair follicles Filaggrin, trichohyalin Regulation of epidermal functions 
PAD4 
Neutrophils, monocytes, 
macrophages, mammary 
gland epithelial cells 
Histones H2A, H3 and H4, 
p300/CBP, nucleophosmin, 
nuclear lamin C 
Chromatin decondensation, 
transcription regulation 
PAD6 Eggs, ovary, early embryo Unknown 
Oocyte cytoskeletal sheet 
formation and female fertility 
 
P. gingivalis is a major periodontal pathogen involved in PID [153]. P. gingivalis PAD 
(PPAD) can be observed as a secreted or a cell/membrane vesicle-associated 
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enzyme. This bacterial PAD enzyme isoform (AAF06719) is not calcium dependent 
and, contrary to human isoforms, is able to convert both free L-arginine and peptidyl-
bound arginine residues [110, 154]. Citrullination by PPAD enzyme affects complement 
activity [155], inactivates epidermal growth factors [156] and contributes to infection of 
gingival fibroblasts and stimulation of the prostaglandin E2 synthesis [157], promoting 
the survivability of P. gingivalis. Furthermore, the production of ammonia, as a bi-
product of the citrullination reaction, increases the environmental pH of the mouth and 
impairs neutrophil responses [110, 158]. The PPAD enzyme is able to citrullinate 
bacterial and host proteins [158], suggesting its involvement in the breakdown of the 
immune system associated with autoimmune diseases. 
Generally, citrullination results in a decrease in the net positive charge of the 
protein, as arginine is a positively charged amino acid and citrulline is a neutral amino 
acid. Arginine is involved in the maintenance of ionic interactions with other amino acid 
side chains and in the establishment of hydrogen bonds with the peptide backbone and 
other amino acid side chains, being a key amino acid in the three-dimensional structure 
of proteins and in the interaction with other molecules. Consequently, the conversion of 
arginine into citrulline via citrullination results in the loss of potential ionic bonds and 
interferes with hydrogen bonds. These changes induce partial unfolding of the protein, 
leading to the formation of new motifs and the generation of neo-epitopes [146]. The 
involvement of citrullination in the breakdown of the immune system in RA and PID is 
detailed in the next sections. 
1.3.2. Rheumatoid arthritis 
RA is a chronic autoimmune disease, characterised by the accumulation of 
inflammatory cells (T and B cells, neutrophils and monocytes) in the synovial 
membrane. The inflammatory response in RA is mediated by the activation of T cells, 
macrophages and fibroblast-like synoviocytes, leading to the production of pro-
inflammatory cytokines, like TNF and IL-6, and, ultimately, to tissue and bone 
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destruction [159, 160]. Clinically, RA is marked by pain, deformity and impaired 
functionality of the joints. According with the World Health Organisation (WHO) RA 
affects 0.3–1% of the adult population worldwide and has a higher incidence in women 
and in developed countries. The initiating event in the origin of RA is not known but 
genetic and environmental factors are involved in the pathogenesis of this disease 
[161-163]. Fifty to sixty per cent (50–60%) of RA susceptibility is associated with 
genetic factors, in particular with the presence of a specific allele in the HLA-DR gene 
[159, 164-166]. The first evidence for this association was demonstrated by Gregersen 
et al. in 1987 [167]. These authors proposed that a specific amino acid motif (Arginine, 
Alanine, Alanine – RAA) was shared by HLA-DR1 alleles associated with RA. Later, 
this shared epitope (SE) was shown to correlate with RA susceptibility and severity 
[166, 168, 169]. The presence of this SE motif induces the expression of MHC-II 
molecules with a different anchoring pocket that, consequently, will affect the 
interaction between MHC-II molecules and CD4 T cells [167, 170-172].  
The environmental influence on RA pathogenesis is based on factors such as 
smoking, infections, caffeine intake and exposure to silica [109]. Smoking is the most 
established environmental risk factor for RA and increases by 50% the risk of 
developing RA [159, 162, 173-177]. 
The autoimmune nature of RA has been associated with the presence of 
autoantibodies in the serum and synovial fluid of RA patients, in particular rheumatoid 
factors (RF) and anti-citrullinated protein antibodies (ACPA) [178-182]. RF are 
antibodies directed against the Fc region of immunoglobulin G. Most of the ACPA-
positive RA patients are also positive for RF, but ACPA are more specific and sensitive 
for the diagnosis of RA and are better predictors of poor prognostic outcomes [183]. 
Moreover, the presence of ACPA is related to the expression of SE, suggesting that a 
MHC-II:CD4 T cell response may be involved in the initiation of the immune reaction 
observed in RA [170, 184]. ACPA also appear to be associated with the early 
development of RA [185] and the severity and progression of the disease [186].  
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Dysregulation of PAD enzyme activity has been implicated in the origin of 
multiple disorders, such as psoriasis, multiple sclerosis, tumorigenesis and RA [109]. In 
RA, PAD2 and PAD4 enzymes were found in the synovial membrane of RA patients 
[187-189] and in synovial fluid cells [133]. Neutrophils and monocytes/macrophages 
are sources of PAD2 and PAD4 enzymes in RA. The activation of neutrophils leads to 
the amplification of the disease due to the production of reactive oxygen species 
(ROS), proteolytic enzymes and pro-inflammatory cytokines. Neutrophil immune 
responses include engulfing and degradation of microorganisms or opsonised 
particles, release of lytic enzymes to destroy extracellular pathogens and release of 
neutrophil extracellular traps (NET) that can trap and kill microbes [190, 191]. NET 
consist of nuclear chromatin associated with nuclear histones, granular antimicrobial 
proteins and cytoplasmic proteins [192]. The formation of NET, known as NETosis, 
was shown to depend on the citrullination of histones by PAD4 [193, 194]. In addition, 
PAD2 and PAD4 enzymes can be found attached to NET in the synovial fluid of RA 
patients [195]. PAD2 and PAD4 enzymes have also been reported in activated 
macrophages that infiltrate the synovium of RA patients [133]. Under normal 
physiological conditions, cytosolic calcium concentration is not sufficient for PAD 
activity, suggesting that intracellular citrullination only occurs when calcium 
homeostasis is lost, in situations like cell stimulation or after membrane disintegration 
resultant from apoptosis or NETosis [196]. Both intracellular and extracellular proteins 
have been reported to be citrullinated in RA, such as vimentin, fibronectin, fibrinogen, 
fibrin and α-enolase [184, 197-201]. Citrullinated fibrin, for example, was detected in 
the synovial membrane of RA patients [202] and ACPA were observed in the serum of 
RA patients. ACPA described so far include: anti-perinuclear factor [203, 204] and anti-
keratin autoantibodies [205, 206] against citrullinated fillagrin [207]; anti-Sa 
autoantibodies against citrullinated vimentin [199, 208]; and anti-cyclic citrullinated 
peptide autoantibodies [209, 210]. Moreover, plasma cells with the ability to produce 
ACPA were found in the synovial membrane of RA patients [211]. This evidence 
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strongly suggests that the occurrence of citrullination in the synovium has a major role 
in driving the production of ACPA and, consequently, in triggering the immune 
response and chronic inflammation observed in RA [212].  
1.3.3. Periodontitis 
PID is a chronic inflammatory disease that affects the periodontal tissue and is 
characterised by the accumulation of lymphocytes and monocytes, tissue oedema, 
endothelial cell proliferation and matrix degradation. Clinically, PID is manifested by 
gingival bleeding, increased pocket depth, periodontal bone loss, increased tooth 
mobility and, ultimately, tooth loss [213]. PID affects 10–15% of the worldwide adult 
population [214]. PID susceptibility is also related with genetic and environmental 
factors. A genetic risk factor for PID is the presence of the SE and the environmental 
risk factors associated with PID are mainly smoking and stress [215],216]. PID can be 
categorised from gingivitis to aggressive periodontitis according with the composition of 
the subgingival microbial flora and also the factors that influence the host response to 
the microbial attack [161, 213]. A subgingival biofilm consisting of hundreds of 
anaerobic Gram-negative bacterial species is the source of the chronic inflammation 
responsible for the clinical manifestations of PID [213, 216]. Recent metagenomics, 
metatranscriptomic and mechanistic studies data [217-222] suggested that PID 
pathogenesis results from polymicrobial synergy and dysbiosis, which perturb the 
balanced biofilm associated with periodontal tissue homeostasis [223-225]. Bacteria 
implicated in the origin of PID include Aggregatibacter actinomycetemcomitans, 
Porphyromonas gingivalis, Prevotella intermedia, Parvimonas micra, Treponema 
species and Tannerella forsythia [153, 226]. Among these, P. gingivalis appears to be 
the major infectious agent associated with PID, since it is detected in higher 
abundance in patients with aggressive forms of PID [227]. The virulence associated 
with P. gingivalis is caused by fimbriae, degradative enzymes (like PPAD and 
gingipains), exopolysaccharide capsule and atypical lipopolysaccharide [228, 229]. 
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PPAD is able to citrullinate both bacterial and host proteins, inducing an autoimmune 
response [230]. The amino acid sequence of PPAD and human PAD enzymes is very 
distinctive and the main difference in the mechanism of action of these enzyme is the 
fact that PPAD citrullinates preferentially C-terminal arginine residues and does not 
require calcium for activity, in contrast to human PAD enzymes that citrullinate internal 
arginine residues on a calcium-dependent manner [110]. PPAD is able to citrullinate 
human fibrinogen and α-enolase after the cleavage of these proteins by gingipains, 
which exposes target C-terminal arginine residues [231]. This particular processing 
induces the formation of neoepitopes and consequent generation of autoantibodies. In 
addition, the citrullination of epidermal growth factor (EGF) by PPAD was found to 
inhibit EGF-induced fibroblast proliferation and migration, affecting the healing process 
on periodontal tissue and consequently delaying the resolution of inflammation [156]. 
Other substrates of PPAD enzyme include fibrin, vimentin and bradykinin [110]. 
The autoimmune nature of PID involves autoreactive T cells, NK cells, anti-
neutrophil cytoplasmic autoantibodies, heat shock proteins, autoantibodies and genetic 
factors. Since 1970, when Ivanyi and Lehner first suggested a cell-mediated immunity 
in PID [232], several studies have found evidence for the role of T cells in the 
homeostasis of periodontal tissues [233], modulation of the immune responses [234] 
and mediation of the bone loss characteristic from PID [235]. Periodontopathic bacteria 
have been shown to be involved in the suppression of lymphocyte induction [236-240], 
in particular P. gingivalis was shown to down-regulate over one thousand genes and 
up-regulate about thirty genes in both CD4 and CD8 subsets of T cells in mice. From 
the total of down-regulated genes most are metabolism-associated genes but some 
encode for proteins involved in the immune response, in particular for cytokines and 
cytokine receptors [241]. Furthermore, T cells with decreased ability to respond in an 
autologous mixed lymphocyte reaction and reduced production of IL-2 and IL-2R 
expression were extracted from PID patients’ tissues [242, 243]. The association 
between different T cell subsets and PID progression has also been investigated. 
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Decreased CD4:CD8 ratio was found on T cells isolated from PID patients’ gingival 
tissues [242, 244] and in histological samples from PID patients [245, 246]. However, 
there is no consensus from studies on T cell subset involvement in PID and no 
differences [247, 248] and increases [249, 250] in the CD4/CD8 T cell ratio have also 
been reported.  
The impact of PID spreads from the oral cavity to the systemic circulation. PID 
has been associated with increased susceptibility of PID patients to diseases such as 
atherosclerosis [251, 252], adverse pregnancy outcomes [253], RA [254] and cancer 
[255]. High levels of bacterial pro-inflammatory components and Gram-negative 
bacteria were found in circulation in patients with severe PID compared with healthy 
individuals [256-258]. In particular, P. gingivalis DNA was detected in plasma and 
synovial fluid from RA patients [259]. Furthermore, antibodies against oral pathogens 
can also be found in the plasma of patients with pancreatic cancer, correlating PID with 
increased risk of this type of cancer [260]. Although PID is an irreversible chronic 
inflammatory disease, the levels of P. gingivalis present in the gingival tissue of PID 
patients decreased after non-surgical periodontal treatment and the general 
periodontal health of these patients was increased [261]. Furthermore, plaque removal 
treatment through improved oral hygiene reduces the rate of tooth loss and improves 
general quality of life [262]. 
 
1.4. Rheumatoid arthritis and periodontitis: a link through citrullination 
The association between RA and PID dates back from 400 BC, when Hippocrates 
reported the treatment of a patient with joint pain after the extraction of a single tooth 
[263]. Recently, several epidemiological studies showed that RA patients have a 
significantly increased prevalence in PID, strengthening the link between these two 
diseases [264-272]. Also, the severity of RA is related with the severity of PID and vice-
versa [273-275]. RA and PID are both chronic destructive inflammatory diseases 
characterised by the production of pro-inflammatory cytokines and tissue destruction, 
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in the synovium and periodontium, respectively [197, 216, 276, 277]. Other common 
features between these diseases include increased susceptibility to PID in RA patients 
and vice-versa and increased RA and PID susceptibility in genetically predisposed 
individuals (SE carriers) and the impact of similar environmental risk factors, like 
smoking [216].  
Accumulating evidence support the initiation of an immune response between 
PID and RA: the use of antibiotics against anaerobic bacteria for the successful 
treatment of RA [278]; the presence of P. gingivalis DNA in the plasma and synovial 
fluid of RA patients [259]; the occurrence of high levels of antibodies against oral 
bacteria in the serum and synovial fluid of RA patients [279]. The main theory for the 
link between RA and PID is based on the production of PPAD enzyme by P. gingivalis. 
P. gingivalis is able to impair the epithelial integrity, invade human endothelial cells and 
modify transcription and protein synthesis [254]. The localisation of PPAD at the 
bacterial surface promotes the interaction with host proteins via bacterial adhesins. The 
PPAD enzyme induces the citrullination of host and bacterial proteins in the inflamed 
periodontium, triggering an immune response against self-proteins and promoting the 
production of ACPA in susceptible individuals [280]. ACPA have been extensively 
reported to associate with the early development of RA [185] and are also associated 
with worse outcomes of disease [186]. Increased levels of ACPA have been reported in 
patients with PID when compared with healthy controls [281]. Furthermore, ACPA 
levels in RA patients also correlate with the presence of PID [282]. For example, 
autoantibodies against citrullinated α-enolase, an established RA autoantigen, were 
found to cross-react with α-enolase citrullinated by PPAD [254]. Moreover, increased 
levels of antibodies against citrullinated α-enolase were detected in animal models of 
PID [283]. Immune complexes consisting of ACPA and citrullinated antigens that are 
formed lead to the activation and stimulation of phagocytic cells, like neutrophils and 
macrophages. Activated neutrophils and macrophages, in turn, release inflammatory 
mediators like cytokines, metalloproteinases, eicosanoids and reactive oxygen and 
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nitrogen species, perpetuating the inflammatory response and ultimately leading to 
tissue destruction [284]. After the initial break in the immune tolerance to PPAD-
citrullinated peptides, processes of epitope spreading and molecular mimicry are 
responsible for cross-reactivity of ACPA with joint proteins and formation of immune 
complexes in the inflamed joint, leading to the exacerbation and perpetuation of the 
inflammatory response observed in RA [231, 285]. The chronic inflammation is further 
perpetuated by the citrullination of host proteins by human PAD enzymes, in particular 
PAD2 and PAD4 isoforms [277].  
 
1.5. Hypothesis and aims 
Citrullination studies have previously been focused in the generation of neoepitopes 
that drive an autoimmune response through the formation of immune complexes 
between ACPA and citrullinated antigens. Less importance has been attributed to the 
effects of PAD enzymes on the cells responsible for the immune response. T cells 
have shown to have important roles in the development of the immune response 
observed in RA and PID. Furthermore, the citrullination of HLA binding peptide was 
shown to increase the peptide-MHC affinity, leading to the activation of CD4 T cells in 
animal models [286]. Considering this evidence, this thesis aims to investigate the 
hypothesis that citrullination, as observed in RA and PID, modulates T cell activation. 
To address this question the main objectives established were as it follows: 
 To optimise conditions to detect and identify cellular protein targets of 
citrullination; 
 To establish a functional and biochemical competent T cell model to perform 
citrullination studies; 
 To investigate the effects of PAD enzymes on the activation T cells; 
 To analyse the inflammatory, citrullination and redox status and to compare the 
expression of genes of interest in PID patients. 
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Chapter 2  Materials and methods 
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2.1. Materials 
2.1.1. Consumables 
Cell culture and general plasticware were obtained from Thermo Fisher Scientific lnc. 
(Loughborough, UK). Plasticware for gene expression studies was obtained from VWR 
International Ltd. (Lutterworth, UK). Needles and syringes for blood collection were 
from BD (Becton, Dickinson and Company, Oxford, UK). VACUETTE® 
ethylenediaminetetraacetic acid (EDTA) and VACUETTE® heparin tubes were from 
Greiner Bio-One Ltd. (Stonehouse, UK). All salts, buffers and chemicals were obtained 
from Sigma-Aldrich Co. (Dorset, UK) unless stated. Protein inhibitor cocktail consisted 
of 4-(2-aminoethyl)benzenesulphonyl fluoride hydrochloride (AEBSF, 104 mM), 
aprotinin (80 µM), bestatin (4 mM), E-64 (1.4 mM), leupeptin (2 mM) and pepstatin A 
(1.5 mM). Recombinant human PAD2 and 4 (hPAD2 and hPAD4) enzymes purified 
from bacterial cell lysate using nickel (II)-beads were obtained from ModiQuest 
Research B. V. (Oss, Netherlands). 
2.1.2. Antibodies 
Table 2.1 Details of antibodies used.  
Antigen Application Description Product code Company 
CD25 FC 
Mouse monoclonal [BC96] conjugated 
with APC  
ab134477 
Abcam plc. 
(Cambridge, UK) 
CD28 FS 
Mouse monoclonal [CD28.2] functional 
grade purified 
16-0289 
eBioscience Ltd. 
(Hatfield, UK) 
CD3 FS 
Mouse monoclonal [OKT3] functional 
grade purified 
16-0037 
eBioscience Ltd. 
(Hatfield, UK) 
CD3 IB Rabbit polyclonal IgG ab16044 
Abcam plc. 
(Cambridge, UK) 
CD38 FC 
Mouse monoclonal [HB7] conjugated with 
FITC 
11-0388 
eBioscience Ltd. 
(Hatfield, UK) 
CD4 FC 
Mouse monoclonal [EDU-2] conjugated 
with PE 
ab1155 
Abcam plc. 
(Cambridge, UK) 
CD8 FC 
Mouse monoclonal [RPA-T8] conjugated 
with PE-Cy5.5  
35-0088 
eBioscience Ltd. 
(Hatfield, UK) 
NF-κB 
p65 
IB Rabbit polyclonal IgG ab7970 
Abcam plc. 
(Cambridge, UK) 
Rabbit 
IgG 
IB 
Goat polyclonal conjugated with 
peroxidase 
A6154 
Sigma-Aldrich 
Co. (Dorset, UK) 
APC – allophycocyanin; Cy – cyanine; CD – cluster of differentiation; FC – flow cytometry; FITC – 
fluorescein isothiocyanate; FS – functional studies; IB – immunoblotting; IgG – immunoglobulin; NF-kB – 
nuclear factor-kappa B; PE – phycoerythrin. 
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2.2. Fibrinogen citrullination 
2.2.1. Reagents 
FNG isolated from human plasma, containing more than 80% clottable protein, was 
obtained from Merck Millipore Ltd. (Watford, UK) and Sigma-Aldrich Co. (Dorset, UK). 
Roswell Park Memorial Institute (RPMI) medium (RPMI 1640 with stable L-glutamine) 
was from GibcoTM (Thermo Fisher Scientific lnc., Loughborough, UK).  
2.2.2. Background 
Citrullination is an enzymatic post-translational modification catalysed by PAD 
enzymes (EC 3.5.3.15.). In humans, there are five isoforms of PAD (PAD1–4 and 
PAD6). Citrullination is responsible for the conversion of L-arginine residues into L-
citrulline in the polypeptide chain, in a calcium dependent manner (Figure 1.7) [1]. FNG 
is one of the proteins that has been described as citrullinated in vivo in the context of 
RA [184, 197, 198]. Therefore, FNG was used as an in vitro model to develop methods 
for the detection of citrullination. 
2.2.3. Protocol 
FNG (100 µg) was dissolved in either phosphate buffer saline (PBS) or RPMI and 
citrullinated with 50 mU of hPAD2 or hPAD4 enzymes in 100 μL reaction buffer (100 
mM Tris-HCl, pH 7.5, 5 mM dithiothreitol – DTT, 10 mM calcium chloride – CaCl2). The 
controls used in the experiment included 1) no enzyme, 2) addition of EDTA 
immediately after addition of PAD enzymes and 3) heat inactivated (HI – 30 minutes at 
63°C) PAD enzymes. The reaction was performed for 2 hours at 37⁰ C and was 
stopped by boiling the samples with Laemmli buffer for 3 minutes or by adding 200 mM 
EDTA, according to the follow-up method.  
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2.3. Studies on Jurkat E6.1 T cells  
2.3.1. Reagents 
Jurkat E6.1 T cells were from American Type Culture Collection (ATCC®, Teddington, 
UK). Fetal bovine serum (FBS), penicillin/streptomycin and RPMI medium were from 
GibcoTM (Thermo Fisher Scientific lnc., Loughborough, UK). RPMI complete medium 
(RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin) was stored 
at 4⁰ C and used within a month. 
2.3.2. Background 
Jurkat E6.1 T cells are a subclone of the original Jurkat cells that were derived from a 
14-year-old boy with T cell acute lymphoblastic leukaemia. Jurkat E6.1 T cells have the 
characteristics of immature thymocytes and are regularly used to study TCR signalling 
and cytokine production [287]. Here, we studied the T cell activation response by 
treating Jurkat E6.1 T cells with phytohaemagglutinin-L (PHA-L) or with anti-CD3/anti-
CD28 antibodies. PHA-L is the subunit L of PHA and is responsible for the leukocytic 
activity of this lectin. By crosslinking glycosylated proteins on the surface of T cells 
PHA-L is able to induce TCR activation. Antibodies against CD3 and CD28 receptors 
were used here to mimic the two-step TCR activation by APC. 
2.3.3. Protocol: activation of Jurkat E6.1 T cells 
Jurkat E6.1 T cells were cultured at 37⁰ C in 5% carbon dioxide (CO2) using RPMI 
complete medium. Medium was changed every 4 days and cells were re-seeded at a 
density of 2–5 x 105 cells/mL. On the day of the experiment, cells were washed with 
complete RPMI 1640 medium and 1 mL was added into 24-well plates at a density of 1 
x 106 cells/mL. Cells were then stimulated with PHA-L or with anti-CD3/anti-CD28 
antibodies at 37⁰ C in 5% CO2 for 24, 48 or 72 hours. A non-activated control was also 
included. The concentrations of PHA-L ranged from 0 to 10 μg/mL. The anti-CD3 and 
anti-CD28 antibodies were prepared in sterile PBS and the concentrations of anti-CD3 
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ranged between 0 and 5 μg/mL and the concentration of anti-CD28 was 2 μg/mL. In 
the antibodies activation method, anti-CD3 antibody was pre-coated into a 24-well 
plate. After overnight incubation at 4⁰ C, the plate was washed three times with PBS 
and the cells were seeded. Anti-CD28 antibody was added to the plate immediately 
after addition of the cells. Following incubation, cells were collected and cell viability 
assessed with CellTiter-Blue® cell viability assay (Promega Co., Southampton, UK), as 
described in 2.14, or trypan blue exclusion assay (described in section 2.15). 
 
2.4. Studies on primary T cells in peripheral blood mononuclear cells 
population  
2.4.1. Reagents 
LymphoprepTM was purchased from Axis-Shield (Dundee, UK). FBS, 
penicillin/streptomycin and RPMI medium were from GibcoTM (Thermo Fisher Scientific 
lnc., Loughborough, UK). Bovine serum albumin (BSA) was from Thermo Fisher 
Scientific lnc. (Loughborough, UK). RPMI complete medium was stored at 4⁰ C and 
used within a month. 
2.4.2. Volunteers 
Blood was collected from healthy volunteers aged between 25 and 55 years old. 
Ethical approval was granted by Aston University research ethics committee (ethics 
reference 802). Volunteers were free to withdraw from the study at any time point.  
2.4.3. Background 
Peripheral blood includes many different cells. Peripheral blood mononuclear cells 
(PBMC) are defined as the fraction of the blood that contains round cells with round 
nucleus, including lymphocytes and monocytes. By layering whole blood on top of a 
density gradient of LymphoprepTM (Axis-Shield, Dundee, UK) PBMC and platelets can 
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be separated from granulocytes and erythrocytes according to their different densities 
[288]. 
2.4.4. Protocol: optimisation of peripheral blood mononuclear cells isolation 
Blood from healthy volunteers was collected by venepuncture into VACUETTE® EDTA 
tubes (Greiner Bio-One Ltd., Stonehouse, UK) and PBMC were isolated by 
centrifugation over LymphoprepTM. Briefly, 20 mL of blood was diluted 1:2.5 with sterile 
filtered 0.1% (w/v) BSA in PBS and layered over LymphoprepTM. Different isolation 
conditions and batches of LymphoprepTM were compared (Table 2.2) in order to 
maximise the yield of recovered cells. After centrifugation, the layer between plasma 
and LymphoprepTM, consisting of PBMC, was collected and washed twice with 0.1% 
(w/v) BSA in PBS. Based on the number of PBMC collected from each condition (Table 
2.3), determined by the trypan blue exclusion assay (described in section 2.15), the 
system selected for further experiments with PBMC was a two-step centrifugation for 
the separation of diluted blood over LymphoprepTM (ratio 25:11) and a spin of 400 x g 
for 10 minutes to further pellet the cells. After the first centrifugation, the top clear layer, 
consisting of platelets, was removed. It was also noted that using older batches of 
LymphoprepTM could affect the separation, so LymphoprepTM solution was used within 
1 month after opening. 
 
 
 
 
 
 
 
 
70 
 
Table 2.2 Conditions compared to isolate PBMC from blood (2.5 mL per condition). Batch 1 refers to 
LymphoprepTM solution open and used for more than one month; batch 2 refers to LymphoprepTM solution 
used within one month after opening. 
Condition LymphoprepTM 
Ratio 
LymphoprepTM:blood 
First spin Second spin 
Spin to pellet 
cells 
1 Batch 1 3:6 
800 x g, 20', 
20⁰ C --- 250 x g, 10' 
2 Batch 1 3:6 
800 x g, 20', 
20⁰ C --- 400 x g, 10' 
3 Batch 2 3:6 
800 x g, 20', 
20⁰ C --- 250 x g, 10' 
4 Batch 2 3:6 
800 x g, 20', 
20⁰ C --- 400 x g, 10' 
5 Batch 1 11:25 
160 x g, 20', 
20⁰ C 381 x g, 20', 20⁰ C 250 x g, 10' 
6 Batch 1 11:25 
160 x g, 20', 
20⁰ C 381 x g, 20', 20⁰ C 400 x g, 10' 
7 Batch 2 11:25 
160 x g, 20', 
20⁰ C 381 x g, 20', 20⁰ C 250 x g, 10' 
8 Batch 2 11:25 
160 x g, 20', 
20⁰ C 381 x g, 20', 20⁰ C 400 x g, 10' 
 
 
 
Table 2.3 Total number of PBMC recovered with each of the tested conditions. Cell number was 
determined by the trypan blue exclusion assay. 
Condition Cell count (x 106)  
1 2.0 
2 1.8 
3 2.1 
4 1.1 
5 2.1 
6 1.5 
7 2.9 
8 3.3 
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2.4.5. Protocol: activation of primary T cells from peripheral blood mononuclear 
cells  
Blood from healthy volunteers was collected by venepuncture into VACUETTE® EDTA 
tubes (Greiner Bio-One Ltd., Stonehouse, UK) and PBMC were isolated by 
centrifugation over LymphoprepTM. Briefly, 20 mL of blood was diluted 1:2.5 with sterile 
filtered 0.1% (w/v) BSA in PBS and 25 mL was layered over 11 mL of LymphoprepTM. 
After two centrifugation steps (160 x g at 20⁰ C for 20 minutes; 381 x g at 20⁰ C for 20 
minutes), the layer between plasma and LymphoprepTM, consisting of PBMC, was 
collected and washed twice with 0.1% (w/v) BSA in PBS. The cells were resuspended 
into complete RPMI 1640 medium at a density of 0.5 x 106 cells/mL in a 24-well plate 
(1 mL per well) and stimulated with PHA-L or antibodies against CD3 and CD28 for 24, 
48 or 72 hours at 37⁰ C in 5% CO2. The concentrations of PHA-L ranged from 0 to 5 
μg/mL, the concentrations of anti-CD3 ranged between 0 and 5 μg/mL and the 
concentration of anti-CD28 was 2 μg/mL. After the incubation period, cells were 
collected and further analysed.  
2.4.6. Protocol: citrullination of peripheral blood mononuclear cells  
PBMC (5 x 105) isolated from healthy volunteers, as previously described in 2.4.5, were 
pre-treated with 125, 250, 500 or 1000 mU of hPAD2 or hPAD4 enzymes in RPMI 
complete medium. After 2 hours of incubation at 37⁰ C in 5% CO2, enzymes were 
washed off from the cell culture (by centrifuging at 400 x g for 5 minutes) and replacing 
with fresh medium then cells were activated with 1 μg/mL of anti-CD3 antibody and 2 
μg/mL of anti-CD28 antibody at 37⁰ C in 5% CO2 for 24 hours. Controls without the 
enzymes and without activation were also included. After the activation period, cells 
were collected for further analysis. 
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2.5. Clinical samples 
2.5.1. Reagents 
FBS, PBS (without calcium and magnesium) and RPMI medium were from GibcoTM 
(Thermo Fisher Scientific lnc., Loughborough, UK). BSA, Dynabeads® CD4 positive 
isolation kit and Dynabeads® CD8 positive isolation kit were from Thermo Fisher 
Scientific lnc. (Loughborough, UK). Periopaper™ strips were obtained from Oraflow 
Inc. (Plainview, NY, USA). 
2.5.2. Volunteers 
Blood and gingival crevicular fluid (GCF) samples from chronic PID patients were 
collected from patients attending the periodontal clinic at Birmingham Dental Hospital. 
Age-matched, periodontally healthy controls were collected from staff of the 
Birmingham Dental Hospital (Table 2.4). Both patient and healthy samples were 
prepared and kindly provided by Professor Iain Chapple and Dr Paul Weston, 
Birmingham Dental Hospital. Chronic PID, as previously described [289], was defined 
as the presence of at least two non-adjacent sites per quadrant with probing pocket 
depths ≥ 5 mm which bled on probing and which demonstrated radiographic bone loss 
≥ 30% of the root length (non-first molar or incisor sites). All study participants were 
systemically healthy, did not use recreational drugs and had no special dietary 
requirements. Ethical approval was granted by South Birmingham Local Research 
Ethics Committee (ethics reference 14/SW/1148). Volunteers were free to withdraw 
from the study at any time point.  
 
Table 2.4 Demographics of the sample population.  
Parameter HC group PID group 
N 6 6 
Gender (M/F) 1/5 3/3 
Age (years) 49.0 ± 10.1 49.5 ± 9.4 
HC – healthy controls; M/F – male/female gender; N – number of subjects in each group; PID – 
periodontitis patients; Age is expressed as mean ± SD. 
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2.5.3. Background 
Plasma is the extracellular matrix of blood cells. Plasma consists of molecules 
absorbed from the gut and secreted from the cells, including proteins, lipids, glycans, 
nutrients and salts. To obtain plasma, whole blood is treated with an anticoagulant and 
the cells are removed by centrifugation [290].  
GCF is found at the gingival margin or within the gingival crevice. In periodontal 
disease GCF is rich in bacterial enzymes, bacterial degradation products, connective 
tissue degradation products, host-derived enzymes, inflammatory mediators and 
extracellular matrix proteins making this fluid an important source for biochemical 
analysis [291].  
Isolation of CD4 and CD8 T cells was performed using a positive isolation 
method. This technique consists of the separation of cells from a mixed population by 
immunoaffinity. In this case, CD4 and CD8 T cells were isolated from the PBMC 
population by incubating the entire cell population with magnetic beads conjugated with 
an antibody specific for CD4 or CD8, respectively. The unbound cell population is then 
removed and the cells of interest are detached from the magnetic beads.  
2.5.4. Solutions 
 Buffer 1: 
o PBS, without calcium and magnesium  
o 0.1% (w/v) BSA  
o 2 mM EDTA  
o pH 7.4 
 
 Buffer 2: 
o RPMI 1640 
o 1% (v/v) FBS 
 
74 
 
2.5.5. Protocol: CD4 and CD8 T cells positive isolation from whole blood 
CD4 T cells were isolated from whole blood using Dynabeads® CD4 positive isolation 
kit according to the manufacturer’s instructions. Briefly, 5 mL of whole blood was 
diluted with 10 mL of buffer 1 and centrifuged at 600 x g for 10 minutes at 4⁰ C. The 
upper layer, consisting of plasma and platelets, was discarded and the blood 
resuspended in 5 mL of buffer 1. Pre-washed anti-CD4 Dynabeads (12.5 µL per mL of 
blood) were added to the blood and incubated for 30 minutes at 4⁰ C with gentle tilting 
and rotation. Bead-bound cells were isolated using a magnet and resuspended in 100 
μL buffer 2 per mL blood in the original sample. The remaining cells were used for CD8 
T cell isolation using Dynabeads® CD8 positive isolation kit in accordance with the 
manufacturer’s instructions. Briefly, pre-washed anti-CD8 Dynabeads (12.5 µL per mL 
of blood) were added to CD4 T cell-depleted blood and incubated for 30 minutes at 
4⁰ C with gentle tilting and rotation. Bead-bound cells were isolated using a magnet 
and resuspended in 100 μL buffer 2 per mL of blood in the original sample. To 
separate CD4 or CD8 T cells from Dynabeads, 10 μL DETACHaBEAD solution was 
added per mL of initial blood used and cells incubated for 45 minutes at room 
temperature (RT) with gentle mixing. Dynabeads were recovered using a magnet while 
supernatants containing released CD4 or CD8 T cells were transferred to a new tube 
and washed from DETACHaBEAD with 10 mL buffer 2. CD4 and CD8 T cells were 
resuspended in 1 mL buffer 2, counted with trypan blue exclusion assay (described in 
section 2.15) and collected for further analysis. 
2.5.6. Validation of CD4 and CD8 T cells isolation 
To assess the purity of CD4 and CD8 T cell isolated from whole blood, 1 x 106 cells in 
buffer 2 were incubated on ice for 15 minutes and then with anti-CD4-PE (130 ng) or 
anti-CD8-PE-Cy5.5 (125 ng) antibodies, respectively, for 30 minutes on ice. Cells were 
then analysed by flow cytometry on a Cytomics FC 500 and CXP® software (Beckman 
Coulter Inc., London, UK). The respective isotype controls (mouse IgG2a PE and 
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mouse IgG1 PE-Cy5.5) were also used. Data were analysed using Flowing software v 
2.5.  
2.5.7. Protocol: plasma collection 
After collection, 4 mL of whole blood was centrifuged twice at 1600 x g for 10 minutes 
to remove cells and the plasma was aliquoted into new tubes and stored at -80⁰ C until 
analysis. Plasma (99 μL) to be analysed for GSH quantification was mixed with 1 μL of 
sulfosalicylic acid (SSA), centrifuged at 13,000 x g for 90 seconds and stored at -80⁰ C 
until further analysis. 
2.5.8. Protocol: gingival crevicular fluid collection 
GCF samples were collected from a mesio-buccal and disto-lingual site on each of 
three teeth (a molar, pre-molar and canine or incisor) in the left and right quadrant, 
providing four samples. GCF samples were collected for 30 seconds on Periopaper™ 
strips (Oraflow Inc., Plainview, NY, USA) from volunteers with chronic periodontitis and 
matched controls, GCF volumes were measured using a pre-calibrated Periotron 
8000™ (Oralflow Inc., Plainview, NY, USA) equipment, as described previously [289], 
snap frozen in liquid nitrogen and stored at -80⁰ C until analysed. GCF was extracted 
from the strips into 180 µL PBS with 1% protease inhibitor cocktail for 30 minutes at 
RT. 
 
2.6. Protein quantification by bicinchoninic acid assay (BCA) 
2.6.1. Background 
Protein determination by BCA assay is based on a 2-step process. In the first step, 
biuret reaction, peptide bonds in proteins reduce divalent copper ions (Cu2+) from 
copper sulphate (CuSO4) to monovalent copper ions (Cu
+), in an alkaline environment, 
forming a coloured chelate complex. In the second step, colour development reaction, 
each cuprous cation (from step one) reacts with two molecules of BCA forming a 
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purple-coloured product that absorbs light at 562 nm. The amino acids responsible for 
the Cu2+ reduction are cysteine, tyrosine and tryptophan, and the amount of 
Cu2+ reduced is proportional to the amount of protein present in solution (Figure 2.4) 
[292]. 
 
 
Figure 2.1 Schematic representation of the BCA 2-step reaction for protein quantification. 
2.6.2. Protocol 
Protein content was determined by adding 200 μL CuSO4:BCA solution (1:50 – v/v) to 
10 μL of sample or BSA standards (ranging from 0 to 1 mg/mL) in a 96-well plate. After 
incubating the plate for 30 minutes at 37⁰ C the absorbance was measured at 570 nm 
on a microplate reader (BioTek Instruments Inc., Swindon, UK) and protein content in 
unknowns was determined by interpolating from the standard curve. 
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2.7. Protein quantification by Bradford assay 
2.7.1. Reagents 
Bradford reagent was from Pierce (Thermo Fisher Scientific lnc., Loughborough, UK). 
2.7.2. Background 
In the Bradford assay protein content determination is based on the formation of a 
protein-Coomassie Brilliant Blue (CBB) G250 complex, in acidic conditions, that shifts 
the absorption maximum of CBB G250 from 465 to 595 nm. The increase of 
absorbance at 595 nm is proportional to the amount of protein in solution. The main 
amino acids responsible for the colour development in this method are arginine, lysine 
and histidine. The main advantage of this method is its compatibility with most salts, 
solvents, buffers, thiols and reducing agents present in protein samples [293].  
2.7.3. Protocol 
Protein content was determined by adding 200 μL Bradford reagent to 10 μL of sample 
or BSA standards (ranging from 0 to 1 mg/mL) in a 96-well plate. After incubating the 
plate for 10 minutes at RT the absorbance was measured at 595 nm on a microplate 
reader (BioTek Instruments Inc., Swindon, UK) and protein content in unknowns was 
determined by interpolating from the standard curve. 
 
2.8. Protein separation by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
2.8.1. Reagents 
Precision Plus Protein™ Kaleidoscope™ Standards were obtained from Bio-Rad 
Laboratories Ltd. (Hemel Hempstead, UK). Acetic acid and methanol were from Fisher 
Chemicals (Thermo Fisher Scientific lnc., Loughborough, UK).  
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2.8.2. Background 
SDS-PAGE is a protein separation method, where the electrophoretic mobility reflects 
length, conformation and charge of a protein. SDS-PAGE involves the denaturation of 
the protein with a reducing agent, usually ȕ-mercaptoethanol (ȕ-ME), and the binding 
of SDS to the linear protein, providing a uniform negative charge. Subsequently, 
negatively charged proteins are forced to pass through a gel containing acrylamide by 
applying an electrical field. Polymerised acrylamide creates pores that confer 
resistance to protein migration and allow proteins to be separated according to their 
molecular weight (MW) [294, 295]. 
Proteins separated by SDS-PAGE can be detected by staining the gel with 
dyes such as CBB R250 or CBB G250, or by immunoblotting. Furthermore, 
electrophoresed proteins can be extracted, digested and identified by mass 
spectrometry (MS) [296]. 
CBB R250 and CBB G250 are disulphonated triphenylmethane compounds 
that, in acidic conditions, bind to proteins through basic amino acids (primarily arginine, 
lysine and histidine) enabling their visualisation on a gel. CBB G250 has two additional 
methyl groups compared with to CBB R250, allowing it to be used as a colloidal stain 
[297]. Immunoblotting technique will be addressed and described later (section in 2.9). 
2.8.3. Solutions 
 Resolving gel buffer: 
o 1.5 M Tris-base 
o 0.4% (w/v) SDS 
o pH 8.4 
 
 Stacking gel buffer: 
o 0.5 M Tris-base 
o 0.4% (w/v) SDS 
o pH 6.8 
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 Ammonium persulphate (APS): 
o 10% (w/v) APS in double-distilled water  
 
 Electrophoresis running buffer: 
o 20 mM Tris-base 
o 192 mM glycine 
o 0.1% (w/v) SDS  
 
 CBB R250 staining solution: 
o 0.05% (w/v) CBB R250 
o 50% (v/v) methanol 
o 10% (v/v) acetic acid 
 
 Destaining solution: 
o 50% (v/v) methanol 
o 10% (v/v) acetic acid 
 
2.8.4. Protocol 
A fixed amount of protein was mixed with Laemmli buffer (1:1 ratio) and incubated at 
95⁰ C for 3 minutes. Samples were resolved in 7.5, 10 or 12% acrylamide gels, after 
being concentrated in a 3% stacking gel (composition of the gels is described in table 
2.5). Electrophoresis was performed at 115 V for 105 minutes in electrophoresis 
running buffer using a Mini-PROTEAN Tetra cell (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK). Following electrophoresis, gels were stained overnight with CBB 
R250 staining solution, destained at least three times for one hour with destaining 
solution and visualised and analysed using a G:BOX Chemi HR 1.4 imaging system 
and GeneTools 4.03 image analysis software (Syngene, Cambridge, UK).  
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Table 2.5 Composition of SDS-PAGE resolving and stacking gels (volumes are per gel). 
Reagent 7.5% resolving 10% resolving 12% resolving 3% stacking 
Bi-distilled water 6 mL 5 mL 7.2 mL 4.87 mL 
Resolving gel buffer 3 mL 3 mL 3 mL - 
Stacking gel buffer - - - 1.87 mL 
Acrylamide/bis-acrylamide 
(29:1) 30% solution 
3 mL 4 mL 4.8 mL 0.75 mL 
APS 100 µL 100 µL 100 µL 100 µL 
Tetramethylethylenediamine 
(TEMED) 
10 µL 10 µL 10 µL 10 µL 
 
2.9. Immunoblotting 
2.9.1. Reagents 
Methanol was obtained from Fisher Chemicals (Thermo Fisher Scientific lnc., 
Loughborough, UK). Amersham enhanced chemiluminescence (ECL) Prime Western 
Blotting detection reagent and Amersham Hybond P 0.45 µm polyvinylidene difluoride 
(PVDF) were from GE Healthcare Life Sciences Ltd. (Little Chalfont, UK).  
2.9.2. Background 
Immunoblot or Western blot is a technique that uses antibodies to specifically detect 
targeted proteins. Proteins are first separated by electrophoresis, then transferred to a 
nitrocellulose or PVDF membrane and finally probed with specific antibodies. Transfer 
of proteins usually occurs by electroblotting, where an electric current forces proteins to 
move from the gel to the membrane, maintaining the same organisation and being 
exposed on a thinner surface. Before incubating the membrane with the antibody of 
interest, non-specific interactions between the membrane and the antibody are blocked 
using BSA or non-fat dry milk. The membrane is then probed for a specific antigen 
using an antibody conjugated with a reporter enzyme or a combination of primary and 
secondary antibodies, where the second is directed to a species-specific portion of the 
first and is conjugated with a reporter enzyme. Usually, secondary antibodies are 
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conjugated with horseradish peroxidase (HRP), which enables the chemiluminescence 
detection of the proteins of interest [296]. 
2.9.3. Solutions 
 Transfer buffer: 
o 20 mM Tris-base 
o 192 mM glycine 
o 25% (v/v) methanol  
 
 Tris buffered saline (TBS) solution:  
o 150 mM sodium chloride (NaCl) 
o 20 mM Tris-HCl 
o pH 7.5 
 
 Washing solution (TTBS):  
o 0.05% (v/v) Tween-20 in TBS 
 
 Blocking solution: 
o 3% (w/v) BSA in TTBS 
 
2.9.4. Protocol 
Proteins separated by SDS-PAGE were electro-transferred into a PVDF membrane 
using a Criterion™ blotter wet system (Bio-Rad Laboratories Ltd., Hemel Hempstead, 
UK) at 240 mA for 105 minutes in transfer buffer. PVDF membrane was soaked in 
100% methanol for 1 minute and washed in transfer buffer for 5 minutes prior to 
transfer. Following transfer, membranes were incubated with blocking solution 
overnight at 4⁰ C or 2 hours at RT and probed with an antibody targeted to a specific 
protein and subsequently the adequate secondary antibody conjugated with HRP. 
Antibodies were diluted in blocking solution and incubations were either overnight at 
4⁰ C or for 2 hours at RT. After the incubation steps, membranes were washed 6 times 
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for 5 minutes each with TTBS. Bands were detected with ECL and visualized on a 
G:BOX Chemi HR 1.4 imaging system and GeneTools 4.03 image analysis software 
(Syngene, Cambridge, UK). 
 
2.10. Protein separation by two-dimensional isoelectric focusing/SDS-
PAGE (2D IEF/SDS-PAGE) 
2.10.1. Materials and reagents 
10% Criterion™ Tris-HCl gel, Bio-Lyte® 3/10 ampholyte, FlamingoTM fluorescent gel 
stain solution, Precision Plus Protein™ Kaleidoscope™ standards, ReadyPrepTM 2-D 
clean-up kit, ReadyStripTM immobilized pH gradient (IPG) strips (+3–10) and TGS 
buffer were obtained from Bio-Rad Laboratories Ltd. (Hemel Hempstead, UK). Acetic 
acid and ethanol were from Fisher Chemicals (Thermo Fisher Scientific lnc., 
Loughborough, UK). Amberlite resin and DeStreak™ reagent were from GE Healthcare 
Life Sciences Ltd. (Little Chalfont, UK).  
2.10.2. Background 
2D IEF/SDS-PAGE is one of the most widely used analytical techniques to separate 
mixtures of proteins. The principle of 2D IEF/SDS-PAGE is the separation of proteins in 
two dimensions: 1) based on their net charges by IEF and 2) based on their MW by 
SDS-PAGE. In IEF, proteins are applied into IPG strips containing a fixed pH gradient. 
When an electrical field is applied, proteins migrate through the pH gradient becoming 
immobilized when they approach their specific isoelectric point (pI). Following IEF, IPG 
strips can be applied to SDS-PAGE, allowing separation of the proteins in a second 
dimension, according with their MW. After 2D separation, gels can be stained for 
protein visualisation and analysis. With 2D IEF/SDS-PAGE, hundreds of proteins can 
be separated and detected. However, one of the major drawbacks of this technique is 
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the difficulty to separate low abundant and hydrophobic proteins [298]. This will be of 
particular relevance when analysing MP. 
2.10.3. Solutions 
 Solubilisation buffer: 
o 8 M urea  
o 2 M thiourea 
o 4% (w/v) 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulphonate hydrate (CHAPS) 
 
 Rehydration buffer: 
o 8 M urea 
o 2 M thiourea 
o 2% (v/v) CHAPS 
o 0.2% (v/v) Bio-Lyte® 3/10 ampholyte 
o 1% (v/v) DeStreak™ reagent 
 
 Equilibration buffer: 
o 6 M urea 
o 2% (w/v) SDS 
o 30% (v/v) glycerol 
o 1% (w/v) DTT 
o 50 mM Tris-HCl, pH 8.6 
 
 Fixative buffer: 
o 40% (v/v) ethanol  
o 10% (v/v) acetic acid 
 
2.10.4. Protocol 
Proteins were prepared for 2D IEF/SDS-PAGE using ReadyPrepTM 2-D clean-up kit 
according with the manufacturer’s instructions. Briefly, 125 µg of protein were 
transferred into a new tube and incubated with 300 µL precipitating agent 1 for 15 
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minutes on ice. Proteins were then mixed with precipitating agent 2 and centrifuged at 
12,000 x g for 5 minutes. Supernatant was discarded and samples were centrifuged 
briefly (approximately thirty seconds) to collect residual liquid. Wash reagent 1 (40 µL) 
was added to the pellet and centrifuged at 12,000 x g for 5 minutes. Supernatant was 
discarded and the pellet was resuspended with 25 µL ultrapure water, followed by 1 mL 
of wash reagent 2 (pre-chilled at -20⁰ C for at least 1 hour) and 5 µL of wash 2 
additive. The tubes were then incubated at -20⁰ C for 30 minutes (vortexed for 30 
seconds every 10 minutes). After the incubation period, the tubes were centrifuged at 
16,000 x g for 5 minutes and the supernatant was discarded. The pellet was briefly 
centrifuged again to remove residual liquid and air-dried at RT for 5 minutes. Protein 
pellets were then solubilised overnight at 20⁰ C in solubilisation buffer with gentle 
agitation. Protein concentration was determined by Bradford assay (described in 
section 2.7). Urea/thiourea solutions were deionised before use by incubating with 1% 
(w/v) Amberlite mixed bed resin for 10 minutes. Samples (50 µg) were diluted in 
rehydration buffer, applied to IPG strips and incubated overnight at 20⁰ C. After 
rehydration, IPG strips were focused using a Protean i12 IEF apparatus (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK) with the following programme: 0–800 V for 
800 Vh, 800–8,000 V for 8,000 Vh and 8,000 V for 96,000 Vh at 20⁰ C. The IPG strips 
were incubated in equilibration buffer for 15 minutes and then in equilibration buffer 
with 4.7% (w/v) iodoacetamide (IAM) for 15 minutes. For the second dimension, 
samples were resolved by SDS-PAGE on 10% CriterionTM Tris-HCl gels in TGS buffer. 
Electrophoresis was performed at 150 V for 85 minutes using a Criterion™ Cell (Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK). Following electrophoresis, gels were 
fixed for 16 hours in fixative buffer and stained with Flamingo fluorescent gel stain 
solution for 8 hours. The stained gels were visualised and analysed using a molecular 
imager PharosFXTM and Quantity One software (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK). 
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2.11. Protein separation by 2D blue native (BN)/SDS-PAGE  
2.11.1. Reagents 
8–16% Mini-PROTEAN® TGX Stain-Free® precast gels and Precision Plus Protein™ 
Kaleidoscope™ Standards were from Bio-Rad Laboratories Ltd. (Hemel Hempstead, 
UK). CBB G250, n-dodecyl-beta-maltoside (DDM), NativeMarkTM protein standards and 
NativePAGE™ Novex® 4–16% Bis-Tris gels were obtained from Thermo Fisher 
Scientific lnc. (Loughborough, UK). 
2.11.2. Background 
2D BN/SDS-PAGE is an electrophoresis technique that enables the separation of 
associated proteins in native and denaturing conditions. Combinations of different 
techniques and dimensions enable analysis of various characteristics of the separated 
proteins. BN-PAGE was first applied to separate protein complexes from mitochondrial 
extracts and then applied to biological membranes and total cell and tissue 
homogenates. Protein complexes are initially separated by size in a first native 
dimension. This provides information about native protein or protein complexes size 
and relative abundance, since protein complexes are not disturbed [299, 300]. The 
incorporation of CBB G250 in the samples prior to separation confers the negative 
charge that will allow the complexes to migrate into the gel. After the first dimension, 
native complexes can be extracted and used for 2D crystallisation, electron 
microscopy, in-gel activity assays or native electroblotting and immunodetection. 
Alternatively, protein complexes can be further separated in a second dimension by 
SDS-PAGE followed by immunoblotting (3D) or IEF followed by SDS-PAGE (3D) for 
the separation of the complexes’ subunits. The combination of second and third 
dimensions allow to obtain information about different complexes that share common 
subunits, presence of free monomeric forms of individual subunits, and whether these 
parameters change upon cell stimulation or treatment [301-303]. 
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2.11.3. Solutions 
 BN sample buffer (BN SB): 
o 750 mM aminocaproic acid (ACA) 
o 50 mM Bis-Tris pH 7.0 
o 0.5 mM disodium EDTA (EDTA-Na2) 
 Loading buffer (LB): 
o 750 mM ACA 
o 50 mM Bis-Tris pH 7.0 
o 5% (w/v) CBB G250 
o Stored at -20⁰ C 
 Dialysis buffer: 
o Loading buffer without CBB G250 10x diluted 
o Stored at 4⁰ C 
 DDM solution: 
o 10% (w/v) DDM in BN SB 
 BN cathode running buffer (10x): 
o 500 mM tricine 
o 150 mM Bis-Tris pH 7.0 
o 0.2% (w/v) CBB G250 
o Stored at 4⁰ C 
 BN anode running buffer (10x): 
o 500 mM tricine 
o Stored at 4⁰ C 
 SDS-PAGE running buffer (10x): 
o 250 mM Tris 
o 1.92 M glycine 
o 1% (w/v) SDS 
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 Overlay solution: 
o 0.5% (w/v) agarose in 1x SDS-PAGE running buffer 
o Microwave to dissolve 
 Fixing solution: 
o 40% (v/v) methanol 
o 10% (v/v) acetic acid 
 Destaining solution: 
o 8% (v/v) acetic acid 
 CBB high sensitivity staining solution: 
o 0.02% (w/v) CBB G250 
o 5% (w/v) aluminium sulphate hydrate 
o 10% (v/v) ethanol 
o 2% (v/v) o-phosphoric acid 
o Stored at RT 
 CBB high sensitivity destaining solution: 
o 10% (v/v) ethanol 
o 2% (v/v) o-phosphoric acid 
o Stored at RT 
2.11.4. Protocol 
BN-PAGE and 2D BN/SDS-PAGE were performed as previously described by 
Reisinger and Eichacker [304]. First dimension BN-PAGE was performed using 
NativePAGE™ Novex® 4–16% Bis-Tris gels assembled on an XCell SureLock™ Mini-
Cell Electrophoresis System from Thermo Fisher Scientific lnc. (Loughborough, UK). 
For the second dimension 8–16% Mini-PROTEAN® TGX Stain-Free® precast gels 
assembled on a Mini-PROTEAN Tetra Cell (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK) were used.  
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MP were isolated from 5 x 105 cells as further described in section 2.13 and 
dialysed against 10x diluted BN loading buffer using Slide-A-Lyzer™ Dialysis 
Cassettes, 3.5K MWCO, 0.5 mL (Thermo Fisher Scientific lnc., Loughborough, UK). 
Protein concentration after dialysis was determined by the BCA method (described in 
section 2.8) and samples were further evaporated in a centrifugal concentrator 
(Eppendorf AG, Loughborough, UK). FNG (10 µg) and MP (25 µg) were resuspended 
in 20 µL of BN SB and mixed with DDM solution to a final concentration of 0.625% (v/v) 
of DDM. Samples were vortexed every 5 minutes while incubating on ice for 1 hour. 
Insolubilized material was pelleted by centrifuging at 16,900 x g for 30 minutes at 4⁰ C. 
The supernatant was transferred to a new tube containing 5 µL of LB (with 1% 
protease inhibitor cocktail) and incubated on ice for 5 minutes. After assembling the 
electrophoresis apparatus, 1x BN cathode running buffer and 1x BN anode running 
buffer were poured into the upper and lower chambers, respectively. Samples and 
protein markers were loaded and BN-PAGE performed at 4⁰ C at 150 V for 60 minutes. 
After 60 minutes, the voltage was increased to 250 V and the electrophoresis 
continued for 30–60 minutes until the blue front reached the bottom of the gel. 1D BN-
PAGE gels were fixed with 100 mL of fixing solution for 15 minutes at RT, destained 
with 100 mL of destaining solution until the desired background was obtained and 
visualized and analysed using a G:BOX Chemi HR 1.4 imaging system and GeneTools 
4.03 image analysis software (Syngene, Cambridge, UK). 
To perform 2D BN/SDS-PAGE, 1D gel strips of interest were excised and the 
proteins denatured with Laemmli buffer (incubation at 95⁰ C for 15 minutes followed by 
incubation at RT for 1 hour, in 15 mL conical tubes). After denaturation, 1D strips were 
assembled in the 2D gels on the top of a layer of overlay solution and sealed with 
another layer of overlay solution. 2D SDS-PAGE was performed at 150 V for 
approximately 1 hour at RT. 2D BN/SDS-PAGE gels were washed thrice with water for 
10 minutes and stained overnight with CBB high sensitivity staining solution. Gels were 
then rinsed twice with water and destained with CBB high sensitivity destaining solution 
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for 1 hour. After a final rinse with water the gels were visualized and analysed using a 
G:BOX Chemi HR 1.4 imaging system and GeneTools 4.03 image analysis software 
(Syngene, Cambridge, UK) and SameSpots software (TotalLab ltd., Newcastle upon 
Tyne, UK), respectively. In the SameSpots analysis software (TotalLab ltd., Newcastle 
upon Tyne, UK), gel images were cropped to the area containing the proteins spots. A 
reference image was then selected according with the conditions under study. The 
software matches the spots, the spot volumes are normalised to the reference gel and 
the resultant up- or down-regulated spots are statistically analysed using analysis of 
variance (ANOVA) test. The resultant spots can then be filtered for fold changes higher 
or equal to two and p-values higher or equal to 0.05. 
 
2.12. Protein identification by mass spectrometry  
2.12.1. Reagents 
Acetic acid, acetonitrile (ACN) and methanol were from Fisher Chemicals (Thermo 
Fisher Scientific lnc. (Loughborough, UK). Trypsin gold and chymotrypsin were from 
Promega Co. (Southampton, UK).  
2.12.2. Background  
Proteomic studies depend on the separation of proteins, usually by electrophoresis, 
cleavage of polypeptide chains into small peptides by proteases, separation of 
digested peptides by liquid chromatography (LC) and ionisation and detection of the 
ions according with their mass/charge (m/z) ratio by MS. This combination of 
techniques allows the identification of proteins in a complex mixture, detection of PTM 
in a protein and it can also provide quantitative information about the analysed 
molecules [305].  
Commonly, proteins are converted into small peptides after being separated by 
SDS-PAGE. Gel bands are excised and proteins digested with proteases. Trypsin is 
the most common protease used in proteomics, but others can be used, such as 
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chymotrypsin or Glu-C. Trypsin cleaves polypeptide chains at the carboxyl side of 
lysine or arginine residues, except when these are followed by proline. Chymotrypsin 
cleaves at the carboxyl side of tyrosine, phenylalanine, tryptophan and leucine amino 
acids. Glu-C cleaves peptide bonds at the carboxyl side of glutamic residues but it can 
also cleave at both glutamic and aspartic residues, depending on the buffer used. The 
original procedure for in-gel digestion, first introduced in 1992 by Rosenfeld [306], 
underwent several modifications during the years. The method developed by 
Shevchenko in 2006 is currently one of the most commonly used and comprises of 
destaining the gel bands, reduction and alkylation of the cysteine residues in the 
protein, proteolytic cleavage of the protein and extraction of the generated peptides 
[307]. After protein digestion, peptides can be analysed by MS. This technique allows 
the acquisition of MW and structural information of a compound with high sensitivity, 
being the most comprehensive and versatile technique in proteomics. A mass 
spectrometer is organised in sample introduction device, ionisation source (for ion 
generation), mass analyser (for ion separation) and ion detector (to transform analogue 
signals into digital signals and record a mass spectrum). The equipment used in this 
study by Dr Creese at University of Birmingham was a linear trap quadrupole (LTQ)-
Orbitrap Velos electron transfer dissociation (ETD) mass spectrometer (Thermo Fisher 
Scientific lnc., Loughborough, UK) coupled to a Dionex Ultimate 3000 high 
performance liquid chromatography (HPLC) system (Sunnyvale, USA). The mass 
spectrometer components described here are based on this equipment.  
Coupling MS to a reversed phase (RP)-HPLC system allows the separation and 
simplification of complex biological samples prior to mass analysis. HPLC allows the 
separation of peptides according to their hydrophobicity. After separation, peptides are 
ionised by electrospray ionisation (ESI) transferring the analytes into the gas phase 
maintaining their non-covalent interactions [308]. ESI involves the application of a high 
voltage to a flow of liquid creating an electrically charged spray, formed by small 
charged drops. The solvent on these drops is further evaporated, creating charged ions 
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in the interface with the mass spectrometer [309]. In the mass analyser, the ions are 
separated by electric or magnetic fields. LTQ-Orbitrap is a hybrid mass analyser that 
combines linear and orbital trapping of ions in its electrostatic fields, featuring high 
resolution, high mass accuracy, high speed and high sensitivity and enabling tandem 
MS [308]. In ion trap equipment, ions are imprisoned inside while the MS operations 
(full scan, precursor selection, fragmentation and product ion analysis) take place 
[309]. Tandem MS mass analysis is carried out on intact molecular ions (full scan) or 
on collision induced dissociation (CID) fragmented precursor ions (MSn scan). CID 
fragmentation is a thermal process that leads to the cleavage of the amine bond on 
peptide ions producing b and y fragment ions (Figure 2.2), that provides sequence 
information, which can be searched against protein databases [310]. Peptide 
fragmentation spectra (plot of ion abundance versus m/z ratio) are matched against in 
silico calculated spectra leading to protein identification [308]. Alternatively to CID, 
ETD, which involves radical ion chemistry, randomly cleaves along the peptide 
backbone, producing c and z fragment ions (Figure 2.2) that leave side chains and 
modifications intact [310]. In a variant of ETD, supplemental activation ETD (saETD), 
the charge-reduced ion is activated by collision, thus disrupting any non-covalent 
bonding [311]. 
 
 
Figure 2.2 Schematic representation of a, b, c, x, y and z ions during peptide fragmentation in tandem MS. 
Characterisation of citrullination by direct tandem MS is very challenging due to the low 
abundance of this modification in complex samples and also because the 0.98 Da 
mass difference between citrulline and arginine can be misidentified by other 
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modifications, such as deamination (removal of an amine group from a molecule), or 
the simple MS sample processing [312]. To counteract this, Creese and colleagues 
developed a method based on the occurrence of neutral loss of isocyanic acid (43 Da) 
from citrullinated peptides (Figure 2.3) that enables differentiating citrullination from 
deamination. In this method, if neutral loss of isocyanic acid is observed in the CID 
spectrum, saETD of the parent ion is performed, improving the identification and 
localisation of the modification site [310]. 
 
 
Figure 2.3 Schematic representation of the neutral loss of isocyanic acid (HNCO) (43 Da) from 
citrullinated peptides by CID. 
 
2.12.3. Solutions 
 Reducing solution: 10 mM DTT in 100 mM ammonium bicarbonate (ABC) 
 Alkylating solution: 55 mM iodoacetamide (IAM) in 100 mM ABC 
 Digestion solution 1: 10 mM ABC, 10% (v/v) ACN 
 Digestion solution 2: 100 mM Tris-HCl 
 Extraction buffer: 5% (v/v) formic acid/ACN (1:2 ratio) 
2.12.4. Protocol: in-gel protein digestion for mass spectrometry analysis 
Proteins separated on gels were stained with either CBB R250 or CBB G250 (as 
previously described in sections 2.8 and 2.11) and the selected bands excised, 
destained and dehydrated prior to proteolytic digestion using standard protocols [307]. 
Briefly, gel pieces were washed twice with 100 mM ABC/100% (v/v) ACN (1:1 ratio) for 
30 minutes with agitation. Washed gel pieces were incubated with 100% (v/v) ACN for 
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10 minutes at RT. Supernatants were discarded and gel pieces were reduced with 
reducing solution for 30 minutes at 56°C. Reducing solution was discarded and gel 
pieces incubated with 100% (v/v) ACN for 10 minutes. Subsequently, supernatants 
were discarded and gel pieces alkylated with alkylating solution for 30 minutes at RT. 
Alkylating solution was discarded and gel pieces incubated with 100% (v/v) ACN for 10 
minutes. Reduced and alkylated gel pieces were enzymatically digested with 30 µL of 
trypsin solution (13 ng/mL) solubilised in digestion solution 1 or α-chymotrypsin (13 
ng/mL) solubilised in digestion solution 2 and incubated for 2 hours on ice. Following, 
20 µL of 100 mM ABC was added to activate the enzymes and samples were 
incubated overnight at 37⁰ C. The digests were extracted from the gel pieces by 
incubating with 100 µL extraction buffer for 15 minutes at 37⁰ C. Supernatants were 
dried in a centrifugal concentrator for 1–2 hours and the precipitate resuspended in 20 
µL of 0.5% (v/v) trifluoroacetic acid (TFA). Peptides were desalted and concentrated 
using ZipTip® pipette tips (Merck Millipore Ltd., Watford, UK) according with the 
manufacturer’s instructions. Briefly, the tips were sequentially washed with 20 µL ACN, 
2 x 0.1% (v/v) TFA, ACN/0.1% (v/v) TFA (1:1 ratio) and 2 x 0.1% (v/v) TFA. Samples 
were then aspirated with the tips (15–20 times) and after the tips were washed twice 
with 20 µL 0.1% (v/v) TFA. Finally, the peptides were eluted with 20 µL ACN/0.1% (v/v) 
TFA (1:1 ratio), dried in a vacuum centrifuge and stored at -20⁰ C for further MS 
analysis. 
2.12.5. Protocol: analysis of protein digests by LC-CID-saETD-MS/MS 
Digested peptides were resuspended in 10 µL 0.1% (v/v) formic acid prior to LC-MS 
analysis. Peptides were separated and analysed using a Dionex Ultimate 3000 HPLC 
system (Sunnyvale, USA) and a LTQ-Orbitrap Velos ETD mass spectrometer (Thermo 
Fisher Scientific lnc., Loughborough, UK) as described previously [310]. This work was 
performed in collaboration with Dr Andrew Creese, Advanced Mass Spectrometry 
Facility, School of Biosciences, University of Birmingham. 
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Samples (5 µL) were loaded onto a 75 µm (internal diameter) Acclaim 
PepMap100 (LC Packings, Sunnyvale, USA) C18 column (length 10 cm) and 
separated over a 30 minute gradient from 3.2% to 44% acetonitrile [0.1% (v/v) formic 
acid]. Peptides were infused by use of an Advion Triversa Nanomate (Ithaca, USA) ESI 
source directly into a Thermo Fisher Scientific lnc. (Loughborough, UK) LTQ-Orbitrap 
Velos ETD mass spectrometer (Bremen, Germany), at a flow rate of 350 nLmin−1, 
applied at a voltage of 1.7 keV. The mass spectrometer alternated between a full 
Fourier transform mass spectrometry (FTMS) scan (m/z 380–1600) and subsequent 
MS/MS scan(s) of the most abundant precursor ions. Survey scans were acquired in 
the Orbitrap with a resolution of 60,000 at m/z 400. Precursor ions were isolated and 
subjected to CID in the linear ion trap. Isolation width was 2 Th. Automatic gain control 
(AGC) was used to accumulate sufficient precursor ions (target value 1 x 105 charges, 
maximum fill time 25 ms). CID was performed with helium gas at a normalised collision 
energy of 35%. Parent ions were activated for 10 ms. Dynamic exclusion was used (60 
seconds exclusion window). If one of the three most abundant fragment ions in the CID 
mass spectrum corresponded to a neutral loss of 43 Da (isocyanic acid) from the 
precursor peptide, saETD of the precursor ion was triggered. saETD was performed in 
the ion trap and detected in the Orbitrap with a resolution of 7500 at m/z 400. 
Precursor ions were isolated in the ion trap with an isolation width of 3 Th. AGC target 
value was 2 x 105 charges, maximum fill time 1000 ms with 2 microscans co-added per 
mass spectrum. saETD was performed for 130 ms with a normalised supplemental 
activation energy of 25%. 
Data were analysed by Xcalibur 2.1 software. Data from the samples containing 
the singly citrullinated peptides were searched against the IPI human database (v3.66, 
containing 86,850 sequences) added using the SEQUEST algorithm within the 
Proteome Discoverer 1.0 SP1 software package (Thermo Fisher Scientific lnc., 
Loughborough, UK). Mono-isotopic precursor and fragment ions were searched with a 
mass tolerance of 5 ppm (precursor) and 0.1 Da (fragment) for CID and 0.02 Da for 
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saETD. Proteome Discoverer separated the CID and ETD data prior to searches. For 
CID data, b and y ions were considered. For saETD data, c and z ions were 
considered. Carboxymethylation of cysteine was specified as a fixed modification and 
phosphorylation (serine, threonine and tyrosine), oxidation (methionine), acetylation 
(lysine), deamidation (asparagine and glutamine) and citrullination (arginine) were set 
as variable modifications in the search. The maximum number of missed cleavages 
allowed was 2. 
The results were filtered using XCorr versus charge state (2+ ions with a score 
less than 2 were rejected, 3+ ions with scores <2.25 were rejected and 4+ ions with 
scores <2.5 were rejected). XCorr is a measure of how close an experimental MS/MS 
spectrum is to the theoretical MS/MS spectrum. Higher scores equate to greater 
confidence in a peptide match. XCorr values were calculated by Proteome Discoverer 
1.0 SP1 software package (Thermo Fisher Scientific lnc., Loughborough, UK). 
 
2.13. Membrane proteins extraction  
2.13.1. Reagents 
Mem-PER Plus membrane protein extraction kit was obtained from Pierce (Thermo 
Fisher Scientific lnc., Loughborough, UK).  
2.13.2. Background 
MP are key components of biological membranes, being involved in processes such as 
cell signalling, molecule and ion transport and cell adhesion [12]. To study the effects 
of PAD enzymes on MP, MP were isolated from PBMC after treatment with PAD 
enzymes and activation with anti-CD3/anti-CD28 antibodies. 
 The Mem-PER Plus membrane protein extraction kit uses a mild detergent-
based selective extraction protocol for the separation between cytosolic and membrane 
proteins. The cells are first permeabilised with a mild detergent, allowing soluble 
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cytosolic proteins to be released. After, a second detergent is used to solubilise the 
MP. 
2.13.3. Protocol 
Jurkat E6.1 T cells (5 x 106) or PBMC (5 x 105) were harvested by centrifugation at 300 
x g for 5 minutes and washed twice with cell wash solution. Washed cells were 
resuspended in 0.75 mL of permeabilisation buffer (with 1% protease inhibitor cocktail) 
and incubated 10 minutes at 4⁰ C with constant mixing. The permeabilised cells were 
centrifuged for 15 minutes at 16,000 x g. Supernatant containing cytosolic proteins 
(CP) was collected and the pellet resuspended with 0.5 mL of solubilisation buffer (with 
1% protease inhibitor cocktail) and incubated 1 hour at 4⁰ C with constant mixing. The 
solubilised MP were centrifuged for 15 minutes at 16,000 x g and stored at -80⁰ C for 
further analysis. 
2.13.4. Membrane proteins extraction validation 
To validate the efficacy of MP extraction 5 x 106 Jurkat E6.1 T cells were harvested and 
CP and MP fractions isolated according with the protocol described above (section 
2.13.3). Fractions were dialysed against 75 mM ACA, 50 mM Bis-Tris pH 7.0 as 
outlined in section 2.11 and analysed by immunoblotting with antibodies against CD3 
and NF-κB p65. Briefly, 15 µg of CP or MP were separated by SDS-PAGE on an 11% 
gel and electro transferred to a PVDF membrane. After, the membrane was blocked 
with 3% (w/v) BSA in TTBS overnight at RT and probed for CD3 or NF-κB with specific 
antibodies diluted 1:1000 in blocking solution for 2 hours at RT. After a second 
incubation with goat anti-rabbit antibody (1:5000 in blocking solution), the signal was 
developed with ECL reagent and visualised in a G:BOX Chemi HR 1.4 imaging system 
and GeneTools 4.03 image analysis software (Syngene, Cambridge, UK). The 
immunoblot on figure 2.4 validates the efficiency of the separation between CP and 
MP, since CD3 was detected in the MP fraction and the p65 subunit of NF-κB was 
detected in the CP fraction.  
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Figure 2.4 Validation of CP and MP fractioning using Mem-PER Plus membrane protein extraction 
kit. CP and MP were isolated from 5 x 106 Jurkat E6.1 T cells and dialysed against 75 mM ACA, 50 mM 
Bis-Tris pH 7.0. Immunoblotting was performed after running 15 µg protein in an 11% gel and transferring 
to a PVDF membrane. Anti-CD3 and anti-NF-κB p65 were diluted 1:1000 in blocking solution and 
incubated with the membrane for 2 hours at RT. Proteins were detected after incubation with goat anti-
rabbit antibody (1:5000 in blocking solution) and ECL reagent. The gels and immunoblots are 
representative of two independent experiments. 
 
2.14. Determination of cell viability using CellTiter-Blue® cell viability 
assay 
2.14.1. Reagents 
CellTiter-Blue® cell viability assay was obtained from Promega Co. (Southampton, 
UK). 
2.14.2. Background 
The CellTiter-Blue® assay relies on the ability of living cells to convert resazurin, a 
redox dye, into resorufin. Nonviable cells, due to the loss of metabolic capacity, are not 
able to produce resorufin. The reduction of resazurin to resorufin is responsible for a 
shift in the visible light absorbance properties of the CellTiter-Blue® reagent, which can 
be monitored by spectrophotometry (Figure 2.5).  
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Figure 2.5 Schematic representation of the metabolic conversion of resazurin into resorufin in live cells. 
 
2.14.3. Protocol 
After treating Jurkat E6.1 T cells and PBMC, cell viability was determined with 
CellTiter-Blue® cell viability assay, according with the manufacturer’s instructions. 
Briefly, 20 μL of CellTiter-Blue® reagent were added to 100 μL of each cell condition, 
into a 96-well plate, in duplicate, and shaken for 10 seconds. After overnight incubation 
at 37⁰ C in 5% CO2 the optical density at 490 nm of each well was measured using a 
spectrophotometric plate reader (BioTek Instruments Inc., Swindon, UK). Cell viability 
was calculated using the following equation, where control corresponds to the control 
condition: 
OD490nm sample 
OD490nm control ×100 
Equation 1 Determination of cell viability (%) using CellTiter-Blue® cell viability assay. 
 
2.15. Determination of cell viability using trypan blue exclusion assay  
2.15.1. Background 
Trypan blue is a vital stain that dyes cells with damaged cellular membranes. The 
trypan blue exclusion method is based on the principle that live cells have intact 
membranes and, therefore, exclude the dye, whereas dead cells, with compromised 
membranes, are not able to do that [313]. 
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2.15.2. Protocol 
Viable and nonviable cells were counted on a haemocytometer after performing a 1:1 
dilution with 0.4% trypan blue solution. Cell viability was determined using the following 
equation: 
 
 
Equation 2 Determination of cell viability (%) using trypan blue exclusion assay. 
 
2.16. Cytokine quantification by sandwich enzyme linked immunosorbent 
assay (ELISA) 
2.16.1. Reagents 
BSA was obtained from Thermo Fisher Scientific lnc. (Loughborough, UK). Human IL-2 
ELISA development kit was obtained from Peprotech EC Ltd. (London, UK). Human IL-
6 and IL-8 ELISA kits were obtained from R&D systems (Abingdon, UK).  
2.16.2. Background 
Sandwich ELISA, or ELISA, is a detection and quantification plate-based method that 
can be used with peptides, proteins and antibodies. By immobilizing specific antigens 
between two antibodies it is possible to detect them in a complex mixture. Typically the 
second antibody is conjugated with an enzyme or fluorophore that allows signal 
detection. In Peprotech ELISA development kits, the detection antibody is conjugated 
with biotin. By adding avidin conjugated with HRP and HRP chromogenic substrate (as 
o-phenylenediamine dihydrochloride – OPD – or 3,3’,5,5’-Tetramethylbenzidine – TMB) 
in consequent steps, the amount of antigen in the plate can be detected and 
interpolated from a standard curve. 
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2.16.3. Protocol 
Secretion of IL-2 by cells was quantified by ELISA using human IL-2 development kit 
(Peprotech EC Ltd., London, UK), according to the manufacturer’s instructions. Briefly, 
a monoclonal capture antibody (2 µg/mL in PBS) was coated onto a NUNC MaxiSorp™ 
96-well plate overnight at RT. The following day, the wells were blocked with 1% (w/v) 
BSA in PBS for 1 hour at RT and triplicates of standards or samples were incubated 2 
hours at RT. After, the plate was incubated for 2 hours with a biotinylated polyclonal 
detection antibody (6.25 µg/mL in 0.1% BSA in 0.05% Tween-20 in PBS) and 30 
minutes with 1:2000 Avidin-HRP (protected from light). Four washes with 0.05% (v/v) 
Tween-20 in PBS were performed between each incubation step. The amount of 
bound avidin was assessed using SIGMAFAST™ OPD and the reaction stopped with 2 
M sulphuric acid (H2SO4). Absorbance of each well at 490 nm was measured in a plate 
spectrophotometer (BioTek Instruments Inc., Swindon, UK) and concentration of 
cytokine interpolated from a standard curve (0.06 to 4 ng/mL). 
 IL-6 and IL-8 levels in the plasma of HC and PID patients were quantified with 
IL-6 and IL-8 Quantikine ELISA kits (R&D systems, Abingdon, UK), respectively, 
according with the manufacturer’s instructions. Briefly, duplicates of standards or 
samples were added to a monoclonal antibody specific for IL-6 or IL-8, respectively, 
pre-coated 96-well plate and incubated for 2 hours at RT. After, the plate was 
incubated with human IL-6 or IL-8 conjugate, respectively, for 1 hour at RT. Four 
washes with wash buffer were performed between incubation steps. The plate was 
then incubated with substrate solution for 30 minutes at RT and protected from light 
and the colorimetric reaction stopped with stop solution. Absorbance of each well at 
450 nm was measured in a plate spectrophotometer (BioTek Instruments Inc., 
Swindon, UK) and concentration of the cytokines interpolated from a standard curve 
(IL-6: 3.1 to 300 pg/mL; IL-8: 31.3 to 2000 pg/mL). Correction of wavelength was 
performed at 570 nm. 
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2.17. Analysis of membrane protein expression by flow cytometry 
2.17.1. Reagents 
FC antibodies and respective isotype controls were obtained from Abcam plc. 
(Cambridge, UK), eBioscience Ltd. (Hatfield, UK) and AbD Serotec® (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK) according with table 2.6.  
 
Table 2.6 Details of the antibodies use to detect membrane protein expression by flow cytometry.  
Antigen Description 
Product 
code 
Company 
Volume per 1 x 106 
cells (µL) 
CD25 
Mouse monoclonal [BC96] 
conjugated with APC  
ab134477 Abcam plc. 5 
CD38 
Mouse monoclonal [HB7] conjugated 
with FITC 
11-0388 eBioscience Ltd.  5 
CD4 
Mouse monoclonal [EDU-2] 
conjugated with PE 
ab1155 Abcam plc.  10 
CD8 
Mouse monoclonal [RPA-T8] 
conjugated with PE-Cy5.5  
35-0088 eBioscience Ltd.  5 
IC 
Mouse IgG1 isotype control 
conjugated with RPE 
MCA928PE AbD Serotec® 10 
IC 
Mouse F(ab')2 IgG1 [15H6] 
conjugated with APC 
ab37391 Abcam plc. 10 
IC 
Mouse IgG1 K isotype control 
conjugated with FITC 
11-4714 eBioscience Ltd. 5 
IC 
Mouse IgG1 K isotype control 
conjugated with PE-Cy5.5 
35-4714 eBioscience Ltd. 10 
APC – allophycocyanin; CD – cluster of differentiation; Cy – cyanine; FITC – fluorescein isothiocyanate; IC 
– isotype control; PE – phycoerithirn. 
 
2.17.2. Background 
FC is a laser-based technique that allows to measure size, granularity and 
fluorescence intensity of cells. A flow cytometer is composed by fluidics, optics and 
electronics systems. The fluidics system is responsible for the transport of single 
particles such as cells, on a stream of fluid to the laser beam. The optics system 
consists of lasers that illuminate the particles on the stream and of optical filters that 
direct the light signals to the detectors. As particles pass through the laser beam, light 
is scattered according to the physical properties of the particle. Forward-scatter light 
(FSC) depends on the size of the particle while side-scattered light (SSC) is 
proportional to cell granularity or internal complexity. Additionally, a flow cytometer can 
be used to detect fluorescence emitted from fluorescent dyes or fluorophores that have 
102 
 
been excited by the lasers. Using antibodies conjugated with fluorophores allows the 
detection and quantification of specific antigens on cells. Finally, the electronics system 
is responsible for the conversion of light signals into electronic signals that can be 
processed and analysed by a computer. Here, antibodies conjugated with specific 
fluorophores were used to analyse the expression of specific markers on the surface of 
the studied cells [314]. 
2.17.3. Protocol 
After the treatments, cells in RPMI complete medium were collected into 1.5 mL tubes 
and incubated on ice for 15 minutes. Samples were then incubated with a specific 
antibody conjugated with a fluorophore or a negative isotype control according with 
table 2.7, for 30 minutes on ice and analysed on a Cytomics FC 500 and CXP® 
software (Beckman Coulter Inc., London, UK). Data were analysed using Flowing 
software v 2.5. MFI represents median fluorescence intensity. Median is a more robust 
statistic measure than the mean, since it is less influenced by skew or outliers. Details 
of the antibodies used are described on table 2.7. 
 
Table 2.7 Fluorescence details of the antibodies used for flow cytometry.  
 
 
 
 
 
APC – allophycocyanin; CD – cluster of differentiation; Cy – cyanine; FITC – fluorescein isothiocyanate; FL 
– fluorescence; PE – phycoerithirn. 
 
Antigen Fluorophore Excitation (nm) Emission (nm) Laser 
CD25 APC 645 660 FL4 
CD38 FITC 488 517 FL1 
CD4 PE 488 575 FL2 
CD8 PE-Cy5.5 488 690 FL4 
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2.18. Quantification of reduced glutathione in plasma by the recycling 
assay 
2.18.1. Background 
GSH is the major antioxidant system in living organisms and is present in cells mainly 
on its reduced form. GSH is a tripeptide (Ȗ-glutamylcysteinylglycine) and its oxidation 
leads to the formation of GSSG. The recycling assay for the detection of GSH involves 
the oxidation of GSH to GSSG by 5’, 5’-dithio-bis(2-nitrobenzoic acid) (DTNB), 
generating 2-nitro-5-thiobenzoic acid (TNB) that can be detected by spectrophotometry 
at 412 nm. Generated GSSG can be recycled to GSH by GSR in the presence of 
NADPH, being available for further oxidation by DTNB (Figure 2.6). The colour 
development will be proportional to the amount of glutathione present in the samples 
and can be interpolated from a standard curve.  
 
 
Figure 2.6 Schematic representation of the recycling assay for the quantification of reduced 
glutathione. DTNB – 5,5'-dithiobis-(2-nitrobenzoic acid); GSH – reduced glutathione; GSSG – oxidised 
glutathione; GSR – glutathione reductase; TNB – trinitrobenzene. 
2.18.2. Solutions 
 Stock buffer: 
o 125 mM sodium phosphate 
o 6.3 mM disodium EDTA (monobasic anhydrous) 
o pH 7.5 
 Daily buffer: 
o 3 mg NADPH in 10 mL stock buffer 
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 SSA solution: 
o 1 g SSA in 1 mL bi-distilled water 
2.18.3. Protocol 
Plasma samples stored with 1% SSA were analysed for GSH content by the recycling 
assay. Briefly, 25 μL plasma and standards (0–80 μM) were loaded into a 96-well plate 
in triplicate and incubated with 150 μL daily buffer and 50 μL of 6 mM DTNB for 5 
minutes. Immediately after, 25 μL GSR (4 U/mL in stock buffer) were added and the 
absorbance at 410 nm was measured in a microplate reader (BioTek Instruments Inc., 
Swindon, UK) at 5 time points. GSH concentration was interpolated from the standard 
curve. 
 
2.19. Antibody based assay for peptidylarginine deiminase activity 
(ABAP) 
2.19.1. Reagents 
ABAP kit assay was obtained from Modiquest Research B. V. (Oss, Netherlands). BSA 
was obtained from Thermo Fisher Scientific lnc. (Loughborough, UK). 
2.19.2. Background 
ABAP is a commercial 96-well plate ELISA based assay for determination of PAD 
enzyme activity. The wells of the plate were coated with peptides containing arginine. 
As positive control, well H of each strip was coated with a deiminated arginine-
containing peptide. When solutions containing PAD enzymes are added to the plate, 
the arginines coated to the plate are deiminated and can then be detected by a 
monoclonal antibody specific for deiminated arginine. Subsequently, a second HRP-
labelled polyclonal anti-mouse immunoglobulin antibody is added to the plate, followed 
by HRP substrate what allows colour development to occur. Optical density is directly 
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proportional to the amount of arginines that have been deiminated and can be 
measured by spectrophotometry [315]. 
2.19.3. Protocol 
PAD enzyme activity was measured using the ABAP assay (Modiquest Research B. 
V., Oss, Netherlands) according with the manufacturer’s instructions. Briefly, 
deimination buffer (100 µL) was incubated in the ABAP plate for 30 minutes at 37⁰ C. 
After incubation, the ABAP plate was emptied by inversion and placed on ice. Samples 
and standards (prepared in deamination buffer) were then added to the ABAP plate 
and incubated for 1 hour and 15 minutes at 37⁰ C in a humidified chamber. After five 
washes with wash buffer [0.05% (v/v) Tween-20 in PBS], MQR mouse anti-deiminated 
arginine antibody [1:1000 in 1% (w/v) BSA in wash buffer] was added and the ABAP 
plate was incubated for 1 hour at 37⁰ C in a humidified chamber. Next, the ABAP plate 
was washed five times with wash buffer, HRP-labelled anti-mouse Ig antibody [1:2000 
in 1% (w/v) BSA in wash buffer] was added and the plate was incubated for 1 hour at 
37⁰ C in a humidified chamber. After five washes with wash buffer and three washes 
with PBS, OPD reagent was added to the ABAP plate for colour development and the 
reaction was stopped with 2 M H2SO4. Absorbance of each well at 450 nm was 
measured in a plate spectrophotometer (BioTek Instruments Inc., Swindon, UK) and 
PAD enzyme activity interpolated from a standard curve. 
 
2.20. Determination of endotoxin content by limulus amebocyte lysate 
(LAL) assay 
2.20.1. Reagents 
Pierce™ LAL Chromogenic Endotoxin Quantitation Kit was obtained from Thermo 
Fisher Scientific Inc. (Loughborough, UK). Acetic acid was from Fisher chemicals 
(Thermo Fisher Scientific Inc., Loughborough, UK). 
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2.20.2. Background 
Endotoxins are lipopolysaccharides naturally present in the outer cell membrane of 
Gram-negative bacteria that can influence growth and functionality of a different range 
of cells. LAL assay allows the quantification of Gram-negative bacterial endotoxins in a 
chromogenic detection method based on the ability of endotoxins to catalyse the 
activation of a proenzyme. The activated proenzyme can then catalyse the removal of 
coloured p-nitroaniline (pNA) from a colourless substrate (Ac-lle-Glu-Ala-Arg-pNA). The 
amount of pNA released can be measured by spectrophotometry (405–410 nm) and 
the amount of endotoxin interpolated from a standard curve [316].  
PAD enzymes used in this work were recombinant produced in bacterial cells, 
so it was vital to test the presence of endotoxin in PAD enzyme samples.  
2.20.3. Protocol 
Endotoxin levels in PAD enzymes were determined using LAL Chromogenic Endotoxin 
Quantitation Kit (Pierce, Thermo Fisher Scientific Inc., Loughborough, UK) according 
with the manufacturer’s instructions. Briefly, a 96-well plate was equilibrated for 10 
minutes at 37ºC. Duplicates of standards and samples (50 µL) were dispensed into the 
plate and incubated for 5 minutes at 37ºC. After, 50 µL LAL was added, the plate was 
shaken for 10 seconds and then incubated at 37ºC for 10 minutes. After exactly 10 
minutes, 100 µL of substrate solution was added, then the plate was shaken for 10 
seconds and incubated at 37ºC for 6 minutes. The reaction was stopped by adding 50 
µL of 25% acetic acid, the absorbance at 405–410 nm was read on a plate reader 
(BioTek Instruments Inc., Swindon, UK) and the concentration of endotoxin in EU/mL 
was interpolated from a standard curve. 
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2.21. Gene expression analysis 
2.21.1. Reagents 
miRNeasy Micro Kit, mRNeasy Plus Mini Kit, QuantiTect® primers and trizol lysis 
solution were obtained from Qiagen Ltd. (Manchester, UK). qScriptTM complementary 
DNA (cDNA) Synthesis Kit and PerfeCTa® SYBR® Green SuperMix were obtained 
from Quanta Biosciences (Gaithersburg, MD, USA). Chloroform and ethanol were from 
Fisher chemicals (Thermo Fisher Scientific lnc., Loughborough, UK). Nuclease free-
water was obtained from Thermo Fisher Scientific lnc. (Loughborough, UK). 
2.21.2. Background 
Studying the expression of mRNA coding for particular genes is a pivotal area in 
molecular biology. The detection of changes in the expression of a specific gene in 
response to specific treatments allows collecting important information about cellular 
functions [317]. Two methods were used here to quantify mRNA and, consequently, 
obtain information about gene expression: 1) microarray and 2) real time – quantitative 
polymerase chain reaction (RT-QPCR).  
Isolation of RNA from the cells is a critical step for both microarray and RT-
QPCR. Qiagen RNA isolation kits supply lysis buffer containing guanidine thiocyanate. 
This chemical disrupts non-covalent interactions leading to protein denaturation. 
Consequently, ribonucleases (RNase) that possibly degrade RNA will be inactivated. 
After this, lysed solutions are passed through a silica gel membrane where nucleic 
acids are retained and other contaminants are removed. In a final step, nucleic acids 
are eluted from the membrane and RNA concentration and integrity can be determined 
by a bioanalyser or a spectrophotometer. Both techniques were used here. The 
Agilent® 2100 Bioanalyzer™ instrument (Agilent Technologies LDA UK Ltd., Stockport, 
UK) was used at University of Birmingham prior to microarray experiments. This 
equipment allows evaluation of the RNA concentration and extent of degradation 
through a combination of microfluidics, capillary electrophoresis and fluorescent 
108 
 
labelling. To spectrophotometrically quantify mRNA, a NanoDrop 1000 (Thermo Fisher 
Scientific Inc., Loughborough, UK) analyser was used. This instrument relies on the 
principles of light absorption and has the advantage of using a small volume of sample 
(microliter range). Nucleic acids, proteins and other contaminants have specific 
absorbance maxima at 260, 280 and 230, respectively. The ratio of absorbances at 
these wavelengths is commonly used to infer the purity of the nucleic acid extraction. 
A260/A280 and A260/A230 ratios of approximately 2 are considered as “pure” RNA 
[318]. 
mRNA expression profiling using microarrays allows to analyse the expression 
of thousands of genes in a quick and efficient manner. This technique is based on the 
ability of complementary nucleic acid sequences in two different DNA strands to 
specifically pair with each other. A typical microarray experiment involves the isolation 
of RNA, its conversion to complementary deoxyribonucleic acid (cDNA) by reverse 
transcription and consequent hybridisation on a solid support where cDNA probes had 
been pre-immobilised. Hybridisation extent can be fluorescent-determined using 
labelled target sequences and fluorescence intensity can be used to assess the 
expression of a particular gene.  
RT-QPCR technique is based on the same principle as microarray 
(hybridisation) but primers for targeted genes are used individually. This is a sensitive 
and robust method to evaluate gene expression and is particularly useful when genes 
of interest have been identified (for instance by microarray). RT-QPCR principle is 
based on two stages. The first involves the reverse transcription of mRNA into cDNA. 
In the second stage, the cDNA template is amplified by QPCR. The heating of the 
sample leads to the denaturation of the original double stranded cDNA. Following, new 
DNA is synthesised in the presence of DNA polymerase, deoxyribonucleoside 
triphosphates (dNTP) and specific PCR primers. Repeating these steps in a cycler 
equipment through temperatures that allow denaturation, annealing and synthesis, 
leads to exponential amplification of the initial product. Analysing the fluorescent signal 
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resultant from the introduction of SYBR Green, a DNA-intercalating dye, into the 
reaction mixture allows evaluating the PCR product synthesis [319]. Quantitative gene 
expression can be analysed by absolute or relative quantification. In absolute 
quantification the copy number of the gene is interpolated from a standard curve. In 
relative quantification the copy number of the gene of interest is relative to a calibrator 
or internal control (housekeeper) gene. The relative quantification method adopted 
here was the comparative threshold cycle (CT) or 2(-ΔΔCT) method. In this method, the 
difference between the CT values (ΔCT) of the gene of interest and the housekeeping 
gene is first calculated for each experimental sample. Then, the difference between the 
ΔCT values (ΔΔCT) of the experimental and control samples is calculated. The fold-
change in the expression of the gene of interest is then equivalent to 2^(-ΔΔCT) [320, 
321]. 
2.21.3. Protocol: RNA extraction 
Total RNA was isolated from 5 x 105 PBMC using RNase-free plasticware and the 
miRNeasy Micro Kit according with the manufacturer’s instructions. Briefly, 5 x 105 
PBMC were harvested by centrifugation at 300 x g for 5 minutes and lysed with 700 μL 
QIAzol Lysis Reagent. The homogenate was then mixed with 140 μL chloroform and 
the phases separated by centrifugation for 15 minutes at 12,000 x g at 4⁰ C. The upper 
aqueous phase was mixed with 1.5 volumes of 100% ethanol in a new collection tube 
and transferred into an RNeasy MinElute spin column. The column was then washed 
with 700 µL buffer RWT, 500 µL buffer RPE and 80% ethanol. RNA was eluted from 
the RNeasy MinElute spin column by adding 14 μL of RNase-free water and 
centrifuging for 1 minute at full speed. 
Total RNA was isolated from an average of 1.1 x 106 CD4 and CD8 T cells 
using RNase-free plasticware and the RNeasy Plus Mini Kit according to the 
manufacturer’s instructions. Briefly, after isolation of cells, they were counted, collected 
by centrifugation at 300 x g for 5 minutes and lysed with 350 µL of buffer RLT Plus with 
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1% (v/v) -ME. The lysate was then transferred to a QIAshredder spin column and 
centrifuged for 2 minutes at maximum speed. The homogenised lysate was transferred 
to a gDNA Eliminator spin column and centrifuged for 30 seconds at 8000 x g. The 
flow-through was mixed with 1 volume of 70% ethanol and transferred to an RNeasy 
spin column that was then washed with 700 µL buffer RW1 and twice with 500 µL 
buffer RPE. RNA was eluted from the RNeasy membrane by adding 30–50 μL of 
RNase-free water and centrifuging for 1 minute at 8000 x g.  
Total RNA quality and quantity were assessed spectrophotometrically using 
NanoDrop 1000 (Thermo Fisher Scientific Inc., Loughborough, UK). The ratio of 
A260/A280 of approximately 2 and A260/A230 between 2 and 2.2 were considered as 
“pure” RNA. 
2.21.4. Protocol: cDNA synthesis 
cDNA was synthesised according with the manufacturer’s instructions (Quanta 
Biosciences Inc., Gaithersburg, MD, USA). Briefly, RNA samples were mixed with 
water to a final concentration of 100 ng (in 20 µL) in PCR tubes and cDNA master mix 
was prepared according with the number of reactions + 1 [for 1 reaction: 4 µL qScript 
Reaction Mix (5x), 1 µL qScript RT]. RNA samples or water as control (20 µL) were 
mixed with 5 µL cDNA master mix and reversed transcribed in a thermal cycler with the 
following program: 1 cycle – 22⁰ C, 5 minutes; 1 cycle – 85⁰ C, 5 minutes; 4⁰ C, 
hold. After completion of cDNA synthesis, samples were stored at -20⁰ C. 
2.21.5. Protocol: RT-QPCR 
cDNA products were diluted 1/5 and reaction mix was prepared according with the 
number of reactions + 3 (for 1 reaction: 5.5 µL nuclease-free water, 5.0 µL specific 
primer, 12.5 µL PerfeCTa® SYBR® Green SuperMix). cDNA samples (2 µL) were 
dispensed into PCR plate wells and 23 µL of reaction mix added. A negative control 
with 2 µL nuclease-free water instead of cDNA was also included. RT-QPCR was 
performed in an Agilent Mx3000PTM QPCR System (Agilent Technologies LDA UK Ltd, 
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Stockport, UK) using the MxPro QPCR software with the following protocol: 1 cycle – 
95⁰ C, 2 minutes; 45 cycles – 95⁰ C, 10 sec + 60⁰ C, 30 sec; 1 cycle – 60⁰ C, 30 sec + 
95⁰ C, 30 sec. 
The results obtained were then analysed using the comparative CT method and 
the mRNA levels were normalised to 18S or YWHAZ mRNA. 
2.21.6. Protocol: microarray  
RNA quantity was validated using an Agilent® 2100 Bioanalyzer™ instrument (Agilent 
Technologies LDA UK Ltd, Stockport, UK) and microarray experiment was performed 
at University of Birmingham according with the manufacturer’s instructions. Fluorescent 
array images were collected using Agilent DNA microarray scanner and microarray 
data was analysed using GeneSpring GX software (Agilent Technologies LDA UK Ltd, 
Stockport, UK). Shift to 75.0 percentile was used as normalisation and median of all 
samples was applied as baseline transformation. Venn diagrams were used to identify 
the up- and down-regulated genes against an experimental control, based on entities 
with a p-value equal or lesser than 0.05 and a fold-change equal or higher than two.  
 
2.22. L-lactate quantification 
2.22.1. Reagents 
The L-lactate assay kit was purchased from Abcam plc. (Cambridge, UK).  
2.22.2. Background 
Lactate is a by-product of glycolysis, and is a metabolic indicator of cell metabolic 
activity. 
In the L-lactate assay kit from Abcam plc. (Cambridge, UK) the levels of L-
lactate are detected by the oxidation of this compound into pyruvate that can then 
interact with water soluble tetrazolium salts to produce formazan. Formazan can then 
be spectrophotometrically detected (Figure 2.7). 
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Figure 2.7 Schematic representation of the detection of L-lactate by the L-lactate assay kit from Abcam 
plc.. NAD+ – nicotinamide adenine dinucleotide ion; NADH – nicotinamide adenine dinucleotide. 
 
2.22.3. Protocol 
L-lactate levels in the supernatant of PBMC pre-treated with PAD enzymes and 
activated with anti-CD3/anti-CD28 antibodies were quantified using a L-lactate assay 
kit (Abcam plc., Cambridge, UK) according with the manufacturer’s instructions. Briefly, 
cells were harvested by centrifugation at 300 x g for 5 minutes and the supernatant 
collected into a new tube and deproteinised. For deproteinisation, samples (200 µL) 
were mixed with 4 M perchloric acid (PCA) to a final concentration of 1 M and 
incubated on ice for 5 minutes. After centrifuging at 13,000 x g for 2 minutes at 4⁰ C, 
supernatants were transferred to a fresh tube and the excess of PCA was precipitated 
with 200 µL of ice-cold 2 M potassium hydroxide (KOH). The pH of the samples was 
then adjusted to 6.5–8 with 0.1 M KOH and the supernatants were collected after 
centrifugation at 13,000 x g for 15 minutes at 4⁰ C. Next, 50 µL of samples and 
standards (ranging from 0 to 10 nmol) were loaded in duplicates into the wells of a 96-
well plate and after preparing a master mix according to the number of samples + 1 (for 
1 reaction: 46 µL lactate assay buffer, 2 µL lactate probe and 2 µL lactate enzyme 
mix), 50 µL lactate reaction mix was added to the plate. Background sample wells 
(without lactate enzyme) were also included. The plate was incubated for 30 minutes at 
113 
 
RT, the absorbance was read at 450 nm in a microplate reader (BioTek Instruments 
Inc., Swindon, UK) and the concentration of L-lactate was interpolated from a standard 
curve. 
 
2.23. Statistical analysis 
Data obtained was analysed using GraphPad Prism (v6.02) and presented as mean ± 
standard error of the mean (SEM), unless otherwise specified. Experiments were 
performed in duplicate or triplicate. Comparison between two groups was performed 
using Mann-Whitney test. Comparison between three or more groups was performed 
using Kruskal-Wallis test followed by Dunn’s multiple comparison test or one-way 
ANOVA followed by Tukey’s multiple comparison test, according with non-parametric 
or parametric distribution of the data, respectively. Statistical significance was defined 
as * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001 and **** p-value < 0.0001. 
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Chapter 3  Methodological 
optimisation: analysing citrullination 
and isolating T cell membrane proteins 
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3.1. Preface 
This chapter describes the optimisation of a method to detect and identify citrullination 
modifications in human FNG, as a model protein. Proteomics techniques, such as, 
SDS-PAGE, 2D IEF/SDS-PAGE, 2D BN/SDS-PAGE and MS were used in this chapter 
to detect citrullination by PAD enzymes. Furthermore, methods were optimised for the 
separation of T cell MP by 2D BN/SDS-PAGE. The optimised methods have been 
applied in later chapters.  
116 
 
3.2. Introduction 
3.2.1. Fibrinogen 
FNG is a soluble 340 kDa glycoprotein [322]. Human FNG comprises of three pairs of 
non-identical polypeptide chains: Aα, Bȕ and Ȗ [323] (Figure 3.1), that are encoded by 
gene loci FGA, FGB and FGG, respectively, located in chromosome 4 [324]. The three-
dimensional structure of FNG is arranged in three main domains: two terminal D 
domains consisting of a triple-stranded array of α helical coiled coils and a central E 
domain which is stabilised by 29 disulphide bonds (Figure 3.1) [325]. FNG molecules 
show high variability resulting from alternative splicing [324], PTM (including 
phosphorylation, sulphation, glycosylation and hydroxylation), proteolytic degradation 
and polymorphic variation of Aα and Bȕ [323]. The predominant Aα, Bȕ and Ȗ chains 
contain 610 amino acids (70 kDa), 461 amino acids (56 kDa) and 411 amino acids (48 
kDa), respectively [323] (Figure 3.2). FNG is synthesised in the liver and is secreted 
into the blood stream, where it can be found at a concentration of 9 µM with a half-life 
of approximately 100 hours [323].  
 
 
Figure 3.1 Schematic representation of human fibrinogen (Protein data base – PDB – reference: 
3GHG). The crystal structure of human FNG, isolated from human blood plasma, was determined at 
approximately 3.3 Å resolution. Blue – α-chain; green – ȕ-chain; red – Ȗ-chain; yellow – carbohydrate 
ligand; grey – synthetic peptide knob; light green – calcium ion. 
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Figure 3.2 Human fibrinogen amino acid sequence. a – α-chain; b – ȕ-chain; c – Ȗ-chain. Residues highlighted in red indicate arginines available for citrullination. 
118 
 
Biologically, the main function of FNG is clot formation. Following vascular damage and 
blood leakage in the perivascular space, tissue factor (TF), a transmembrane 
glycoprotein of the perivascular tissue, is activated. TF associates with factor VII and 
activates factor X, directly or through the activation of factor IX. The activation of factor 
X mediates the cleavage of prothrombin into thrombin that can then act on fibrinogen. 
Thrombin releases fibrinopeptides A and B from the amino-terminal ends of Aα and Bȕ 
chains of FNG, respectively, leading to the conversion of FNG into fibrin monomers 
[323]. The fibrin clot is then formed by spontaneous polymerisation of fibrin monomers 
followed by intermolecular cross-linking catalysed by transglutaminase (factor XIIIa) 
(Figure 3.3) [326].  
 
 
Figure 3.3 Schematic representation of the coagulation cascade. The activated factor Xa converts 
prothrombin to thrombin. Thrombin then activates factor XIII to XIIIa and converts fibrinogen into fibrin 
monomers. Fibrin monomers associate spontaneously forming polymers that can then cross-link and form 
a clot. 
 
In addition to its role in coagulation, FNG is also involved in the regulation of cell 
adhesion, spreading, migration and proliferation [323], with particular emphasis in 
inflammatory processes. Inflammation and coagulation are activated by the same 
stimuli and occur in the same tissues and diseases [327]. FNG expression is regulated 
at the transcriptional level and is increased during inflammation which is induced by IL-
6, glucocorticoids and oncostatin M [323]. FNG has several interaction sites but their 
accessibility depends on the molecular state of FNG (native FNG versus fibrin and 
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fibrin polymers) [326]. FNG or its derivatives can interact with other haemostatic 
factors, with pro- and anti-fibrinolytic proteins and with extracellular matrix proteins and 
cellular receptors [328]. In the context of inflammation, the interaction of FNG with its 
integrin receptor promotes leukocyte adhesion to the vascular endothelium, infiltration 
into the affected site [329, 330] and chemotactic responses by monocytes and 
neutrophils [331-333]. Importantly, pro-inflammatory and pro-coagulation functions that 
result from FNG signalling are regulated through different domains and, consequently, 
do not restrict each other [334].  
3.2.2. Peptidylarginine deiminase enzymes and citrullination 
Citrullination, as described previously in section 1.3.1, is an enzymatic post-
translational modification mediated by PAD (EC 3.5.3.15.) enzyme. In humans, five 
isoforms of PAD enzymes (PAD1–4 and PAD6) have been identified on chromosome 
1p36. Citrullination is responsible for the conversion of peptidylarginine into 
peptidylcitrulline in a calcium dependent manner (Figure 1.7) [109]. This conversion 
results in the loss of positive charge in the protein, affecting the protein structure and 
leading to the formation of new motifs and the generation of neoepitopes [109, 335]. 
Physiologically, citrullination is essential since citrulline is a non-standard amino acid. 
PAD enzyme isoforms are differentially expressed in specific tissues and have discrete 
roles, however, they are highly conserved (70–95% identical amino acids). PAD1 
enzyme is mainly expressed in the epidermis and is involved in the flexibility of the 
keratin cytoskeleton [109, 277, 336, 337]. PAD2 enzyme is the most abundant isoform, 
being expressed in skeletal muscle, brain, spleen, secretory glands, macrophages and 
monocytes. In the brain, PAD2 enzyme is associated with the plasticity of the central 
nervous system. In macrophages, PAD2 enzyme citrullinates the intermediate filament 
vimentin, associating citrullination with apoptosis mechanisms [133]. PAD3 enzyme 
expression is restricted to hair follicles and is linked to the firmness of the tube that 
guide hair fibre growth. PAD4 enzyme is expressed by the cells of the hematopoietic 
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lineage and can be detected intracellularly and in the nucleus in different tissues. The 
PAD4 enzyme is involved in gene regulation; it has been implicated in cell apoptosis 
and negative feedback processes associated with histone functionality and p53 and 
oestrogen pathway regulation. The PAD6 enzyme is found in early embryos and 
ovaries and is associated with the reorganisation of egg cytoplasmic sheets during 
early embryo development [109, 277, 336]. The PAD5 enzyme was initially described 
as a new PAD enzyme isoform but was then confirmed to be the same as PAD4 
enzyme [336]. 
3.2.3. Citrullination in rheumatoid arthritis 
RA is an autoimmune disease characterised by chronic inflammation, oedema, 
augmented angiogenesis and extensive fibrin deposition in the synovial tissue. These 
processes lead to degeneration and impairment of the affected joints [338]. The 
presence of fibrin and fibrin degradation products in the joints and synovial fluid of 
patients with RA [338-341] suggests the importance of this molecule in the 
pathophysiology of RA. The role of FNG and its products in RA inflammation have 
been extensively documented in in vitro and in vivo studies [342-354].  
In addition to the local pro-inflammatory role of FNG and its derivatives in RA, 
antibodies against citrullinated FNG are also strong markers of RA. ACPA were first 
described in the context of RA by Schellekens G. and colleagues in 1998 [355]. 
Following the initial finding, many studies have shown the relevance and connection of 
these antibodies with RA. ACPA are highly specific for RA [356], can appear before the 
clinical onset of RA [186, 357, 358] and are correlated with the disease persistence 
and joint destruction observed [359, 360]. Additional to the presence of ACPA, 
isoforms 2 and 4 of the PAD enzyme were also found in the synovial membrane [187-
189, 361] and in synovial fluid cells [133] of RA patients. FNG is amongst the proteins 
found to be citrullinated and involved in the production of ACPA in RA [201, 211, 362, 
363]. Anti–citrullinated fibrinogen antibodies were also shown to induce the production 
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of TNF by macrophages, via co-ligation of Toll-like receptor 4 (TLR4) and Fc-Ȗ 
receptors, suggesting that citrullination potentiates the role of FNG as an endogenous 
innate immune ligand [358]. Furthermore, citrullination of fibrin α and ȕ chains was also 
detected in the synovium of RA patients [201, 202, 361, 364].  
3.2.4. T cell surface proteins 
Cell membranes are key elements to maintain cellular homeostasis within subcellular 
compartments and between the intra- and the extra-cellular environment. 
Approximately 50% of the cell surface membrane consists of proteins (MP) responsible 
for cell-cell contact, surface recognition, cytoskeleton contact, signalling, enzymatic 
activity and transport across the membrane functions [12]. These proteins at the cell 
membrane with exposed domains towards the extracellular space constitute the cell 
surfaceome [365]. In T cells, the immune response relies on MP as it requires the 
engagement of the TCR/CD3 complex and the co-receptor, CD4 or CD8, with antigens 
presented through MHC-I or MHC-II molecules by antigen presenting cells (APC) [366]. 
So far, approximately 300 proteins have been identified in the T cell surfaceome [365]. 
Additionally, it is known that T cell MP can undergo modifications such as glycosylation 
[367, 368], phosphorylation [369] and ubiquitination [370] that affect the development, 
survival or reactivity of these cells. However, there is no information in the literature 
about citrullination of T cell MP or the effects of PAD enzymes on the activation of 
these cells.  
In order to be able to study the effects of citrullination on T cell MP in future 
chapters, analytical methods were first optimised and are described in this chapter. 
Therefore, the aims of this chapter are as follows: 
 To optimise conditions to detect citrullination in FNG; 
 To optimise conditions to identify the FNG arginine residues modified by PAD 
enzymes; 
 To optimise conditions to separate and detect MP isolated from T cells. 
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3.3. Methods 
3.3.1. Fibrinogen citrullination 
Endotoxin content of hPAD enzymes was determined by the chromogenic LAL assay 
as described in section 2.20.  
FNG was citrullinated with hPAD2 and hPAD4 enzymes as outlined in section 
2.2.  
 
3.3.2. Analysis of fibrinogen citrullination 
Fibrinogen citrullinated with hPAD2 and hPAD4 enzymes was analysed by SDS-
PAGE, 2D IEF/SDS-PAGE and 2D BN/SDS-PAGE as outlined in sections 2.8, 2.10 
and 2.11, respectively. 
 
3.3.3. Identification of fibrinogen and citrullinated peptides by LC-CID-saETD-
MS/MS 
Citrullinated FNG separated by SDS-PAGE was further analysed by MS to identify the 
protein bands and the residues modified by citrullination, as detailed in section 2.12. 
 
3.3.4. Membrane proteins analysis 
MP were isolated from Jurkat E6.1 T cells as described in section 2.13 and analysed 
by 2D BN/SDS-PAGE (section 2.11). 
 
3.3.5. Statistical analysis 
Data obtained was analysed as described in section 2.23. 
Citrullinated FNG separated by 2D BN/SDS-PAGE was analysed using the 
SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software as described 
in section 2.11. Non-citrullinated FNG was selected as the reference gel. 
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3.4. Results 
3.4.1. Peptidylarginine deiminase enzyme purity  
The presence of endotoxin on hPAD enzyme solutions was assessed using the LAL 
assay (described in section 2.20). The results from this assay showed that hPAD2 and 
hPAD4 enzyme solutions contained high levels of endotoxin (hPAD2: 3.91℮5 EU/mL; 
hPAD4: 0.93℮5 EU/mL). To counteract this obstacle PAD enzymes were HI (30 
minutes at 63⁰ C) and their effects on all outcomes studied, e.g. citrullination of FNG in 
this chapter, was compared with the non-inactivated enzymes in order to identify 
whether any effects observed were due to PAD enzyme activity or LPS contamination 
(presented in section 3.4.3).  
 
3.4.2. Fibrinogen source comparison 
Two commercially available forms of FNG (Sigma-Aldrich Co. and Merck Millipore Ltd.) 
and two commonly used solutions (phosphate buffer saline – PBS and RPMI) were 
compared in an initial study (Figure 3.4). 
 
 
Figure 3.4 Comparison of commercially available FNG (Sigma-Aldrich Co. and Merck Millipore Ltd.) 
dissolved in PBS or RPMI. Ten micrograms (10 µg) of FNG (Sigma-Aldrich Co. or Merck Millipore Ltd.) 
dissolved in PBS or RPMI (serum free) were separated by SDS-PAGE in a 12% acrylamide gel. After 
electrophoresis, the gel was stained with CBB R250. The gel is representative of three independent 
experiments. 
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The bands corresponding to the three chains of FNG were identified in the gel, 
according with their MW (α – 70 kDa; ȕ – 56 kDa; Ȗ – 48 kDa). No differences were 
found between the two commercial sources of FNG or the two solutions used. For 
further studies, FNG from Sigma-Aldrich Co. was dissolved in PBS. 
 
3.4.3. Detection of fibrinogen citrullination by SDS-PAGE 
FNG was citrullinated in vitro with hPAD2 and hPAD4 enzymes in the presence of 
calcium and analysed by SDS-PAGE. As previously shown, it was possible to detect 
the bands corresponding to the three polypeptide chains of FNG, according to their 
MWs. Citrullination of FNG with hPAD2 enzyme did not reveal any changes in the 
profile of the FNG bands when compared with the control lane (Figure 3.5a). However, 
when FNG was incubated with hPAD4 enzyme it was possible to observe a shift to a 
high MW on the band corresponding to the α-chain of FNG (Figure 3.5b). The addition 
of EDTA (a calcium chelator) immediately after the start of the reaction and the use of 
HI PAD enzymes did not affect the profile of FNG separation by SDS-PAGE compared 
to untreated FNG (Figure 3.5). 
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Figure 3.5 In vitro citrullination of FNG by hPAD2 and hPAD4 enzymes. One hundred micrograms 
(100 µg) of FNG was citrullinated with 50 mU of hPAD2 enzyme (a) or hPAD4 enzyme (b) at 37°C for 2h. 
The reaction was stopped with 200 mM EDTA. Twenty micrograms (20 µg) of protein were separated by 
SDS-PAGE in a 7.5% acrylamide gel. After electrophoresis, the gel was stained with CBB R250. Controls 
with only FNG, with the addition of EDTA immediately after the addition of the enzyme and with the heat 
inactivation (63⁰ C for 30 minutes) of the enzymes were included. The right panels represent the 
densitometry histogram for each lane. The gels are representative of three independent experiments. 
 
3.4.4. Identification of fibrinogen citrullination by mass spectrometry 
The identification of citrullinated proteins involved: detection of citrullination, 
identification of target proteins and possible citrullination sites. FNG was initially used 
as a model to study the detection of citrullination. hPAD2- and hPAD4-citrullinated FNG 
was studied by MS to confirm the identification of the polypeptide chains and also to 
identify the citrullination sites on each subunit. The bands identified 1–9 in figure 3.6 
were excised, digested with trypsin and chymotrypsin enzymes and analysed by MS 
using the neutral loss method (described in section 2.12).  
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Figure 3.6 In vitro citrullination of FNG by hPAD2 and hPAD4 enzymes. One hundred micrograms 
(100 µg) of FNG was citrullinated with hPAD2 and hPAD4 enzymes at 37°C for 2h. The reaction was 
stopped with 200 mM EDTA. Twenty micrograms (20 µg) of protein were separated by SDS-PAGE in a 
7.5% acrylamide gel. After electrophoresis, the gel was stained with CBB R250. Controls with only FNG, 
with the addition of EDTA immediately after the addition of the enzyme and with the heat inactivation 
(63⁰ C for 30 minutes) of the enzymes were included. Numbered bands (1–9) represent the bands that 
were excised for polypeptide digestion and MS analysis. 
 
The analysis of the samples by the neutral loss method (LC-CID-saETD-MS/MS) after 
digestion with trypsin and chymotrypsin allowed the identification of the bands 
corresponding to α-, ȕ- and Ȗ-chain of FNG. Additionally, it was possible to identify the 
arginine residues that were converted into citrulline by the PAD enzymes. In total 
twenty-three arginine residues were found to be citrullinated, fourteen of which were 
found in the α-chain, six in the ȕ-chain and two in the Ȗ-chain of FNG (Table 3.1). 
However, four of these arginine residues were also found to be citrullinated in FNG that 
was not treated with PAD enzymes, hence these considered as false positives. The 
coverage of the FNG sequences was lower for the α-chain (56.27%), possibly due to 
its bigger size, but it was similar for the ȕ- (81.94%) and Ȗ-chain (90.6%). 
The detection and identification of FNG subunits and citrullinated sites provides 
evidence that this method can be applied for further studies. 
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Table 3.1 Protein identification of the bands excised from the in vitro citrullination of human FNG 
by hPAD2 and hPAD4 enzymes by LC-CID-saETD-MS/MS.  
Band Sample Identification 
Sequence coverage (%) 
(high confidence) 
Citrullinated sites 
(high confidence) 
1 FNG ɑ-chain 52.89 R353, R394, R573, R510 
2 FNG ȕ-chain 84.11 R121 
3 FNG Ȗ-chain (isoform A) 92.68 - 
4 FNG+hPAD2 ɑ-chain 59.58 
R123, R263, R271, R287, R367, 
R394, R404, R425, R426, R510, 
R512, R547, R573 
5 FNG+hPAD2 ȕ-chain 81.87 R60, R121, R196, R410 
7 FNG+hPAD4 ɑ-chain 56.35 R271, R367, R425, R426, R547, 
R573, R591 
8 FNG+hPAD4 ȕ-chain 79.84 R53, R60, R376 
9 FNG+hPAD4 Ȗ-chain 88.52 R31, R282 
Data from the MS experiment was analysed with Proteome Discoverer software (Thermo Fisher Scientific 
lnc., Loughborough, UK) and the protein identification determined by comparison with the IPI human 
database. Sequence coverage is a measure of how close an experimental MS/MS spectrum is to the 
theoretical MS/MS spectrum. Citrullination sites were identified using the neutral loss method and the data 
was validated by sequence analysis (Appendix 1). High confidence interval corresponds to 1% false 
discovery rate. 
3.4.5. Detection of fibrinogen citrullination by 2D IEF/SDS-PAGE 
Citrullination of FNG was also analysed by 2D IEF/SDS-PAGE. After citrullination with 
hPAD4 enzyme, the sample was de-salted, quantified and focused on IPG strips. The 
IPG strips were then equilibrated and the proteins resolved by SDS-PAGE. After 
staining the gels with Flamingo solution it was possible to visualise alterations in the 
profile of FNG after citrullination with hPAD4 enzyme (Figure 3.7). When observing 
citrullinated FNG, it is possible to detect spots that were absent from FNG control and 
hPAD4 enzyme control (Red circles on figure 3.7c). These results suggest that 
modifications in the chains of FNG due to citrullination occurred and could be visually 
detected by 2D IEF/SDS-PAGE. 
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Figure 3.7 In vitro citrullination of FNG by hPAD4 enzyme. One hundred micrograms (100 µg) of FNG was citrullinated with 50 mU of hPAD4 enzyme at 37°C for 2h. The 
reaction was stopped with 200 mM EDTA. Fifty micrograms (50 µg) of protein were prepared for 2D IEF/SDS-PAGE using ReadyPrepTM 2-D clean-up kit. The protein pellets 
were solubilised and quantified by Bradford assay. Ten micrograms (10 µg) of protein were rehydrated, loaded into IPG strips (11 cm, pH 3–10) and focused in a Protean i12 
IEF equipment (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). In the second dimension, samples were resolved by SDS-PAGE on 10% Criterion pre-cast gels and 
stained with Flamingo solution. The gel is representative of two independent experiments. Red circles identify the spots that were present in citrullinated FNG but absent on the 
controls. 
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3.4.6. Detection of fibrinogen citrullination by 2D BN/SDS-PAGE 
Changes in FNG citrullinated with PAD enzymes can be detected by 2D IEF/SDS-
PAGE, however, the effectiveness of this technique for the separation of MP is 
arguable. 2D IEF/SDS-PAGE is a powerful technique to separate complex mixtures of 
proteins, but due to the high content of hydrophobic amino acid residues, MP show low 
solubility and a high tendency for aggregation that makes 2D IEF/SDS-PAGE 
separation impractical [371]. To counteract this, feasibility of 2D BN/SDS-PAGE 
separation was assessed and implemented to analyse FNG modification by PAD 
enzymes. BN-PAGE, as previously described in section 2.11, has been used for the 
separation of microgram amounts of MP from biological membranes [372-376]. 
First, the separation of native FNG was titrated by 1D BN-PAGE (Figure 3.8). 
For the three concentrations of FNG tested a band at around 700 kDa was detected. 
Although native FNG has a MW of 340 kDa the band detected might represent dimeric 
forms of the protein or the occurrence of PTM. It is also important to notice that some 
of the sample did not migrate into the gel and consequently was not separated. This 
can be observed by the staining of the bottom of the wells (Figure 3.8). After 
separation of different concentrations of native FNG by 1D BN-PAGE, 10 µg was 
selected as the concentration to use in further optimisation studies. 
 
 
Figure 3.8 FNG analysis by 1D BN-PAGE. FNG (50, 10 and 1 µg) was separated by 1D BN-PAGE in a 
NativePAGE™ Novex™ 4–16% Bis-Tris gel. After electrophoresis, the gel was fixed and destained with 
8% acetic acid. The gel is representative of two independent experiments. 
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Next, native FNG was separated in two dimensions by 2D BN/SDS-PAGE (Figure 3.9). 
In figure 3.9 it is possible to observe the separation of native FNG in one band (Figure 
3.9a) followed by the SDS-PAGE separation in a second dimension (Figure 3.9b). This 
combination of dimensions enabled the separation of FNG into its three subunits. As 
observed previously (Figure 3.8), some of the protein did not migrate into the gel. This 
is more obvious on figure 3.9b where spots corresponding to the three subunits of FNG 
can be observed in the left hand side of the gel. 
  
 
Figure 3.9 FNG analysis by 2D BN/SDS-PAGE. FNG (10 µg) was separated by 2D BN/SDS-PAGE. In 
the first dimension a NativePAGE™ Novex™ 4–16% Bis-Tris gel was used (a). In the second dimension, 
the 1D strip was separated in TGX Mini-PROTEAN® TGX™ 8–16% pre-cast gel (b). After 1D 
electrophoresis, the gel was fixed and destained with 8% acetic acid. The 2D gel was stained with high 
sensitivity CBB G250. The gels are representative of two independent experiments. 
 
After evidence that native FNG could be detected by 2D BN/SDS-PAGE, the next step 
was to apply this technique to FNG that had been citrullinated by PAD enzymes. FNG 
was citrullinated with hPAD2 and hPAD4 enzymes and analysed by 2D BN/SDS-
PAGE. On figure 3.10a it is possible to observe the 1D BN-PAGE separation of FNG 
and citrullinated FNG into three bands with equivalent migration to proteins with MW of 
approximately 900, 700 and 400 kDa. It is also possible to observe that all the three 
bands are shifted to higher MW equivalencies on citrullinated FNG samples. 
Furthermore, hPAD4-citrullinated FNG presented an extra band at a lower MW that 
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was also present on the lane of hPAD4 enzyme only control and is probably derived 
from the enzyme itself. 
Figure 3.10b–f represents the 2D BN/SDS-PAGE of FNG samples separated in 
the second dimension. On figure 3.10b, as before in figure 3.9, it is possible to observe 
the separation of native FNG into its three subunits. 
Figures 3.10c and 3.10d represent the separation of the enzymes hPAD2 and 
hPAD4 enzymes by 2D BN/SDS-PAGE. These figures represent controls for figures 
3.10e and 3.10f where citrullinated FNG was separated by 2D BN/SDS-PAGE. 
 
132 
 
 
Figure 3.10 In vitro citrullination of FNG by hPAD2 and hPAD4 enzymes analysed by 2D BN/SDS-
PAGE. One hundred micrograms (100 µg) of FNG was citrullinated with 50 mU of hPAD2 or hPAD4 
enzymes at 37°C for 2h. The reaction was stopped with 200 mM EDTA. Ten micrograms (10 µg) of protein 
were separated by 2D BN/SDS-PAGE. In the first dimension a NativePAGE™ Novex™ 4–16% Bis-Tris 
gel was used (a). In the second dimension, the 1D strip was separated in TGX Mini-PROTEAN® TGX™ 
8–16% pre-cast gel (b–f). b) FNG 1D strip separated by 2D BN/SDS-PAGE. c) hPAD2 enzyme 1D strip 
separated by 2D BN/SDS-PAGE. d) hPAD4 enzyme 1D strip separated by 2D BN/SDS-PAGE. e) FNG + 
hPAD2 enzyme 1D strip separated by 2D BN/SDS-PAGE. f) FNG + hPAD4 enzyme 1D strip separated by 
2D BN/SDS-PAGE. After 1D electrophoresis, the gel was fixed and destained with 8% (v/v) acetic acid. 
The 2D gel was stained with high sensitivity CBB G250. The gels are representative of two independent 
experiments. 
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The five 2D gels were then analysed using the SameSpots (TotalLab ltd., Newcastle 
upon Tyne, UK) analysis software in order to detect differences in the FNG profile 
according with the tested conditions, where non-PAD enzyme treated FNG was 
considered as the reference gel for normalisation effects. As only one replicate was 
performed it was not possible to perform statistical analysis of the identified spots, 
however it was possible to identify the spots with fold changes higher than 2. In total 
nineteen spots were identified across the four test conditions (hPAD2, hPAD4, FNG + 
hPAD2 and FNG + hPAD4) with fold changes higher than 2 relative to the control 
(Figure 3.11 displays the spot position on the reference gel – FNG control), however 
only spots 190, 213, 217, 227, 233, 401, 402, 404, 405, 406, 407, 408, 409 and 413 
were considered for further analysis as the remaining ones were considered speckles 
or protein streaks. 
 
 
Figure 3.11 SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) software spots identification from 
in vitro citrullination of FNG separation by 2D BN/SDS-PAGE. Ten micrograms (10 µg) of FNG were 
separated by 2D BN/SDS-PAGE. The gels images were loaded into the software, the spots were matched 
across gels using FNG control as the reference gel and the spots with fold change higher than 2 between 
conditions identified in the reference gel. 
 
In accordance with the previous 1D SDS-PAGE (Figure 3.5) and 2D BN/SDS-PAGE 
(Figure 3.10) gels and based on the MW of the different FNG chains, figure 3.11 
suggests that: spots 404, 407 and 190 correspond to the α-chain of FNG; spots 217, 
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213 and 401 correspond to the ȕ-chain of FNG; spots 233, 227 and 402 correspond to 
FNG Ȗ-chain; spot 405 corresponds to hPAD4 enzyme. From the graphical 
representation of the normalised spots it is possible to compare the different intensity 
profiles according with the conditions tested (Figures 3.12 to 3.17). However, as this 
analysis results from only one experiment, careful interpretation of the results has to be 
taken into account. Figure 3.12 suggests that spots 404, 407 and 190 are nearly 
absent from conditions where only PAD enzymes were analysed. This can be 
confirmed on the SameSpots software (TotalLab ltd., Newcastle upon Tyne, UK) 
analysis for spot 407. In addition, it can also be inferred that the treatment of FNG with 
hPAD2 induced a shift corresponding to higher MW in 404, 407 and 190 spots. Using 
the same approach, figure 3.13 suggests the absence of FNG from spots 217, 213 and 
401 in non-FNG samples what could be confirmed by the software analysis for spot 
213. Figure 3.14, once again, suggests the absence of FNG on spots 233, 227 and 
402 from PAD only gels, which can be confirmed by software analysis for spot 227. 
Furthermore, the MW of spots 213 and 227, corresponding to ȕ- and Ȗ-chain of FNG, 
respectively, appears to have a lower MW (Figure 3.13 and 3.14). Spot 405 was only 
present on hPAD enzyme treatments and was considered to result from the hPAD4 
enzyme itself (Figure 3.15). The presence of spots 413, 409 and 406 were only 
observed in conditions where FNG was present. Furthermore, it was also possible to 
observe an increase in the correspondent MW of spot 406 on FNG treated with hPAD2 
(Figure 3.16). In figure 3.17, representing spot 408, it is possible to observe the 
presence of this spot only in conditions where FNG was present. A lower MW of spot 
408 in FNG was observed after treatment by both PAD enzymes. 
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Figure 3.12 Graphical representation of normalised intensity profile of spots 404, 407 and 190 
using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software.  
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Figure 3.13 Graphical representation of normalised intensity profile of spots 217, 213 and 401 
using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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Figure 3.14 Graphical representation of normalised intensity profile of spots 233, 227 and 402 
using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
 
 
Figure 3.15 Graphical representation of normalised intensity profile of spot 405 using the 
SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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Figure 3.16 Graphical representation of normalised intensity profile of spots 413, 409 and 406 
using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
 
 
Figure 3.17 Graphical representation of normalised intensity profile of spot 408 using the 
SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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3.4.7. Detection of membrane proteins by 2D BN/SDS-PAGE 
Once it was established that modifications in citrullinated FNG can be detected by 2D 
BN/SDS-PAGE, the next step was to apply this methodology to a more complex 
model. As the main purpose of this work is to identify citrullinated T cell surface 
proteins, MP from Jurkat E6.1 T cells were isolated as described in 2.13 and analysed 
by 2D BN/SDS-PAGE. 
Initially MP were separated in 1D BN-PAGE in the presence of increased 
concentrations of DDM. DDM is a water soluble nonionic detergent commonly used to 
solubilise hydrophobic membrane proteins [300-302]. As shown in figure 3.18 the 
addition of DDM improved the separation of MP by 1D BN-PAGE. The smear and 
narrowing of the bands observed on the first lane of the gel (0% DDM) disappeared 
once the detergent was introduced. The resolution of the bands, however, did not 
seem to improve greatly, probably due to the low amount of protein loaded in the gels 
(15 µg). For further studies, 0.625% DDM was used and the amount of total protein 
loaded was increased to 25 µg. 
 
 
Figure 3.18 MP separation by 1D BN-PAGE. Fifteen micrograms (15 µg) of MP extracted from Jurkat 
E6.1 T cells were separated by 1D BN-PAGE in a NativePAGE™ Novex™ 4–16% Bis-Tris gel in the 
presence of increased concentrations of DDM. After electrophoresis, the gel was fixed and destained with 
8% (v/v) acetic acid. 
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MP (25 µg) from Jurkat E6.1 T cells were then separated by 2D BN/SDS-PAGE in the 
presence of 0.625% DDM. Figure 3.19a shows the 1D separation of the proteins and 
several bands can be observed. Figure 3.19b illustrates the 2D BN/SDS-PAGE 
separation of MP. As previously, there were some proteins that did not migrate into the 
gel and, consequently, were not separated. It is also important to refer the presence of 
some degree of smear. However, the MP seemed to have been separated and clear 
spots can be identified in the gel. This approach is showed as viable to separate MP 
from T cells and will be further used to compare MP from PBMC citrullinated with PAD 
enzymes (chapter 4).   
 
 
Figure 3.19 MP separation by 2D BN/SDS-PAGE. Twenty-five micrograms (25 µg) of MP extracted from 
Jurkat E6.1 T cells using the Mem-PER Plus kit (Pierce, Thermo Fisher Scientific lnc., Loughborough, UK) 
were separated by 2D BN/SDS-PAGE in the presence of 0.625% (v/v) DDM. In the first dimension a 
NativePAGE™ Novex™ 4–16% Bis-Tris gel was used (a). In the second dimension, the 1D strip was 
separated in TGX Mini-PROTEAN® TGX™ 8–16% pre-cast gel (b). After 1D electrophoresis, the gel was 
fixed and destained with 8% (v/v) acetic acid. The 2D gel was stained with high sensitivity CBB G250. The 
gels are representative of two independent experiments. 
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3.5. Discussion 
Citrullination is an important PTM. Physiologically, the conversion of peptidylarginine to 
peptidylcitrulline by PAD enzymes is associated with an increase stiffness of the 
cellular cytoskeleton (citrullination of keratin and fillagrin), the myelin sheets and the 
hair fibres (citrullination of trichohyalin) and is also involved in regulation of gene 
expression, through the modification of arginine residues on histones. Pathologically, 
citrullination is associated with several diseases, including RA and PID [336]. The loss 
of immune tolerance to self-proteins by the human body and consequent production of 
ACPA is the main indicator of the involvement of citrullination in RA. In PID, 
citrullination is linked to the expression of a bacterial PAD enzyme isoform, that is able 
to modify bacterial and human proteins that can trigger an immune response [109]. 
The aim of this chapter was to develop a methodology to detect and identify 
citrullinated proteins. FNG was selected to perform in vitro citrullination studies, since it 
is one of the proteins found to be citrullinated in RA [184, 197, 198]. Autoantibodies 
against citrullinated forms of the α- and ȕ-chain of FNG were reported in the serum and 
synovial fluid of RA patients [170, 201]. Additionally, PAD2 and PAD4 enzymes were 
also identified in the synovium of RA patients [187-189, 361]. Isoforms 2 and 4 of PAD 
enzymes share sequence homology (Appendix 2) and can both be detected in the 
synovium of RA patients. However, these two isoforms are expressed by different cells 
in the synovial tissue, their intracellular localisation is also different and their 
expression and activation are separately regulated at transcription, translation and 
enzyme activation [133]. Furthermore, PAD2 and PAD4 enzyme stability, calcium 
dependency, optimal pH range and substrate specificity are significantly different [377, 
378]. 
FNG isolated from whole blood plasma can be obtained commercially and 
different sources are available. The first step of this study was to compare the 
separation of native FNG obtained from two different companies (Sigma-Aldrich Co. 
142 
 
and Merck Millipore Ltd.) by SDS-PAGE. The original buffer system was also 
addressed, by comparing PBS and RPMI. The separation of native FNG by SDS-
PAGE did not show differences either between the commercial sources or the buffer 
systems studied and it was possible to observe three bands corresponding to the MW 
of FNG subunits in all conditions. FNG was then citrullinated with hPAD2 and hPAD4 
enzyme and separated by three different techniques, SDS-PAGE, 2D IEF/SDS-PAGE 
and 2D BN/SDS-PAGE. Considering that the conversion of peptidylarginine into 
peptidylcitrulline only accounts for 1 Da increase in the MW of the protein [335] it was 
considered unlikely to detect changes in citrullinated FNG by SDS-PAGE. However, it 
was possible to detect differences between unmodified and citrullinated FNG in all the 
separations performed.  
In 1D SDS-PAGE separation the difference between FNG control and hPAD4 
enzyme modified FNG was more obvious than between FNG control and hPAD2 
enzyme citrullinated FNG. The opposite was observed by van Beers and colleagues 
[379], who reported that citrullination of FNG with hPAD2 enzyme was more evident 
than with hPAD4 enzyme based on the mobility shift of the FNG bands by SDS-PAGE 
and the number of citrullinated residues identified by MS. Here, after 1D SDS-PAGE 
separation, citrullinated FNG was digested with two different proteolytic enzymes 
(trypsin and chymotrypsin) to optimise the sequence coverage and minimise the 
influence of citrullination on cleavage. In MS studies, trypsin is the most common used 
protease for the digestion of proteins, once it has high proteolytic activity and cleavage 
specificity. Trypsin is a serine protease that cleaves polypeptide chains at the C-
terminal of arginine and lysine residues. The main drawbacks of the use of this 
protease for protein digestion are the incomplete digestion, the resistance to 
proteolysis by tightly folded proteins and its inhibition by some reagents used in protein 
preparation. As here, the study of citrullination implies the modification of arginine 
residues, this will contribute to lower efficiency rates of trypsin cleavage, once the 
digested peptides will be larger and have lower probabilities to be detected by MS 
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equipment. The combination of proteolytic enzymes is a common approach to improve 
the digestion of larger proteins or proteins suggested to PTM and increase the 
sequence coverage of the resultant peptides [380]. 
The analysis of the digests by MS using CID and ETD fragmentation allowed 
the identification of eighteen arginine residues citrullinated by hPAD2 or hPAD4 
enzymes amongst the three polypeptide chains of FNG. Eleven of these were 
associated with the α-chain of FNG, five with the ȕ-chain and two with the Ȗ-chain. In 
total, 28% of the arginines in FNG were found to be citrullinated by either hPAD2 or 
hPAD4 enzymes. From the total eighteen citrullinated arginine residues, the majority 
was found in FNG treated with hPAD2 enzyme, this time in agreement with van Beers 
and colleagues [379]. Six of the eighteen arginine residues were found citrullinated by 
the two hPAD enzymes, while seven were found to be citrullinated only by hPAD2 
enzyme and five only by hPAD4 enzyme. 
A fact to consider is that PAD enzymes were also present in FNG citrullinated 
samples and consequently they were expected to be separated with FNG. As a control 
for this, controls with just the enzymes in solution were performed. The separation of 
hPAD2 and hPAD4 enzymes by 1D SDS-PAGE and 2D BN/SDS-PAGE indicated that 
hPAD4 enzyme was possible to be detected by these techniques, suggesting that in 
the FNG citrullinated conditions, bands corresponding to this enzyme were also 
expected to be visualised. The presence of hPAD2 enzyme was not evident, because 
the amount of hPAD2 enzyme to the FNG solutions was smaller than the amount of 
hPAD4 enzyme added, due to different intrinsic activity presented by each enzyme.  
Another point to take into account in this study is the contamination of 
recombinant expressed PAD enzymes with endotoxin (lipopolysaccharide – LPS). To 
clarify the effects of contaminating LPS in mediating effects of PAD enzymes on 
different proteins and cell functions, a control with HI (63⁰ C for 30 minutes) PAD 
enzymes was performed. Endotoxins are highly heat-stable and can only be 
inactivated when exposed at temperature of 250⁰ C for more than 30 minutes or 
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180⁰ C for more than 3 hours [381]. However, as PAD enzymes have optimal activity 
at 37ºC [158], by incubating them at 63⁰ C for 30 minutes, the enzymes will lose their 
ability to citrullinate arginine residues. Using HI PAD enzymes did not show any 
differences on the protein profile of FNG compared to controls which suggests that 
endotoxin has no effects on the change in MW observed after treatment with PAD 
enzymes. This control will still need to be performed in further cellular experiments, as 
the presence of endotoxin is likely to cause immune cell activation and affect T cell 
responses. 
The results from this chapter suggest that citrullination of FNG by hPAD2 and 
hPAD4 enzymes can be detected by different electrophoretic techniques. The 
separation of citrullinated FNG by 1D SDS-PAGE allowed to identify the three chains 
of this protein and it was also possible to identify arginine residues citrullinated by 
hPAD2 and hPAD4 enzymes by MS analysis. The separation of citrullinated FNG by 
2D BN/SDS-PAGE allowed detection of native FNG in the first dimension and the three 
chains of the protein in the second dimension, allowing the gathering of more 
information. 2D BN/SDS-PAGE has been extensively used for the analysis of 
respiratory protein complexes of the electron transfer chains of animals and plants, 
providing insight into their native interactions. Recently, this technique has been 
applied to the identification of protein complexes in whole cell lysates from human cell 
lines [382-388]. Applying this technique to the study of MP addressed here, will allow 
the separation of the protein complexes and provide information about protein-protein 
interactions. To corroborate the feasibility of 2D BN/SDS-PAGE in further studies, the 
level of protein complexity was increased, progressing from FNG, a single protein, to 
MP isolated from Jurkat E6.1 T cells. By using this mixture of proteins it was possible 
to assess and validate the applicability of 2D BN/SDS-PAGE to complex samples but 
also in particular to MP, that have been investigated as a target for citrullination in 
following Chapters of this thesis. As biological membranes result from complex 
associations between lipids and proteins, the solubilisation of the lipid components is 
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essential to extract and analyse the protein fraction. However, the complexity here was 
to maintain the native structure and subunit composition of the membrane 
components. The use of detergents has been widely accepted for the extraction and 
analysis of MP by BN-PAGE. Detergents are amphipatic molecules that have the 
ability to dissolve the lipid bilayer and form stable micelles with hydrophobic cores in 
aqueous media, allowing the dissolution of hydrophobic molecules like proteins. DDM 
is one of the most commonly used detergents in BN-PAGE and has 
hydrophobic/hydrophilic properties that facilitate lipid solubilisation and at the same 
time provide a lipid-like environment for MP. The detergent choice is crucial for the 
solubilisation of MP. DDM was selected for this study and showed to improve the 
separation of MP but other detergents can be used, according with the protein nature.  
The combination of proteomic techniques used in this study allowed the 
detection of modifications on FNG citrullination by hPAD2 and hPAD4 enzymes. It was 
possible to identify the three subunits of FNG as well as the arginine residues that 
were modified by citrullination using a MS method specially developed for the detection 
of citrullination (LC-CID-saETD-MS/MS) [310]. 2D BN/SDS-PAGE was also confirmed 
as a valid approach for a complex mixture of MPs. The use of 2D BN/SDS-PAGE and 
LC-CID-saETD-MS/MS is a suitable approach for further studies on the detection and 
identification of T cell surface proteins targets of citrullination. 
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Chapter 4  Analysis of the effects of 
citrullination of PBMC on T cell 
activation 
147 
 
4.1. Preface 
The aim of this chapter was to study the effects of citrullination by PAD enzymes on 
the activation of T cells. Initially, the secretion of IL-2 and the expression of IL-2R 
(CD25) on the surface of cells were used as readouts to select a functional T cell 
activation model. The activation of T cells was compared using PHA-L and anti-
CD3/anti-CD28 antibodies in Jurkat E6.1 T cells and PBMC. After the identification of a 
functional T cell model, the effects of PAD (hPAD2 and hPAD4) enzymes on the 
activation of T cells was studied using gene and cell surface protein expression 
analysis. 
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4.2. Introduction 
The immune system has two main functions, to initiate an inflammatory response when 
the organism is injured and to distinguish between self- and non-self-proteins. Extreme 
importance is attributed to the relationship between these two functions. If the 
organism is not able to identify the self-proteins an inflammatory response can be 
triggered against the self-organism, leading to autoimmune diseases, such as RA [2, 
3]. T cells play a critical role in this differentiation between self and non-self and in the 
initiation of the adaptive immune response. The principal function of T cells is to 
promote efficient removal of foreign material by mounting an effective adaptive immune 
response [12]. The recognition of citrullinated self-peptides as foreign by T cells has 
been suggested as the trigger for the B cell production of ACPA, a major hallmark of 
RA, and the breakdown of the immune system. Furthermore, a genetic association 
between RA susceptibility and severity and the HLA-DR gene that encodes for MHC-II 
molecules has been suggested [159, 164-172]. It has been established that 
citrullination plays a key role triggering the autoimmune response observed in RA [159, 
170, 171, 184, 211, 389, 390]. 
T cell functions are influenced by alterations in redox homeostasis, depending 
on the oxidation state of the cell surface and cytoplasmic protein-thiols. At the T cell 
surface level, proteins with cysteine (Cys) residues have free thiol groups available for 
oxidation/reduction by a network of redox regulating peptides, proteins and enzymes, 
such as GSH, thioredoxins and thioredoxin reductase (TrxR) and protein disulphide 
isomerase (PDI) [391, 392]. GSH, a cysteine containing tri-peptide, is the most 
abundant non-protein thiol, and, in combination with its oxidised dimer (GSSG), plays a 
key role in the maintenance of redox balance and thiol groups. GSH synthesis 
depends on the activity of Ȗ-glutamylcysteinyl ligase (GCL) enzyme and Cys 
availability. The expression of GCL is coupled to the cellular redox state through the 
nuclear factor erythroid 2–related factor 2 – Kelch-like ECH-associated protein 1 (Nrf2-
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KEAP1) system, constituting an oxidative stress sensing mechanism that can induce 
de novo GSH synthesis and restore redox homeostasis [393]. Thioredoxins are a 
group of small redox enzymes involved in cellular functions such as redox control 
[394], protection of proteins from oxidative aggregation and inactivation [394-397], 
helping cells to cope with ROS [398], regulation of programmed cell death [399, 400], 
modulation of the inflammatory response [401-403] and promotion of protein folding 
[404]. PDI is a redox active protein that reduces disulphide bonds in cell surface 
proteins, like ȕ3 integrin on the surface of platelets [405, 406], and it was also shown to 
be involved in facilitating human immunodeficiency virus (HIV) entry into T cells by 
forming complex with HIV gp120, CD4 and CXCR4 on the surface of T cells [407-411]. 
At intracellular level, redox homeostasis is achieved through three major redox 
couples: NADH/NAD+, NADPH/NADP+ and GSH/GSSG [412, 413].  
OXPHOS and glycolysis are the key cellular metabolic pathways and are 
intimately related to redox biology. Glycolysis is the main source for NADPH, which is 
an essential cofactor for NADPH oxidase and for the regeneration of GSH and Trx 
through their respective reductases (Figure 4.1) [414]. Furthermore, the activity of PAD 
enzymes, involved in the citrullination of self-antigens in RA, is also influenced by the 
redox status of the surrounding environment, since the thiol group of Cys351 is 
essential for the catalytic process [415]. 
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Figure 4.1 Link between reducing nucleotides derived from the pentose phosphate pathway and 
maintenance of cellular redox state through reduction of hydrogen peroxide and oxidised proteins. 
Reduced molecules are highlighted in green and oxidised molecules are highlighted in red. GR – 
glutathione reductase; Grx – glutaredoxin; Grx-(SH)2 – reduced glutaredoxin ; Grx-SS – oxidised 
glutaredoxin; GSR – glutathione reductase; GSH – glutathione; GSSG – glutathione disulphide; H2O – 
water; H2O2 – hydrogen peroxide; NADP+ – oxidised nicotinamide adenine dinucleotide phosphate; 
NADPH – reduced nicotinamide adenine dinucleotide phosphate; Prx – peroxiredoxin; Prx-(SH)2 – 
reduced peroxiredoxin; Prx-SOH – peroxiredoxin sulphenate; Prx-SO2H – peroxiredoxin sulphinate; Prx-
SS – oxidised peroxiredoxin; RSH – protein; RSSG – glutathionylated protein; RSOH – protein 
sulphenate; RSSR – protein disulphide; Trx – thioredoxin; TrxR – thioredoxin reductase. 
 
T cells vary in energetic requirements, according to their activity. During maturation 
and exit from the thymus, naïve T cells depend on OXPHOS for their metabolic needs 
[77-81], whereas for proliferation after TCR rearrangement T cells rely on glycolysis 
and glutaminolysis. Once in the periphery (lymphoid organs or in circulation), T cell 
activation induces metabolic reprogramming of the naïve T cell to a program of 
anabolic growth and biomass accumulation that is dependent on aerobic glycolysis 
(conversion of glucose into lactate) [72, 416]. Aerobic glycolysis is less efficient than 
OXPHOS in the production of energy; however, importantly it yields rapid energy and 
metabolic intermediates for cell growth and proliferation. Furthermore, aerobic 
glycolysis also provides a way to maintain cellular redox homeostasis (NAD+/NADH) 
[416-418]. 
Although T cell surface proteins are susceptible to PTM [367-370], there is no 
information in the literature about citrullination of these proteins or the effects of PAD 
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enzymes on the activation of T cells. Therefore, it is important to understand whether 
citrullination occurs on T cells, and how this protein modification affects T cell 
activation. The aims of this chapter are as follows: 
 To compare the activation of Jurkat E6.1 T cells and PBMC with PHA-L and 
antibodies against CD3/CD28 and select a functional T cell model; 
 To investigate the effects of hPAD2 and hPAD4 enzymes on the activation of T 
cells; 
 To explore the effects of hPAD2 and hPAD4 enzymes on gene expression of 
activated T cells; 
 To investigate the effects of PAD enzymes on the citrullination of cell surface 
proteins. 
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4.3. Methods 
4.3.1. Studies on Jurkat E6.1 T cells 
Activation of Jurkat E6.1 T cells with PHA-L and antibodies against CD3 and CD28 
was performed as outlined in section 2.3. Following activation, cell viability was 
assessed and cells were collected for further experiments.  
 
4.3.2. Studies on peripheral blood mononuclear cells population 
PBMC were isolated, pre-treated with PAD enzymes and activated with PHA-L and 
antibodies against CD3 and CD28 as detailed in section 2.4. Following activation, cell 
viability was assessed and cells were collected for further analysis. 
 
4.3.3. Determination of cell viability 
Following the treatments, the viability of Jurkat E6.1 T cells or PBMC was assessed 
using the CellTiter-Blue® cell viability assay or the trypan blue exclusion assay, as 
detailed in sections 2.14 and 2.15, respectively. 
 
4.3.4. Quantification of interleukin-2 secretion levels  
IL-2 levels secreted by Jurkat E6.1 T cells and PBMC were quantified by sandwich 
ELISA, as described in section 2.16. 
 
4.3.5. Quantification of extracellular L-lactate levels 
The levels of L-lactate in the supernatant of PBMC activated with anti-CD3/anti-CD28, 
with and without PAD enzyme treatment were quantified using the L-lactate assay kit 
as described in section 2.22. 
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4.3.6. Analysis of the expression of the interleukin-2 receptor in the surface of T 
cells 
Flow cytometry was used to quantify the expression of CD4 and CD25 (IL-2Rα) at the 
surface of PBMC, as detailed in section 2.17. 
 
4.3.7. Identification of membrane proteins  
Twenty-five micrograms of MP were isolated from PBMC with and without treatment 
with PAD enzymes and activated with anti-CD3/anti-CD28 antibodies, as described in 
section 2.13 and analysed by 2D BN/SDS-PAGE (section 2.11). Following 2D 
BN/SDS-PAGE separation, selected spots from non-PAD treated, hPAD2- and hPAD4-
treated conditions were pooled together alkylated, digested with trypsin and analysed 
by LC-CID-saETD-MS/MS for the protein and citrullinated residues identification, as 
outlined in section 2.12. 
 
4.3.8. Quantification of gene expression 
Total RNA was isolated from 5 x 105 PBMC following treatment with PAD enzymes and 
activation with anti-CD3/anti-CD28 antibodies, converted to cDNA and analysed by 
microarray hybridisation and by RT-QPCR, as outlined in section 2.21. The mean of 
unactivated PBMC was used as a control condition for the comparison of gene 
expression between unactivated and activated PBMC. The mean of activated PBMC 
was used as a control condition for the comparison of gene expression between 
activated PBMC and PAD-treated PBMC followed by activation. 
 
4.3.9. Statistical analysis 
Data obtained was analysed as described in section 2.23. 
Citrullinated protein spots previously separated by 2D BN/SDS-PAGE were 
analysed using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis 
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software as described in section 2.11. A non-citrullinated sample was selected as the 
reference gel. 
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4.4. Results 
4.4.1. Comparison between Jurkat E6.1 T cells and peripheral blood 
mononuclear cells as a model for T cell activation 
In order to study the activation of T cells, an initial comparison with two models of T 
cells and two models of T cell activation was performed. Jurkat E6.1 T cells and PBMC 
were used as a model of T cell activation and PHA-L and antibodies against CD3 and 
CD28 were used as stimuli to induce T cell activation. Activation studies were 
performed for 24, 48 and 72 hours. Following incubation with PHA-L or anti-CD3/anti-
CD28 antibodies, Jurkat E6.1 T cells and PBMC were collected and assessed for 
viability, expression of CD25 at the surface and secretion of IL-2 to the extracellular 
medium.  
Cell viability is an important readout to evaluate if the treatment is associated 
with any cell toxicity. Expression of CD25 at the surface of T cells and secretion of IL-2 
to the extracellular medium are key markers of T cell activation. CD25 is the α-chain of 
the IL-2R and in vivo is highly expressed at the surface of T cells when these are 
proliferating in the thymus [2]. Later, when naïve CD4 T cells become activated in the 
periphery, through the presentation of antigen by APC, the secretion of IL-2 to the 
extracellular medium and the expression of the CD25 are stimulated. The interaction 
between IL-2 and IL-2R induces T cell growth, differentiation and survival [419]. 
The cell viability results, using the trypan blue exclusion assay, showed that a 
high percentage of Jurkat E6.1 T cells lost viability with the PHA-L treatment (Figure 
4.2a). Using increasing concentrations of PHA-L (0, 0.5, 1, 2 μg/mL) for 24 hours the 
viability of Jurkat E6.1 T cells decreased from 96.9 ± 0.4% (0 μg/mL PHA-L) to 81.55 ± 
8.35% (1 μg/mL PHA-L) and to 80.15 ± 5.85% (2 μg/mL PHA-L), but this difference 
was not statistically significant (p-value = 0.267). Treating the Jurkat E6.1 T cells with 
PHA-L for longer periods (48 and 72 hours) had a similar effect on the viability of the 
cells. Jurkat E6.1 T cells stimulated with 0 to 10 μg/mL of PHA-L for 48 hours showed 
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a non-statistically significant decrease of 20.56% (p-value = 0.210) between the 
minimum and maximum concentrations, but a statistically significant decrease of 
29.06% (p-value = 0.03) was observed when Jurkat E6.1 T cells stimulated with 0 to 10 
μg/mL of PHA-L for 72 hours, suggesting that treating Jurkat E6.1 T cells for longer 
periods with high concentrations of PHA-L can be toxic and lead to cell death. 
However, at lower concentrations this toxic effect was not observed. Data from Jurkat 
E6.1 T cells treated with 1 μg/mL of PHA-L for 24, 48 and 72 hours show that cell 
viability was similarly reduced to 81.55 ± 8.35% at 24 hours, 79.70 ± 6.2% at 48 hours 
and 88.5 % at 72 hours (p-value = 0.600).  
PBMC were only stimulated with PHA-L for 24 hours. The viability of these cells 
remained above 86% with the increased concentrations of PHA-L (Figure 4.2b). When 
PBMC were stimulated with increased concentrations (from 0 to 5 μg/mL) of anti-CD3 
antibody in combination with an antibody against CD28 the viability of these cells was 
not affected (lowest value of 89.54 ± 4.08%), even after 72 hours of incubation (Figure 
4.2c). 
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Figure 4.2 Jurkat E6.1 T cells and PBMC viability after activation with PHA-L or anti-CD3/anti-CD28. 
Jurkat E6.1 T cells were cultured in complete RPMI medium. PBMC were isolated from healthy volunteers. 
a) Jurkat E6.1 T cells (1 x 106 cells/mL) were stimulated with concentrations of PHA-L ranged from 0 to 10 
μg/mL and incubated at 37⁰ C for 24, 48 and 72 hours. b) PBMC (5 x 105 cells/mL) were stimulated with 
concentrations of PHA-L ranged from 0 to 5 μg/mL and incubated at 37⁰ C for 24 hours. c) PBMC (5 x 105 
cells/mL) were stimulated with concentrations of anti-CD3 antibody ranged from 0 to 5 μg/mL, followed by 
incubation with antibody against CD28 (2 μg/mL), and incubated at 37⁰ C for 24, 48 and 72 hours. Cell 
viability was assessed by the trypan blue exclusion assay. Mean values are shown with SEM. The values 
are the results from three independent experiments with Jurkat E6.1 T cells and two independent 
experiments with PBMC. Kruskal-Wallis test followed by Dunn’s multiple comparison test were performed 
and revealed no statistical significance. 
 
As previously mentioned, IL-2 secreted into the extracellular medium constitutes a 
relevant readout of T cell activation. The levels of IL-2 in the supernatant of Jurkat E6.1 
T cells and PBMC incubated with PHA-L and anti-CD3/anti-CD28 antibodies was 
assessed by ELISA. When comparing the levels of IL-2 secreted by Jurkat E6.1 T cells 
activated with PHA-L (Figure 4.3a) and anti-CD3/anti-CD28 antibodies (Figure 4.3b) it 
is possible to observe a trend towards increased levels of IL-2 as a response to 
increasing concentrations of PHA-L and anti-CD3 antibody. However, this response 
was more obvious with the antibodies activation method. Nevertheless, the IL-2 levels 
were only increased when the concentration of anti-CD3 antibody was 5 μg/mL and the 
cells were incubated for more than 48 hours. When comparing the activation of T cells 
within the PBMC population with PHA-L and anti-CD3 antibody, both for 24 hours, it 
was again possible to observe that the IL-2 secretion was greater when the 
combination of antibodies against CD3 and CD28 was used instead of PHA-L. Even 
using 5 μg/mL of PHA-L the IL-2 secretion only reached 0.61 ± 0.06 ng/mL, while using 
1 μg/mL of anti-CD3 antibody in combination with 2 μg/mL of anti-CD28 antibody it was 
possible to detect 1.33 ± 0.04 ng/mL of IL-2 (Figure 4.3c). The activation of T cells on 
PBMC with anti-CD3/anti-CD28 antibodies was also compared for 24, 28 and 72 
hours. In figure 4.3d it is possible to observe than IL-2 secretion increased substantially 
when PBMC were activated with 1 μg/mL of anti-CD3 antibody for 24 (0.65 ± 0.03 
ng/mL) or 48 hours (0.90 ± 0.03 ng/mL), when comparing with no activation levels 
(0.02 ± 0.01 ng/mL at 24 hours and 0.04 ± 0.01 ng/mL at 48 hours). However, the IL-2 
levels did not increase proportionally when 5 μg/mL were used instead of 1 μg/mL, 
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changing to 0.69 ± 0.03 ng/mL at 24 hours and to 0.9 ± 0.03 ng/mL at 48 hours. The 
stimulation of the PBMC for 72 hours did not reproduce the increase in IL-2 secretion 
observed in 24 or 48 hours (Figure 4.3d). 
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Figure 4.3 IL-2 secretion from Jurkat E6.1 T cells and PBMC after activation with PHA-L or anti-
CD3/anti-CD28. Jurkat E6.1 T cells were cultured in complete RPMI medium. PBMC were isolated from 
healthy volunteers. a) Jurkat E6.1 T cells (1 x 106 cells/mL) were stimulated with 0 to 10 μg/mL of PHA-L 
and incubated at 37⁰ C for 24, 48 or 72 hours. b) Jurkat E6.1 T cells (1 x 106 cells/mL) were stimulated 
with 0 to 5 μg/mL of anti-CD3 antibody, followed by incubation with anti-CD28 antibody (2 μg/mL) and 
incubated at 37⁰ C for 24, 48 or 72 hours. c) PBMC (5 x 105 cells/mL) were stimulated with 0 to 5 μg/mL of 
PHA-L or anti-CD3 antibody, followed by incubation with anti-CD28 antibody (2 μg/mL) and incubated at 
37⁰ C for 24 hours. d) PBMC (5 x 105 cells/mL) were stimulated with 0 to 5 μg/mL of anti-CD3 antibody, 
followed by incubation with anti-CD28 antibody (2 μg/mL) and incubated at 37⁰ C for 24, 48 or 72 hours. 
Supernatants from each tested condition were collected after the incubation time and the levels of IL-2 
determined using an IL-2 ELISA kit (Peprotech EC Ltd., London, UK). Mean values are shown with SEM. 
The values are the results from three independent experiments with Jurkat E6.1 T cells and two 
independent experiments with PBMC. ANOVA followed by Tukey’s multiple comparison test were 
performed and the significant differences are identified in tables 4.1 and 4.2. 
 
Table 4.1 Resume of statistical significance obtained for Figure 4.3a. Statistical significance was 
defined as * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001. 
Significance 
* ** *** 
1 µg/mL vs 10 µg/mL 
(48h) 
0.5 µg/mL vs 10 µg/mL 
(48h) 
2 µg/mL vs 10 µg/mL 
(48h) 
24h vs 48h (10 µg/mL)   
 
Table 4.2 Resume of statistical significance obtained for Figure 4.3b. Statistical significance was 
defined as * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
Significance 
* ** *** **** 
0.1 µg/mL vs 5 µg/mL 
(24h) 
0 µg/mL vs 2 µg/mL 
(72h) 
0.1 µg/mL vs 2 µg/mL 
(24h) 
0 µg/mL vs 5 µg/mL 
(48h) 
1 µg/mL vs 2 µg/mL 
(72h) 
 0.1 µg/mL vs 2 µg/mL 
(48h) 
0.1 µg/mL vs 5 µg/mL 
(48h) 
  0.5 µg/mL vs 2 µg/mL 
(48h) 
0.5 µg/mL vs 5 µg/mL 
(48h) 
  0.5 µg/mL vs 2 µg/mL 
(72h) 
1 µg/mL vs 5 µg/mL 
(48h) 
   2 µg/mL vs 5 µg/mL 
(48h) 
   0.1 µg/mL vs 2 µg/mL 
(72h) 
   0 µg/mL vs 5 µg/mL 
(72h) 
   0.1 µg/mL vs 5 µg/mL 
(72h) 
   0.5 µg/mL vs 5 µg/mL 
(72h) 
   1 µg/mL vs 5 µg/mL 
(72h) 
   48h vs 72h (5 µg/mL) 
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The levels of CD25 expressed at the surface of PBMC were analysed by flow 
cytometry after T cell activation. As previously observed in figure 4.3c, the activation of 
T cells within the PBMC population with antibodies against CD3 and CD28 was more 
effective than the use of PHA-L (Figure 4.4a). When testing different concentrations of 
anti-CD3 antibodies and increased incubation times for the activation of T cells there 
was a trend to increased levels of CD25 expressed at the surface of CD4 T cells when 
incubating the cells with 1 and 5 μg/mL of anti-CD3 antibody in combination with anti-
CD28 antibody. Even though there seemed to be an increase in the CD25 expressed 
by these cells when incubation with anti-CD3 antibody was performed for 24 or 48 
hours, a longer incubation of 72 hours did not seem to have such a pronounced effect 
(Figure 4.4b). As this data results from only one experiment, interpretation has to be 
carefully made. However, these observations support those in the literature [420], that 
activation of T cells within PBMC population with antibodies against CD3 and CD28 
results in increased levels of CD25 expressed at the surface of CD4 T cells. 
163 
 
 
Figure 4.4 CD4
+
CD25
+
 T cells on the PBMC population after activation with PHA-L or anti-CD3/anti-CD28. PBMC were isolated from healthy volunteers. a) PBMC (5 x 
105 cells/mL) were stimulated with 0 to 5 μg/mL of PHA-L or anti-CD3 antibody, followed by incubation with anti-CD28 antibody (2 μg/mL) and incubated at 37⁰ C for 24 hours. 
b) PBMC (5 x 105 cells/mL) were stimulated with 0 to 5 μg/mL of anti-CD3 antibody, followed by incubation with anti-CD28 antibody (2 μg/mL) and incubated at 37⁰ C for 24, 48 
or 72 hours. One hundred thousand PBMC were used in combination with anti-CD4-PE and anti-CD25-APC conjugated antibodies on a Beckman Coulter flow cytometer. The 
values are the result from one experiment performed in triplicate. 
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The results presented so far in this chapter confirm that, in the conditions used here, 
both Jurkat E 6.1 T cells and T cells within the PBMC population can be activated with 
PHA-L and with the antibodies against CD3 and CD28. These results also show that 
activation by anti-CD3/anti-CD28 antibodies is more effective in the activation of T 
cells, in particular when using PBMC as a T cell source. Therefore, further studies on 
the effects of PAD enzymes in the activation of T cells were performed using PBMC 
activated with anti-CD3 and anti-CD28 antibodies. 
 
4.4.2. Functional effects of peptidylarginine deiminase enzymes on T cell 
activation 
Isolated PBMC were pre-treated with two isoforms of PAD, hPAD2 and hPAD4, 
enzymes followed by activation with the combination of anti-CD3/anti-CD28 antibodies, 
and then they were analysed for T cell activation indicators (IL-2 secretion and CD25 
expression) and also cell viability. Different amounts of the PAD enzymes were tested 
(125, 250, 500 and 1000 mU). Furthermore, in order to investigate whether any 
activation could be attributed to non-enzyme contaminants, a control where PAD 
enzymes had been HI beforehand was also included. 
 As previously, cell viability was investigated as a measure of the toxic effect of 
the treatment in use. After incubation with PAD enzymes and activation by anti-
CD3/anti-CD28 antibodies, PBMC viability was not altered in any of the tested 
conditions (Figure 4.5). 
165 
 
 
166 
 
Figure 4.5 Effects of PAD enzymes on PBMC viability after activation with anti-CD3/anti-CD28 
antibodies. PBMC were isolated from healthy volunteers and seeded at a density of 5 x 105 cells/mL. Five 
hundred thousand cells/mL were incubated with PAD enzymes (2 hours at 37⁰ C), followed by activation 
with 1 μg/mL anti-CD3 antibody and 2 μg/mL anti-CD28 antibody for 24 hours at 37⁰ C. a) Control with 
PAD enzymes treatment but no activation. b) Control with HI PAD enzymes. c) PBMC incubated with 
increasing amounts (0, 125, 250, 500, 1000 mU) of PAD enzymes. Cell viability was assessed using the 
CellTiter-Blue® cell viability assay (Promega Co., Southampton, UK) considering non-treated PBMC as a 
reference control (100%). Mean values are shown with SEM. The values are the results from two 
independent experiments with HI PAD enzymes and 500 and 1000 mU hPAD4 enzyme and at least three 
independent experiments for the other conditions. Kruskal-Wallis test followed by Dunn’s multiple 
comparison test were performed and revealed no statistical significance. 
 
In accordance with previous data, the activation of T cells within the PBMC population 
with anti-CD3/anti-CD28 antibodies resulted in a significant increase in the IL-2 levels 
secreted by these cells (Figure 4.6a). The treatment of PBMC with PAD enzymes 
without further activation did not induce changes in the levels of IL-2 secreted into the 
supernatant (Figure 4.6a). When PBMC were incubated with active hPAD2 and hPAD4 
enzymes prior to activation with antibodies against CD3 and CD28, the levels of IL-2 
secreted by these cells decreased significantly more than 50% (Figure 4.6b). In 
particular, when PBMC were pre-treated with 125mU and 250 mU of hPAD2 and 
hPAD4 enzymes before being activated with anti-CD3/anti-CD28 antibodies, the levels 
of IL-2 secreted into the supernatant decreased by about 50% from 1.4 ± 0.06 ng/mL 
to 0.66 ± 0.03 ng/mL and 0.067 ± 0.04 ng/mL, respectively. Empirically, 23 – 138 mU 
of PAD enzymes would be necessary to citrullinate MP from PBMC isolated from 20 
mL of whole blood, so 250 mU was the amount of PAD enzyme selected to be used in 
further studies. Due to the high amount of endotoxin detected on the PAD enzyme 
solutions (result in chapter 3), it was important to assess whether the effects induced 
by hPAD2 and hPAD4 enzymes were due to enzymatic or endotoxin activity. HI 
enzymes were used to test the effects of non-enzymatic contaminants, such as 
endotoxin, on the activation of T cells within the PBMC population with antibodies 
against CD3/CD28. In figure 4.6c it is possible to observe that the heat inactivation of 
PAD enzymes did not significantly alter the secretion of IL-2 by activated PBMC. 
Moreover, the secretion of IL-2 by PBMC was significantly decreased in PBMC pre-
treated with hPAD2 and hPAD4 enzymes prior to activation when compared to pre-
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treatment with HI PAD enzymes. These facts suggest that the decrease in the IL-2 
levels secreted by activated PBMC is due to the enzymatic activity of PAD enzymes 
and not other non-enzymatic contaminants such as LPS. 
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Figure 4.6 Effects of PAD enzymes on the secretion of IL-2 by PBMC after activation with anti-
CD3/anti-CD28 antibodies. PBMC were isolated from healthy volunteers. Five hundred thousand 
cells/mL were pre-incubated with PAD enzymes (2 hours at 37⁰ C), followed by activation with 1 μg/mL 
anti-CD3 antibody and 2 μg/mL anti-CD28 antibody for 24 hours at 37⁰ C. a) PAD enzymes treatment on 
PBMC. b) PBMC incubated with increasing amounts (0, 125, 250, 500 and 1000 mU) of PAD enzymes. c) 
HI PAD enzymes treatment on PBMC followed by activation. Supernatants from each tested condition 
were collected after the incubation time and the levels of IL-2 determined using an IL-2 ELISA kit 
(Peprotech EC Ltd., London, UK). Mean values are shown with SEM. The values are the results from two 
independent experiments for a) and c) and at least three independent experiments for b). Kruskal-Wallis 
test followed by Dunn’s multiple comparison test were performed. Statistical significance was defined as: 
** p-value < 0.01, *** p-value < 0.001, **** p-value < 0.0001. 
 
The effects of PAD enzymes on the expression of CD25 at the surface of CD4+ PBMC 
was also assessed. In line with the IL-2 data presented above, the median 
fluorescence intensity (MFI) of expression of CD25 at the surface of CD4+ PBMC was 
increased in 2 out of 3 donor cell populations after the cells have been activated with 
anti-CD3/anti-CD28 antibodies (Figures 4.7a and 4.7c). In addition to this, the number 
of CD4+ T cells expressing CD25 significantly increased on activation (Figure 4.7b). 
When PBMC from four independent donors were pre-treated with PAD enzymes prior 
to activation, the effect of activation to increase the percentage of positive cells was 
lost and no significant differences were observed in the expression of CD25 after anti-
CD3/anti-CD28 activation (Figures 4.7b and 4.7d). 
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Figure 4.7 Effects of PAD enzymes on the expression of CD25 on CD4
+
 T cells within the PBMC 
population after activation with anti-CD3/anti-CD28 antibodies. PBMC were isolated from healthy 
volunteers. Five hundred thousand cells/mL were pre-incubated with 250 mU PAD enzymes (2 hours at 
37⁰ C), followed by activation with 1 μg/mL anti-CD3 antibody and 2 μg/mL anti-CD28 antibody for 24 
hours at 37⁰ C. One hundred thousand PBMC were used in combination with anti-CD4-PE and anti-CD25-
APC conjugated antibodies on a Beckman Coulter flow cytometer. a) CD25 MFI. b) Percentage of CD4+ T 
cells expressing CD25 at the surface. c) CD25 MFI for the three independent experiments performed. b) 
Individual values for the percentage of CD4+ T cells expressing CD25 at the surface for the four 
independent experiments performed. Friedman test followed by Dunn’s multiple comparison test were 
performed. Statistical significance was defined as:  ** p-value < 0.01. 
 
These results suggest that PAD enzyme modification prior to activation may affect the 
IL-2 response observed from activated T cells within the PBMC population. 
4.4.3. Effects of peptidylarginine deiminase enzymes on the levels of L-lactate 
on activated T cells  
T cells rely on metabolic changes to fulfil the energy requirements essential for T cell 
proliferation [82, 414]. Lactate is an important by-product of aerobic glycolysis. In order 
to ascertain whether pre-treatment with PAD enzymes affected the PBMC metabolic 
switch after activation, the levels of extracellular lactate were assessed on 
supernatants collected from PBMC pre-treated with PAD enzymes and then activated 
for 24 hours. The activation of T cells in the PBMC population led to a decrease in the 
secretion of lactate to the supernatant. When PBMC were pre-treated with hPAD2 
enzyme prior to activation, the levels of lactate resemble the levels of lactate on 
unactivated cells. The treatment of PBMC with hPAD4 enzyme prior to activation of T 
cells did not show significant alterations in lactate accumulation compared to 
unactivated cells (Figure 4.8). 
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Figure 4.8 Effects of PAD enzymes on L-lactate levels on the supernatant of PBMC after activation 
with anti-CD3/anti-CD28 antibodies. PBMC were isolated from healthy volunteers. Five hundred 
thousand cells/mL were incubated with 250 mU PAD enzymes (2 hours at 37⁰ C), followed by activation 
with antibodies against CD3 and CD28 at 37⁰ C for 24 hours. The concentration of anti-CD3 antibody was 
1 μg/mL and the concentration of anti-CD28 antibody was 2 μg/mL. Supernatants from each tested 
condition were collected after the incubation time and the levels of L-lactate determined using a L-lactate 
assay kit (Abcam plc., Cambridge, UK). Mean values are shown with SEM. The values are the results 
from three independent experiments. Kruskal-Wallis test followed by Dunn’s multiple comparison test were 
performed. Statistical significance was defined as: * p-value < 0.05. 
 
4.4.4. Effects of peptidylarginine deiminase enzymes on gene expression of 
activated T cells  
The previous data has shown that T cell activation and metabolism are affected by pre-
incubation with PAD enzymes. In order to provide insight into the mechanisms by 
which extracellular protein modifications can influence downstream intracellular 
pathways, gene expression array analysis was undertaken. 
Genes with altered expression subsequent to citrullination of PBMC constitute a 
good indicator of signalling pathways affected by PAD enzymes. To investigate this, 
total RNA, including mRNA and micro RNA (miRNA), was isolated from PBMC pre-
treated with and without PAD enzymes and activated with anti-CD3/anti-CD28 
antibodies and analysed by microarray technology. By using this technology, 
thousands of target genes are analysed at the same time within different samples, 
producing complex and extend sets of data, which can be analysed by specific 
software to indicate key pathways that are affected by treatment with PAD enzymes. 
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GeneSpring GX software (Agilent Technologies LDA UK Ltd., Stockport, UK) was used 
to analyse the data produced by microarray and generate heat maps of entities 
determined to have a p-value less or equal to 0.05 and a fold change higher than 2 
between activated cells and the remaining conditions. Clustering analysis was applied 
to organise genes and conditions in the dataset into clusters based on the similarity of 
their expression profiles. The three replicates of unactivated PBMC clustered together 
in one of the branches of the clustering tree, while all the activated replicates (pre-
treated with PAD enzymes or not) clustered on a different branch. In terms of the PAD 
enzyme and activation treatments, the gene expression profile seemed to depend 
more on the replicate (donor) rather than on the treatment (Figure 4.9). 
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Figure 4.9 Clustered gene expression data of the effects of PAD enzymes on activated PBMC. PBMC were isolated from three healthy volunteers. Five hundred 
thousand cells/mL were pre-incubated with 250 mU PAD enzymes (2 hours at 37⁰ C), washed and followed by activation with antibodies against CD3 and CD28 at 37°C for 24 
hours. The concentration of anti-CD3 antibody was 1 μg/mL and the concentration of anti-CD28 antibody was 2 μg/mL. Following activation, mRNA was extracted using the 
miRNA micro kit (Qiagen Ltd., Manchester, UK) and the gene expression of three independent experiments analysed by microarray. Green and red indicate a positive and a 
negative log ratio, respectively. Clustering was carried out using a hierarchical algorithm. Tree diagrams group similar vectors into nodes; the height of each node indicates the 
overall similarity of its members.  
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When analysing the microarray data, activated PBMC were selected as the reference 
condition against which the effects of pre-incubation with PAD enzymes were 
compared. From this analysis, 1431 genes were detected as having increased 
expression on unactivated PBMC, whereas 2497 genes were identified as having 
decreased expression on unactivated PBMC. On PBMC pre-treated with hPAD2 
enzyme prior to activation, 39 genes were identified as up-regulated and 78 as down-
regulated. The treatment of PBMC with hPAD4 enzyme prior to activation led to the 
identification of 58 genes with up-regulated expression and 94 genes with down-
regulated expression. To narrow the dataset results, Venn diagrams were applied in 
order to identify the genes similarly up- or down-regulated by the two PAD enzymes. 
Eight genes were identified as having their expression increased by both hPAD2 and 
hPAD4 enzymes (Figure 4.10a), while thirty-five genes were identified as down-
regulated by the two enzymes (Figure 4.11a). Figures 4.10b and 4.11b represent the 
heat maps of the eight and thirty-five entities determined to be up- or down-regulated, 
respectively, by hPAD2 and hPAD4 enzymes, when compared with activated PBMC.  
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Figure 4.10 Up-regulated genes by hPAD2 and hPAD4 enzymes on activated PBMC. PBMC were 
isolated from three healthy volunteers. Five hundred thousand cells/mL were pre-treated with 250 mU of 
hPAD2 or hPAD4 enzymes, for 2 hours at 37⁰ C, and then stimulated with antibodies against CD3 and 
CD28 at 37⁰ C for 24 hours. The concentration of anti-CD3 antibody was 1 μg/mL and the concentration of 
anti-CD28 antibody was 2 μg/mL. Following activation, mRNA was extracted using the miRNeasy micro kit 
(Qiagen Ltd., Manchester, UK) and the gene expression of three independent experiments analysed by 
microarray using an Agilent DNA microarray scanner. Data was analysed using GeneSpring GX software 
(Agilent Technologies Inc.). Shift to 75.0 percentile was used as normalisation and median of all samples 
was applied as baseline transformation. a) Venn diagrams were used to identify the genes up-regulated by 
both hPAD2 and hPAD4 enzymes. b) Heat map of the eight up-regulated genes by hPAD2 and hPAD4 
enzymes. Green and red indicate a positive and a negative log ratio, respectively. 
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Figure 4.11 Down-regulated genes by hPAD2 and hPAD4 enzymes on activated PBMC. PBMC were 
isolated from three healthy volunteers. Five hundred thousand cells/mL were pre-treated with 250 mU of 
hPAD2 or hPAD4 enzymes, for 2 hours at 37⁰ C, and stimulated with antibodies against CD3 and CD28 at 
37⁰ C for 24 hours. The concentration of anti-CD3 antibody was 1 μg/mL and the concentration of anti-
CD28 antibody was 2 μg/mL. Following activation, mRNA was extracted using the miRNeasy micro kit 
(Qiagen Ltd., Manchester, UK) and the gene expression of three independent experiments analysed by 
microarray using an Agilent DNA microarray scanner. Data was analysed using GeneSpring GX software 
(Agilent Technologies LDA UK Ltd., Stockport, UK). Shift to 75.0 percentile was used as normalisation and 
median of all samples was applied as baseline transformation. a) Venn diagrams were used to identify the 
genes down-regulated by both hPAD2 and hPAD4 enzymes. b) Heat map of the thirty-five down-regulated 
genes by hPAD2 and hPAD4 enzymes. Green and red indicate a positive and a negative log ratio, 
respectively. 
 
To understand what intracellular pathways may be affected by the PAD enzyme 
treatment of PBMC prior to activation, gene ontology (GO) analysis was performed. 
Pathways with a p-value equal or lower than 0.05 and more than one identified entity 
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were considered. Of particular interest, pathways involved in metabolism of amino 
acids and proteins and immune regulation between lymphoid and non-lymphoid were 
identified as being up-regulated by PAD enzymes in PBMC prior to activation (Table 
4.5). The relevant pathways found to be down-regulated on PBMC by PAD enzymes 
prior to activation were associated with the complement system activation, lipid and 
glucose metabolism and the clot cascade (Table 4.6). 
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Table 4.3 Gene ontology analysis of pathways associated with genes up-regulated by hPAD2 and hPAD4 enzymes on PBMC prior to activation. 
Pathway p-value Matched Entities 
Pathway Entities of 
Experiment Type 
Hs_Metabolism_of_amino_acids_and_derivatives_WP2693_76898 3,8E-03 2 184 
Hs_Trans-sulfuration_pathway_WP2333_72015 0.0016 1 10 
Hs_Alanine_and_aspartate_metabolism_WP106_74147 0.0020 1 40 
Hs_GPCRs,_Class_C_Metabotropic_glutamate,_pheromone_WP501_79715 0.0025 1 15 
Hs_Urea_cycle_and_metabolism_of_amino_groups_WP497_72142 0.0033 1 37 
Hs_Trans-sulfuration_and_one_carbon_metabolism_WP2525_78541 0.0051 1 31 
Hs_Selenium_Metabolism_and_Selenoproteins_WP28_71888 0.0079 1 48 
Hs_Vitamin_B12_Metabolism_WP1533_79884 0.0082 1 53 
Hs_Folate_Metabolism_WP176_79883 0.0107 1 67 
Hs_Immunoregulatory_interactions_between_a_Lymphoid_and_a_non-
Lymphoid_cell_WP1829_76993 
0.0126 1 292 
Hs_Selenium_Micronutrient_Network_WP15_79870 0.0135 1 84 
Hs_Gastrin-CREB_signalling_pathway_via_PKC_and_MAPK_WP2664_76844 0.0227 1 147 
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Table 4.4 Gene ontology analysis of pathways associated with genes down-regulated by hPAD2 and hPAD4 enzymes on PBMC prior to activation. 
Pathway p-value Matched Entities 
Pathway Entities of 
Experiment Type 
Hs_Human_Complement_System_WP2806_78589 8,12E+01 3 136 
Hs_Complement_and_Coagulation_Cascades_WP558_79680 1,71E+02 3 61 
Hs_Statin_Pathway_WP430_78268 2,65E+03 2 31 
Hs_Lipid_digestion,_mobilization,_and_transport_WP2764_77026 4,33E+03 2 41 
Hs_Dissolution_of_Fibrin_Clot_WP1802_76989 0.0066 1 8 
Hs_Vitamin_D_Receptor_Pathway_WP2877_79998 0.0099 2 186 
Hs_SREBF_and_miR33_in_cholesterol_and_lipid_homeostasis_WP2011_75253 0.0131 1 18 
Hs_miR-targeted_genes_in_adipocytes_-_TarBase_WP2001_78529 0.0139 1 38 
Hs_Complement_Activation,_Classical_Pathway_WP545_72062 0.0139 1 17 
Hs_Farnesoid_X_Receptor_Pathway_WP2879_79602 0.0156 1 19 
Hs_Sphingolipid_Metabolism_WP1422_79871 0.0172 1 21 
Hs_Transport_of_vitamins,_nucleosides,_and_related_molecules_WP1937_77048 0.0188 1 24 
Hs_Triacylglyceride_Synthesis_WP325_71223 0.0196 1 24 
Hs_Post-translational_modification-_synthesis_of_GPI-anchored_proteins_WP1887_80028 0.0204 1 26 
Hs_Latent_infection_of_Homo_sapiens_with_Mycobacterium_tuberculosis_WP2700_76907 0.0237 1 62 
Hs_Phase_1_-_Functionalization_of_compounds_WP1879_76834 0.0261 1 33 
Hs_Nuclear_Receptors_in_Lipid_Metabolism_and_Toxicity_WP299_78587 0.0269 1 35 
Hs_Fatty_Acid_Beta_Oxidation_WP143_79783 0.0277 1 34 
Hs_Nucleotide-
binding_domain,_leucine_rich_repeat_containing_receptor_(NLR)_signaling_pathways_WP2763_77
025 
0.0285 1 38 
Hs_DAP12_interactions_WP2694_76901 0.0285 1 45 
Hs_NOD_pathway_WP1433_80018 0.0333 1 41 
Hs_Complement_cascade_WP1798_77042 0.0333 1 192 
Hs_Vitamin_A_and_Carotenoid_Metabolism_WP716_79968 0.0341 1 43 
Hs_Sphingolipid_metabolism_WP2788_77079 0.0365 1 46 
Hs_Binding_and_Uptake_of_Ligands_by_Scavenger_Receptors_WP2784_77068 0.0373 1 195 
Hs_Aryl_Hydrocarbon_Receptor_WP2586_79995 0.0381 1 48 
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Table 4.4 Continuation.  
Pathway p-value Matched Entities 
Pathway Entities of 
Experiment Type 
Hs_Differentiation_Pathway_WP2848_80009 0.0389 1 50 
Hs_Glycolysis_and_Gluconeogenesis_WP534_78585 0.0397 1 49 
Hs_Vitamin_B12_Metabolism_WP1533_79884 0.0405 1 53 
Hs_Transport_of_glucose_and_other_sugars,_bile_salts_and_organic_acids,_metal_ions_and_amin
e_compounds_WP1935_76949 
0.0421 1 52 
Hs_RANKL-RANK_Signaling_Pathway_WP2018_79959 0.0444 1 55 
Hs_Extracellular_matrix_organization_WP2703_76914 0.0468 1 58 
Hs_Kit_receptor_signaling_pathway_WP304_78799 0.0476 1 59 
Hs_Oxidation_by_Cytochrome_P450_WP43_79993 0.0492 1 64 
Hs_Integrin_cell_surface_interactions_WP1833_77019 0.0499 1 64 
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Based on function and localisation of the protein products, five of the forty-three 
identified genes were selected for further investigation. The genes with up-regulation 
selected for further analysis were ASS1 (encodes for argininosuccinate synthase 1 – 
ASS1) and CTH (encodes for cystathionine Ȗ-lyase – CTH) and the genes with down-
regulation selected were HK3 (encodes for hexokinase 3 – HK3), CD163 (encodes for 
CD163 molecule) and SGMS2 (encodes for sphingomyelin synthase 2 – SGMS2). The 
individual expression profile of these genes can be found in appendix 3. The 
expression of these selected genes was confirmed by RT-QPCR, since this is a more 
specific and accurate technique. When assessing gene expression by RT-QPCR, the 
experimental control previously used (unactivated PBMC treated with PAD enzymes 
but not activated) was also incorporated in the analysis. However, only one 
independent experiment was performed with the unactivated PBMC treated with 
hPAD2 enzyme.  
In general, the CT values obtained from RT-QPCR for the genes of interest and 
the housekeeper used were high which corresponds to low levels of gene expression 
(Tables 4.5 and 4.6). The biggest differences in CT values were observed in the 
expression of CTH, however, the expression levels of this gene were very low, with 
average CT values of 35.2 (Table 4.6) from one donor PBMC only. Expression could 
not be detected in PBMC from other volunteers.  
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Table 4.5 Raw CT values of the housekeeper 18S in the plate of each of the selected genes analysed by RT-QPCR. After PBMC treatment with PAD enzymes and 
activation with anti-CD3/anti-CD28 antibodies, the mRNA was extracted, converted into cDNA and used to evaluate the levels of ASS1, CTH, HK3, CD163, SGMS2 transcripts 
by RT-QPCR in a Agilent Max3000P QPCR system (Agilent Technologies LDA UK Ltd, Stockport, UK). Raw CT values are presented. N = number of independent experiments 
(healthy donors) performed. 
 
18S CT values for each primer plate 
 
ASS1 primer CTH primer HK3 primer CD163 primer SGMS2 primer 
 
Mean SEM N Mean SEM N Mean SEM N Mean SEM N Mean SEM N 
Unactivated 15.45 1.28 3 13.18 0.89 3 14.04 0.61 3 13.77 0.71 3 13.31 0.72 3 
Unactivated + hPAD2 16.27 0.08 1 21.66 3.08 1 16.51 0.14 1 16.02 0.08 1 15.86 0.16 1 
Unactivated + hPAD4 18.5 1.37 2 15.35 0.45 1 15.98 0.50 2 15.75 0.38 2 15.48 0.47 2 
Activated 17.43 1.55 3 14.45 1.81 2 14.79 0.98 3 14.46 1.00 3 13.75 1.12 3 
Activated + hPAD2 15.23 2.13 2 14.7 2.11 2 13.12 0.71 2 12.84 0.81 2 12.45 0.84 2 
Activated + hPAD4 16.94 1.88 3 14.83 0.30 3 15.19 0.27 3 15.18 0.42 2 14.70 0.39 3 
 
Table 4.6 Raw CT values of selected genes analysed by RT-QPCR. After PBMC treatment with PAD enzymes and activation with anti-CD3/anti-CD28 antibodies, the mRNA 
was extracted, converted into cDNA and used to evaluate the levels of ASS1, CTH, HK3, CD163, SGMS2 transcripts by RT-QPCR in a Agilent Max3000P QPCR system 
(Agilent Technologies LDA UK Ltd, Stockport, UK). Raw CT values are presented. * values higher than thirty-five were obtained, but these were not included for the data 
analysis. N = number of independent experiments (healthy donors) performed. 
 
CT values 
 
ASS1 primer CTH primer HK3 primer CD163 primer SGMS2 primer 
 
Mean SEM N Mean SEM N Mean SEM N Mean SEM N Mean SEM N 
Unactivated 29.81 0.51 3 32.88 1.01 3* 28.42 0.33 3 27.87 0.57 3 30.04 0.44 3 
Unactivated + hPAD2 31.48 0.41 1 37.75 2.20 1* 30.10 0.07 1 30.76 0.22 1 32.93 0.99 1 
Unactivated + hPAD4 36.86 1.84 2* 41.89 1.58 1* 29.47 0.61 2 30.10 0.57 2 31.60 0.79 2 
Activated 32.41 1.67 3* 31.20 1.85 2* 29.86 0.21 3 31.25 0.56 3 31.81 0.39 3 
Activated + hPAD2 29.15 0.89 2 32.66 3.30 2* 29.80 0.77 2 31.17 1.18 2 32.65 1.06 2* 
Activated + hPAD4 29.91 0.93 3 34.85 1.68 3* 29.96 0.49 3 30.19 0.44 2 32.87 0.87 3* 
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The expression of the selected genes in unactivated PBMC treated with PAD enzymes 
was compared within the different conditions using the comparative CT method. In 
addition, the expression of each gene was compared within the same donor that was 
used for all the conditions to access the variability within the same individual. From 
these results it was possible to observe that the gene expression showed high 
variation. The treatment of unactivated PBMC with hPAD4 enzyme showed a trend to 
an increase in the expression of ASS1 and HK3 and a decrease in the expression of 
CD163. The expression of SGMS2 showed no consistency between the treatment with 
hPAD2 and hPAD4 enzymes, being decreased with hPAD2 and increased with hPAD4 
(Figure 4.12). 
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Figure 4.12 Effect of PAD enzymes in the expression of selected genes in unactivated PBMC. After 
PBMC treatment with PAD enzymes, the mRNA was extracted, converted into cDNA and used to evaluate 
the levels of ASS1 (a, b), HK3 (c, d), CD163 (e, f), SGMS2 (g, h) transcripts by RT-QPCR. Results were 
obtained with the comparative CT method and are expressed as fold change relative to unactivated cells. 
Mean values are presented with SEM. The values are the result from the number of individual donors 
indicated, analysed in triplicate (Figures on the left). Same individual donor was analysed in triplicate to 
assess intra-assay variability (Figures on the right). One-way ANOVA followed by Tukey’s multiple 
comparison test was performed and no statistical significant differences were found. 
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The activation of T cells within the PBMC population induced a decrease in the 
expression of ASS1 and CD163, an increase in the expression of HK3 and no 
differences in the expression of SGMS2. From one experiment only, CTH expression 
was increased after the activation of T cells with anti-CD3/anti-CD28 antibodies, in line 
with previous microarray experiments (Figure 4.13). 
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Figure 4.13 Fold changes in the expression of selected genes in activated PBMC. After PBMC 
treatment with PAD enzymes and activation with anti-CD3/anti-CD28 antibodies, the mRNA was 
extracted, converted into cDNA and used to evaluate the levels of ASS1 (a), CTH (b), HK3 (c), CD163 (d), 
SGMS2 (e) transcripts by RT-QPCR. Results were obtained with the comparative CT method and are 
expressed as fold change relative to unactivated cells. Mean values are presented with SEM. The values 
are the result from the number of individual donors indicated, analysed in triplicate. Paired t-test was 
performed and no statistical significant differences were found. 
 
When analysing the expression of the selected genes in PBMC pre-treated with PAD 
enzymes followed by activation with the anti-CD3/anti-CD28 antibodies, the level of 
variation in the results was again high, in particular in conditions where hPAD2 enzyme 
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was used (Figure 4.14). ASS1 and CTH were the two genes selected after microarray 
analysis with increased expression in activated PBMC pre-treated with the two 
isoforms of PAD enzymes. When analysed by RT-QPCR, an increase in the 
expression of ASS1 was observed in PBMC pre-treated with both PAD enzymes prior 
to activation, when compared with activated PBMC, which is not statistically significant 
(Figure 4.14a). An increase in the expression of CTH was also observed in PBMC pre-
treated with both PAD enzymes prior to activation, when compared with activated 
PBMC. However, this resulted from the analysis of only one replicate data (Figure 
4.14b). HK3, CD163 and SGMS2 were the selected genes for which down-regulation 
of expression was observed by microarray after PAD enzyme treatments. HK3 
expression was non-significantly decreased in PBMC pre-treated with PAD enzymes 
prior to activation when compared with activated PBMC (Figure 4.14c). The expression 
of CD163 and SGMS2 in PBMC prior to activation showed a trend to differential 
regulation by PAD enzymes, showing decreased levels with hPAD2 enzyme and 
increased levels with hPAD4 enzyme (Figure 4.14d and 4.14e). Overall, the effect of 
hPAD2 pre-treatment prior to activation was greater than hPAD4 pre-treatment. 
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Figure 4.14 Effect of PAD enzymes in the expression of selected genes relative to activated PBMC. 
After PBMC treatment with PAD enzymes and activation with anti-CD3/anti-CD28 antibodies, the mRNA 
was extracted, converted into cDNA and used to evaluate the levels of ASS1 (a), CTH (b), HK3 (c), 
CD163 (d), SGMS2 (e) transcripts by RT-QPCR. Results were obtained with the comparative CT method 
and are expressed as fold change relative to activated cells. Mean values are presented with SEM. The 
values are the result from the number of experiments indicated. One-way ANOVA followed by Tukey’s 
multiple comparison test was performed and no statistical significant differences were found. 
 
High variation in the expression levels of the selected genes was found in the RT-
QPCR data. Individual donor variability and the use of the entire PBMC population are 
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possible explanations for this. For the study of these genes in clinical samples, in 
chapter 5, more samples will be analysed and the gene expression will be assessed in 
CD4 and CD8 T cell subsets instead of the total PBMC population.  
 
4.4.5. Effects of peptidylarginine deiminase enzymes on cell surface proteins of 
PBMC after T cell activation 
In order for PAD enzymes to exert any effects on activation pathways of T cells, 
modification of cell surface proteins or MP by citrullination is predicted. To investigate 
this, MP were extracted from unactivated PBMC, activated PBMC and activated PBMC 
pre-treated with PAD enzymes obtained from three healthy individuals, then they were 
pooled together and analysed by 2D BN/SDS-PAGE, as previously validated in chapter 
3. 
 The gels of MP separated by 2D BN/SDS-PAGE from studied conditions were 
compared using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis 
software (Figure 4.15). “Activated PBMC” was the condition selected as reference and 
in figure 4.15a it is possible to observe two predominant spots in the right side of the 
gel with molecular weights in the region of 25–100 kDa. In the upper left region of all 
the gels, corresponding to proteins/complexes with lesser migration in the 1D BN-
PAGE, a smear was visible, suggesting that high MW protein complexes were not 
completely separated or were not completely denatured to run accurately on the 2D 
BN/SDS-PAGE (Figure 4.15). Figures 4.15b–e represent the overlay between the 
reference gel (“activated PBMC”) and the other tested conditions. For all of them it is 
possible to observe some alterations in the two spots previously mentioned. However, 
the profile of the tested conditions was similar to the reference condition. Using the 
SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software it was possible 
to compare the normalised intensity of particular spots in the different conditions 
tested. One hundred and fifty spots were identified by the software as having 
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normalised intensity with fold changes higher than two between the different conditions 
tested (Figure 4.16a). The large area of unresolved proteins at the top of the gel was 
excluded from the analysis as well as speckles and the borders of the gels. 
Comparison was then performed manually and nine spots were identified across the 
five conditions (Figure 4.16b). The top spot was divide into six smaller regions, 
identified by spots 260, 258, 249, 246, 247 and 250. The individual analysis of each 
spot did not show consistency between PAD treated and non-PAD treated conditions 
(Figures 4.17, 4.18 and 4.19). The bottom spot was divided into three smaller spots 
(242, 244 and 245) and the individual analysis of these revealed some difference 
between PAD-treated activated and non-PAD treated activated conditions for spots 
244 and 245, where a decreased intensity was observed when PBMC were pre-treated 
with PAD enzymes (Figure 4.20). Spots 244 and 245 were then selected for 
identification by mass spectrometry. 
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Figure 4.15 SameSpots software gels comparison from PBMC MP separation by 2D BN/SDS-PAGE. PBMC were isolated from healthy volunteers. Five hundred 
thousand cells/mL were incubated with 250 mU PAD enzymes (2 hours at 37⁰ C), followed by activation with antibodies against CD3 (1 µg/mL) and CD28 (2 µg/mL) at 37°C 
for 24 hours. After, MP from three independent experiments were extracted using the Mem-PER Plus membrane protein extraction kit (Thermo Fisher Scientific lnc., 
Loughborough, UK) and pooled together. Twenty-five micrograms (25 µg) of MP were separated by 2D BN/SDS-PAGE in the presence of 0.625% (v/v) DDM. In the first 
dimension a NativePAGE™ Novex™ 4–16% Bis-Tris gel was used and in the second dimension, the 1D strip was separated in TGX Mini-PROTEAN® TGX™ 8–16% pre-cast 
gel. After separation, the gels stained with high sensitivity CBB G250 and analysed using SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) software. Activated PBMC 
were used as the reference gel (a) and aligned with the unactivated PBMC gel (b), activated PBMC pre-treated with hPAD2 enzyme (c), activated PBMC pre-treated with 
hPAD4 enzyme (d) and unactivated PBMC treated with hPAD4 enzyme (e). Pink gel represents the reference gel (activated PBMC) and the green gel represents the 
comparison.  
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Figure 4.16 SameSpots software spots identification from PBMC MP separation by 2D BN/SDS-
PAGE. After PBMC treatment with PAD enzymes and activation with anti-CD3/anti-CD28 antibodies, MP 
were extracted using the Mem-PER Plus membrane protein extraction kit (Thermo Fisher Scientific lnc., 
Loughborough, UK). Twenty-five micrograms (25 µg) of MP pooled together from three independent 
experiments were separated by 2D BN/SDS-PAGE in the presence of 0.625% (v/v) DDM. In the first 
dimension a NativePAGE™ Novex™ 4–16% Bis-Tris gel was used and in the second dimension, the 1D 
strip was separated in TGX Mini-PROTEAN® TGX™ 8–16% pre-cast gel. After separation, the gels 
stained with high sensitivity CBB G250 and analysed using SameSpots (TotalLab ltd., Newcastle upon 
Tyne, UK) software. Activated PBMC were used as the reference gel. (a) Initial spot detection by the 
SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) software. (b) Spots manually selected for further 
investigation by visual analysis. 
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Figure 4.17 Graphical representation of normalised expression profile of spots 260, 258 and 249 
using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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Figure 4.18 Graphical representation of normalised expression profile of spots 246 and 247 using 
the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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Figure 4.19 Graphical representation of normalised expression profile of spot 250 using the 
SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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Figure 4.20 Graphical representation of normalised expression profile of spots 242, 244 and 245 
using the SameSpots (TotalLab ltd., Newcastle upon Tyne, UK) analysis software. 
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4.4.6. Identification of membrane proteins modified by PAD enzymes by mass 
spectrometry 
The analysis of the samples by the neutral loss method (LC-CID-saETD-MS/MS) after 
digestion with trypsin allowed the identification of several proteins for each of the spots 
analysed. The results obtained were filtered according with the number of unique 
peptides and the sequence coverage. Proteins with more than two peptides identified 
and sequence coverage higher than ten per cent were considered for analysis 
(Appendix 4). To note, the main hits for all the conditions were human keratin and 
human serum albumin and these were not further considered.  
Plasma and intracellular organelle MP were identified in the analysed spots 
(244 and 245) from different conditions. In order to narrow down the dataset results, 
Venn diagrams were applied to identify the proteins exclusively associated with PAD 
enzymes. Despite the fact that all of the proteins identified exclusively associated with 
PAD enzymes on spots 244 and 245 can be found in the extracellular milieu or at the 
plasma membrane, some of them exert their main functions in the membrane of 
intracellular organelles, as described later on. 
In spot 244, thirty-seven proteins were identified in all the conditions. From 
these, proteins complement component 1 Q subcomponent-binding protein (C1QBP), 
mitochondrial (fragment), Rho GDP-dissociation inhibitor 1 (RhoGDI) (fragment) and 
synaptogyrin-2 were only identified in the gels from PBMC treated with hPAD2 and 
hPAD4 enzymes (Figure 4.21a and table 4.7). C1QBP is an inhibitor of the classical 
pathway of the complement system since it binds to component C1q and consequently 
inhibits its association with C1r and C1s, suggesting a relationship with the innate 
immune system. RhoGDI is involved in the regulation of intracellular signalling through 
Rho GTPases. Synaptogyrin-2 is a membrane protein expressed with pre-synaptic 
vesicles in neuronal cells, being involved in synaptic plasticity. 
In spot 245 it was possible to identify a total of thirteen proteins amongst all the 
conditions. Two proteins, ATP synthase subunit beta, mitochondrial (ATP5B), and 
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calreticulin (CRT), were only identified in the gels from PBMC treated with hPAD4 
enzyme while no proteins were specifically identified in the gels from PBMC treated 
with hPAD2 enzyme (Figure 4.21b and table 4.8). ATP5B is part of the complex of 
ATPase that is responsible for the synthesis and/or hydrolysis of ATP combined with 
the transport of protons across the mitochondrial membrane. CRT is involved in the 
secretory pathway, where its main function is to prevent misfolded proteins from being 
exported from the endoplasmic reticulum to the Golgi apparatus. 
 
 
Figure 4.21 Venn diagrams representation of the proteins identified by LC-CID-saETD-MS/MS in 
spots 244 (a) and 245 (b). PBMC were isolated from healthy volunteers. Five hundred thousand cells/mL 
were pre-treated with 250 mU of hPAD2 or hPAD4 enzymes, for 2 hours at 37⁰ C, and then stimulated 
with antibodies against CD3 and CD28 at 37⁰ C for 24 hours. The concentration of anti-CD3 antibody was 
1 μg/mL and the concentration of anti-CD28 antibody was 2 μg/mL. Following activation, MP from three 
independent experiments were extracted using the Mem-PER Plus membrane protein extraction kit 
(Thermo Fisher Scientific lnc., Loughborough, UK). Twenty-five micrograms (25 µg) of MP were separated 
by 2D BN/SDS-PAGE in the presence of 0.625% (v/v) DDM. In the first dimension a NativePAGE™ 
Novex™ 4–16% Bis-Tris gel was used and in the second dimension, the 1D strip was separated in TGX 
Mini-PROTEAN® TGX™ 8–16% pre-cast gel. After separation, the gels were stained with high sensitivity 
CBB G250 and spots 244 and 245 were collected, the proteins digested with trypsin gold and the resulting 
peptides extracted and analysed by LC-CID-saETD-MS/MS in a LTQ-Orbitrap Velos ETD mass 
spectrometer (Thermo Fisher Scientific lnc., Loughborough, UK) coupled to a Dionex Ultimate 3000 HPLC 
system (Sunnyvale, USA). Data were analysed using Proteome Discoverer 1.0 SPI software (Thermo 
Fisher Scientific lnc., Loughborough, UK). 
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Table 4.7 Proteins identified for spot number 244 exclusively associated with hPAD2 and hPAD4 enzymes treated PBMC. The accession number is the unique 
identifier used for the protein sequence. 
Accession 
number 
Protein Function Localisation 
I3L3Q7 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial (Fragment) 
Inhibition of C1 activation 
Cytosol, extracellular, mitochondrion, nucleus, 
plasma membrane 
J3KTF8 Rho GDP-dissociation inhibitor 1 (Fragment) 
Regulation of signalling through 
Rho GTPases 
Cytoskeleton, cytosol, extracellular 
O43760 Synaptogyrin-2 Synaptic plasticity Extracellular, plasma membrane 
 
Table 4.8 Proteins identified for spot number 245 exclusively associated with hPAD4 enzyme treated PBMC. The accession number is the unique identifier used for the 
protein sequence. 
Accession 
number 
Protein Function Localisation 
P06576 
ATP synthase subunit beta, 
mitochondrial 
ATP synthesis 
Extracellular, mitochondrion, nucleus, plasma 
membrane 
P27797 Calreticulin 
Promotes folding, oligomeric assembly and quality control in the 
endoplasmic reticulum 
Cytosol, endoplastic reticulum, extracellular, 
nucleus 
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Two citrullinated peptides were found in proteins from the two analysed spots 
(Appendix 4): actin, cytoplasmic 1; and complement component 1 Q subcomponent-
binding protein. From these, the peptide where citrullination was detected in actin (spot 
245 in hPAD2- and hPAD4-treated PBMC) was the same identified in non PAD-treated 
actin, cytoplasmic 1 (spot 244). The citrullinated peptide identified in complement 
component 1 Q subcomponent-binding protein (spot 244 in hPAD4-treated PBMC) was 
not identified in any of the non PAD-treated samples. However this is a mitochondrial 
protein and consequently, not one of the specific targets of this study.  
 These results suggest that the approach used here, 2D BN/SDS-PAGE 
followed by LC-CID-saETD-MS/MS, might not be the most effective method for the 
identification of citrullinated MP in the conditions studied here. The fact that MP contain 
less arginine residues than intracellular proteins is one of the limitations of this 
approach since the available sites for tryptic cleavage will be considerably decreased. 
The identification of only one citrullinated arginine residue might be reflection of this.  
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4.5. Discussion 
Citrullination is the enzymatic PTM mediated by PAD enzymes, responsible for the 
conversion of peptidylarginine into peptidylcitrulline in a calcium dependent manner 
[109]. This conversion results in the loss of positive charge in the protein, affecting the 
protein structure and leading to the formation of new motifs and the generation of 
neoepitopes [109, 335]. Citrulline is a non-essential amino acid, consequently 
citrullination is a vital physiological reaction, being involved in keratinization of epithelial 
cells [120-124], inflammation [133, 147-150] and apoptosis [133, 140]. Five human 
isoforms of PAD enzymes (PAD1–4 and PAD6) have been described and are 
differentially expressed in specific tissues. Except for the PAD4 enzyme, which 
translocate to the nucleus, PAD enzymes are typically located in the cytoplasm of 
different cell types [336]. Of particular interest, PAD enzymes expressed in white blood 
cells recruited to inflammation sites, can be released to the extracellular environment 
when apoptosis occurs and act on extracellular proteins. This will lead to the formation 
of neoantigens and the triggering of an immune response through the production of 
ACPA. This mechanism of citrullination-induced autoimmunity has been described in 
RA [421] and PID [286]. RA and PID share similar pathological processes, including 
gene- and environmentally-associated disease susceptibility, soft and hard tissue 
destruction triggered from an exaggerated inflammatory response and the involvement 
of bacteria in the aetiology of the disease [284, 422]. Other key factors linking these 
two inflammatory diseases include the local and systemic production of autoantibodies 
[282, 355, 422-425] and the production of citrullinated peptides recognised by 
autoreactive T cells [285, 426]. 
FNG is an example of an extracellular protein that is found to be citrullinated in 
RA. ACPA against citrullinated FNG were found in the serum and synovial fluid of RA 
patients and constitute a well-known marker for RA with excellent sensitivity and 
specificity [363, 427]. 
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It is then established that citrullination is involved in the breakdown of the 
immune system in diseases as RA and PID. However, to date, no studies have 
investigated the role of these enzymes in the activation of T cells. 
The activation and proliferation of T cells induced by antigens are important 
characteristics of adaptive immune responses. The activation of T cells is triggered by 
the presentation of antigen peptides to TCR/CD3 through MHC molecules, but co-
stimulatory molecules are also essential for the activation of T cells, such as CD28/B7 
[428]. When T cells become activated, the secretion of IL-2 to the extracellular medium 
and the expression of the CD25 are up-regulated [429-431]. The interaction between 
IL-2 and CD25 induces T cell growth, differentiation and survival [419, 432]. 
In this chapter, different models of T cell activation were studied and the effects 
of PAD enzymes on T cell activation were investigated by analysing the secretion of IL-
2 and the expression of CD25 at the cell surface. Furthermore, the consequences of 
PAD enzyme treatments were also assessed at nuclear (gene expression) and cell 
membrane (MP at the cell surface) levels. 
Jurkat E6.1 T cells and PBMC were the two T cell models compared. Since 
Jurkat E6.1 T cells are an immortalised cell line it was important to compare their 
activation responses with primary immune cells. Primary T cell responses were studied 
within the PBMC population, where T cell activation is closer to physiological 
conditions. Furthermore, it was previously shown that essential stimulatory signals for 
T cell proliferation are provided by non-T cells [433-435]. PHA-L and anti-CD3/anti-
CD28 antibodies were the two stimulation methods selected. PHA-L crosslinks 
glycosylated proteins on the surface of T cells, resembling what happens during TCR 
activation [436]. Antibodies against CD3 and CD28 activate T cells similarly to APC, 
proving the initial (CD3 binding) and the co-stimulatory (CD28 binding) signals. 
Secretion of IL-2, quantified by ELISA, and expression of CD25 at the cell surface, 
analysed by flow cytometry, were compared on the different tested combinations. From 
these data, PBMC stimulated with 1 µg/mL anti-CD3 and 2 µg/mL anti-CD28 for 24 
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hours were the combination selected for the subsequent citrullination studies. These 
were not the conditions that induced maximal changes in IL-2 and CD25 levels, 
however, as there was no indication on the effect of citrullination on the activation of T 
cells, a maximal T cell stimulation in control conditions without PAD enzymes was not 
the considered objective. Duarte et al., showed previously that T cells stimulated with 
PHA lose their ability to respond to allogenic stimulation or viral antigens in vitro, 
whereas immune functions are preserved on CD3/CD28-stimulated T cells. The 
hypothesised reason for this is the distribution of CCR7/CD45RA T cell functional 
subsets. The activation of T cells via CD3/CD28 mimics the lineage differentiation 
pattern induced by antigens in physiological conditions, while in PHA induced 
activation the distribution of the CCR7/CD45RA functional T cell subsets is skewed, 
with near disappearance of the subpopulations that display the effector phenotype 
[437]. 
Here, PBMC were incubated with PAD enzymes (isoforms 2 and 4), followed by 
activation with the conditions selected previously (1 µg/mL anti-CD3 and 2 µg/mL anti-
CD28 for 24 hours) and analysed for IL-2 secretion and IL-2Rα expression. PBMC 
viability after the treatments was also assessed and showed no differences when 
compared with unactivated and untreated PBMC, suggesting that citrullination was not 
toxic for the cells. Flow cytometric analysis of CD4/CD25 double-stained PBMC 
allowed evaluation of the number of CD4 T cells expressing CD25 at their surface and 
also the amount of CD25 expressed by CD4 T cells. The PBMC population was 
narrowed to CD4 T cells in this case since these cells are involved in the humoral 
immune response associated with citrullination. The flow cytometry results showed an 
increase in the percentage of CD4 T cells expressing CD25 at the surface. PBMC from 
healthy individuals consist of 70–90% of lymphocytes (B and T cells) and within the 
lymphocyte population, approximately 75% consist of CD4 and CD8 T cells [438]. In 
vivo, CD25 is expressed by CD4 T cells upon activation, accounting for approximately 
205 
 
30–40% of the total population of PBMC. Here, an average 35% of CD4 T cells were 
found to express CD25 at their surface after activation with anti-CD3/anti-CD28.  
In PBMC pre-treated with hPAD2 or hPAD4 enzymes, then activated the 
number of CD4 T cells expressing CD25 at the surface was lower than in activated 
PBMC. However, the level of CD25 expressed by CD4 T cells pre-treated with PAD 
enzymes did not show consistent results between the replicates. The levels of IL-2 
secreted by the cells showed a significant increase when the cells were activated via 
CD3/CD28. However, no difference was observed when the cells were treated with 
hPAD2 or hPAD4 enzymes without activation, suggesting that PAD enzymes by 
themselves do not induce alterations in the secretion of IL-2 by T cells. PBMC pre-
treated with hPAD2 and hPAD4 enzymes, then activated showed a significant 
decrease of more than 50% in the levels of secreted IL-2, when compared with 
activated cells. This was observed for all the tested concentrations of PAD enzymes. 
The HI-PAD enzyme pre-treatment effect on IL-2 secretion was not significantly 
different from activation alone. In chapter 3 it was shown that FNG treated with HI PAD 
enzymes had a similar SDS-PAGE profile to FNG treated with PAD enzymes in the 
presence of EDTA, suggesting that HI was effective for denaturing PAD. 
Several studies have previously reported impairments in T cell responses in 
PID models [232, 236-240, 439]. Furthermore, deficits in the IL-2 response were 
reported in T cells from PID patients [243, 440].  
Human PAD2 and hPAD4 enzymes share 50% of sequence homology. 
However, these two PAD enzyme isoforms localise differently inside the cell, are 
expressed by different cells and their expression and activation are separately 
regulated [133, 149, 441, 442]. Human PAD2 and hPAD4 enzymes also differ in 
stability, calcium dependency, optimal pH range and substrate specificity [377, 378]. 
These isoforms were chosen due to their increased expression in the synovium of RA 
patients [187] and their presence in the inflamed gingiva of periodontitis patients [443]. 
Darrah et al. suggested that substrate specificity and activity of different PAD enzymes 
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are linked with the specific distribution of each PAD enzyme isoform [442]. 
Physiologically these enzymes are localised intracellularly. However, in pathological 
conditions, apoptosis or necrosis of cells (macrophages and neutrophils) leads to the 
release of intracellular content, including intracellular PAD enzymes. Here, hPAD2 and 
hPAD4 enzymes were added to the extracellular medium of PBMC, to mimic 
pathological conditions. To estimate the amount of PAD enzyme necessary to 
citrullinate MP in the PBMC population it was calculated that from 40 x 106 PBMC 
obtained from 20 mL of blood, 200–1200 µg total protein should be achieved [444] and 
of this 23% would be membrane-spanning proteins [445]. ModiQuest Research B. V. 
(Oss, Netherlands), the commercial supplier of PAD enzymes, recommends the use of 
50 mU of hPAD2 or hPAD4 enzyme for the citrullination of 100 µg of pure protein. 
According to this, 23–138 mU of PAD enzymes would be enough for the conversion of 
arginine residues on MP isolated from 20 mL of whole blood. The different 
concentrations of PAD enzymes used here showed similar results on the impairment of 
IL-2 secretion from T cells and, consequently, 250 mU was the concentration selected 
for further studies, since it is above the required amount estimated empirically, and 
was used for 2 hours, as this time was previously shown to be sufficient for PAD 
enzymatic activity, given the necessary cofactors are in place [196]. After treatment, 
PAD enzymes were removed by careful washing to minimise the risk of citrullination of 
the activation antibodies. 
A key regulator of PAD enzyme activity is calcium. The binding of calcium 
changes the conformation of the catalytic site of PAD enzymes, affecting the enzyme-
substrate interaction [111]. Half-maximal PAD enzyme activities are reached at calcium 
concentrations ranging from 40 μM to 3.3 mM [196, 315, 446, 447]. In resting cells, the 
levels of intracellular calcium are low and not sufficient for PAD enzyme activity. 
However, after cell stimulation or with membrane disintegration calcium reach 
maximum levels that allow PAD enzyme activation [448]. Calcium concentration of the 
RPMI medium used in this study is 0.4 mM, being sufficient for PAD enzyme activity.  
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The treatment of PBMC with hPAD2 and hPAD4 enzymes prior to T cell 
activation showed a significant decrease in the IL-2 secretion, suggesting alterations in 
the IL-2 T cell response. IL-2 is essential for T cell activation and proliferation. 
Decreased IL-2 production was previously reported in patients with autoimmune 
disease systemic lupus erythematosus (SLE) [449], in cultured lymphocytes from 
patients with SLE [450] and in SLE murine models [451]. The reduced IL-2 secretion in 
SLE was suggested to be derived from dysregulation of transcription or suppression of 
IL-2 production in SLE T cells [452]. The main consequences of the dysregulation of 
IL-2 secretion in SLE are the reduction in the number of Tregs that are involved in the 
inhibition of autoimmunity, the impairment of AICD, necessary for the down-regulation 
of expanded T cell clones [453, 454], and defective CD8 T cell cytotoxic functions 
[455]. Also consistent with the results observed here, in vitro studies in T cells isolated 
from SLE patients and activated with PHA, revealed impaired IL-2 secretion but normal 
expression of IL-2R [456].  
Upon activation, T cells switch their metabolism from OXPHOS to aerobic 
glycolysis and glutaminolysis [84, 457]. The increased glycolytic flux during T cell 
activation leads to the concomitant production of lactate via aerobic glycolysis [458]. 
However, the results obtained here show a decrease in the extracellular levels of 
lactate in activated PBMC when compared with unactivated cells. In addition to being a 
by-product of highly proliferative cells, lactate, is also thought to be involved in the 
modulation of the immune response [459-462]. In T cells the accumulation of lactate in 
the inflammation site leads to a loss of T cell mobility and their consequent entrapment 
at the site, perpetuating the chronic inflammatory process. Sodium lactate was shown 
to inhibit the mobility of activated CD4 T cells upon engagement of the chemokine 
receptor CXCR3 with the chemokine CXCL10 due to interference with glycolysis. In 
CD8 T cells lactic acid is responsible for cell mobility inhibition, in a glucose-
independent manner [463]. In accordance with this, the results obtained in the PBMC 
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citrullination study show that a higher lactate level was associated with hPAD2 activity, 
with lower IL-2 secretion and, consequently, a non-activated T cell profile.  
Following these findings it was crucial to understand how PAD enzymes 
modifications, both at cell membrane level and intracellularly at gene expression level, 
were affecting the T cell response. 
Alterations in gene expression were evaluated by microarray analysis and 
confirmed by RT-QPCR. In the microarray study, eight genes were identified as up-
regulated by both PAD enzymes in activated PBMC, while thirty-five genes were 
identified as down-regulated in the same conditions. From these, genes involved in 
metabolism, redox signalling or membrane-associated processes were selected for 
further analysis. Up-regulated ASS1 and CTH and down-regulated HK3, CD163 and 
SGMS2 were the genes analysed by RT-QPCR.  
ASS1 encodes for ASS1 enzyme, which is involved in the conversion of 
citrulline into arginine in the urea cycle. ASS1 contributes to T cell differentiation and 
function. Deficiency in ASS1 enzyme (citrullinemia type I) affects in vitro Th1 and Th17 
polarization negatively, and associates with primary immune dysfunction [464]. 
Moreover, it was previously shown that extracellular arginine depletion blocks 
proliferation of activated normal T cells [465-467] and aerobic glycolysis [468], but 
provided that citrulline is present extracellularly, T cells can overcome this impairment 
by de novo synthesis of arginine via ASS1 [464, 468, 469]. The results obtained here 
showed an up-regulation of ASS1 in activated PBMC pre-treated with PAD enzymes, 
suggesting de novo synthesis of arginine possibly to overcome a decrease in the 
arginine supply that is related with impaired T cell proliferation. If this would be the 
case, aerobic glycolysis would also be impaired. To enforce this fact, HK3 expression 
was found to be down-regulated in the microarray results. HK3 encodes for HK3 
enzyme that is responsible for the conversion of glucose into glucose 6-phosphate in 
the first step of glycolysis. Upon activation, T cells rely on glycolysis and glutamine 
oxidation, to produce biosynthetic precursors required for rapid cell growth and 
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proliferation [72]. Here, the treatment of PBMC with PAD enzymes, in particular with 
hPAD2 enzyme, revealed a decrease in the expression of HK3, consistent with an 
impairment of glycolysis. 
CD163 and SGMS2 both encode for cell surface proteins. CD163 is a 
monocyte/macrophage-specific scavenger receptor. As PBMC were used here as the 
studied population, it was not a surprise to detect genes expressed by other cell types 
than T cells. CD163 was previously shown to be up-regulated in RA [470] and 
spondylarthritis (SpA). The soluble form of CD163 was also associated with global 
inflammation and impairment of T cell activation in SpA synovium. [471]. On the 
contrary here, CD163 was found to be down-regulated in activated PBMC pre-treated 
with PAD enzymes. The enzyme SGMS2 is encoded by SGMS2 and is responsible for 
the biosynthesis of sphingomyelin, a key lipid component of the cell and Golgi 
membranes and lipid rafts. SGMS2 is also involved in the regulation of protein 
trafficking and secretion [472]. Furthermore, sphingomyelin is part of the specific 
microdomains of the plasma membrane that are associated with CD3-induced TCR 
activation [473, 474]. Several studies revealed that the sphingomyelin biosynthetic 
pathway is associated with TCR signalling in activated T cells. Asano and colleagues 
showed that SGMS1 and 2 deficiencies in mouse embryonic fibroblasts promote cell 
migration via CXCL12/CXCR4-dependent signalling pathway [475]. In another in vivo 
study, activated T cells from mice with impaired ceramide generation exhibited less 
secretion of IL-2 than wild type animals, due to a dysfunction of the secretory vesicle 
system [476]. SGMS2 was one of the genes identified as down-regulated by PAD 
enzymes on the microarray results which is not in accordance with the studies 
discussed above. When the same experiment was assessed by RT-QPCR down-
regulation of SGMS2 in activated T cell pre-treated with PAD enzymes was not 
observed.  
CTH gene encodes for CTH. This enzyme converts cystathionine into Cys, α-
ketobutyrate and ammonia in one of the steps of the GSH biosynthesis pathway; it is 
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involved in redox signalling. Martin et al. have previously shown that physiological 
oxidative stress up-regulates the expression of this gene in rat hepatic cells [477]. Cys 
is essential for protein synthesis, cell proliferation and T cell activation [478]. However, 
in T cells CTH is not present. To overcome this, cystine can be imported from the 
extracellular environment via the plasma-membrane xc− cystine–glutamate exchanger. 
Once inside the cell, cystine is rapidly reduced to cysteine due to the reducing 
intracellular environment. Naïve T cells express no or very low levels of xc− transporter 
[479-481] and consequently depend on APC to export Cys that can then be imported 
by T cells via their alanine-serine-cysteine transporter and used for the synthesis of 
GSH [478]. In activated T cells, the xc− transporter was found strongly upregulated in 
human and mouse T cells, providing the necessary cystine/cysteine for cell 
proliferation [479, 482, 483]. CTH was detected as up-regulated on the microarray 
study and this was further confirmed by RT-QPCR. A possible reason for the detection 
of this gene and its up-regulation by PAD enzymes is the use of the entire PBMC 
population to study PAD enzyme effects instead of an individual T cell population. 
Despite the fact that CTH was quantified by RT-QPCR it is important to note that a raw 
CT value less than forty was only obtained in one of the independent experiments 
performed, indicating low levels of expression of this gene. 
A common fact between the different genes analysed was the high level of 
variation in the results between experiments. An explanation for this is the fact that the 
entire PBMC population was used for these studies instead of an individual cell 
population. To counteract this and to identify what T cell population is responsible for 
the gene expression, in subsequent studies, CD4 and CD8 T cells were isolated prior 
to RT-QPCR. 
 In combination with the identification of specific genes’ expression affected by 
citrullination, the identification of modified MP that may mediate the effects of 
citrullination in T cells was also an objective of this chapter. In the previous chapter it 
was shown that 2D BN/SDS-PAGE, despite not ideal, could be a technique used for 
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the separation of T cells and that LC-CID-saETD-MS/MS could be used to the 
identification of arginine residues modified by citrullination. From the two analysed 
spots from PBMC citrullinated with PAD enzymes it was possible to identify proteins 
exclusively associated with PAD enzyme treatment: C1QBP, RhoGDI, synaptogyrin-2, 
ATP5B and CRT that associate with membranes. From the 2D BN/SDS-PAGE 
analysis these five proteins appeared to be down-regulated in PAD-treated PBMC. 
C1QBP is a multicompartmental glycoprotein that is involved in inflammation, 
infection, ribosome biogenesis, apoptosis regulation, transcriptional regulation and pre-
mRNA spicing. At the cell surface, this protein is involved in the inhibition of the 
classical pathway of the complement system, through the binding to component C1q 
[484]. In addition, C1QBP can bind to coagulation factor XII, promoting its auto-
activation and the initiation of blood clotting via the intrinsic pathway of coagulation and 
inflammatory reactions [485].  
RhoGDI is involved in the regulation of intracellular signalling through Rho 
GTPases. Rho GTPases are a family of signalling G proteins that are mainly involved 
in the regulation of the actin cytoskeleton but also influence cell polarity, microtubule 
dynamics, membrane transport pathways and transcription factor activity [486]. In T 
cells, the engagement of the TCR leads to the activation of Rac proteins, members of 
the Rho GTPase family, that are implicated in the regulation of MAPK, PI3K and 
calcium pathways [487]. Studies on Rac2 knockout animal models showed decrease 
activation of ERK1/2 and p38 and calcium mobilisation, defective TCR-mediated 
proliferation and lower levels of IL-2 and IFN-Ȗ in CD4 T cells [488, 489]. RhoGDI 
inhibits the activation of Rho GTPases by preventing the dissociation of GDP and by 
blocking their recruitment to the plasma membrane [490]. RhoGDI is a substrate of 
gene related to anergy in lymphocytes (GRAIL), part of E3 ubiquitin ligase enzyme, 
suggesting that ubiquitination of RhoGDI is involved in the establishment of T cell 
anergy [491]. 
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Synaptogyrin-2 is a membrane protein expressed with pre-synaptic vesicles in 
neuronal cells, being involved in synaptic plasticity. In view of its physiological 
localisation, synaptogyrin-2 will not be further considered. 
ATP5B is part of the ATPase complex that is responsible for the synthesis 
and/or hydrolysis of ATP combined with the transport of protons across the 
mitochondrial membrane. ATP5B is localised mainly in the inner membrane of the 
mitochondria, but it can translocate from the mitochondria and be found on the outside 
of the cell membrane [492].  
CRT is mainly localised in the endoplasmic reticulum where it acts as a 
calcium-binding (storage) protein. CRT is involved in the secretory pathway, where it 
main function is to prevent misfolded proteins from being exported from the 
endoplasmic reticulum to the Golgi apparatus. CRT deficiency was associated with a 
dysfunction of the T cell response in immunodeficient mice, suggesting that CRT-
dependent calcium signalling modulates T cell immune response [493]. CRT can also 
be found on the surface of different cells, where it acts as a stimulatory molecule to B 
cells and macrophages via the TLR4/CD14 pathway, and CRT soluble form can be 
found in the sera of RA and SLE patients, suggesting its involvement in the 
pathogenesis of autoimmunity [494].  
The analysis of MP from PBMC treated with hPAD2 or hPAD4 enzymes by 2D 
BN/SDS-PAGE followed by LC-CID-saETD-MS/MS revealed no PAD-specific 
citrullinated arginine residues associated with MP. The citrullinated peptide found in 
actin 1 protein was identified in both non PAD-, PAD2- and PAD4-treated PBMC. The 
citrullinated peptide found in complement component 1 Q subcomponent-binding 
protein from PAD4-treated PBMC was not identified in non-PAD treated PBMC. 
However, as this is a mitochondrial protein it is not one of the main targets of these 
study. Citrullination might not have been efficient as MP contain less arginine residues 
than intracellular proteins. Furthermore, this lower number of arginine residues in 
combination with potentially citrullinated arginine residues provide less possible sites 
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for trypsin cleavage and, consequently, bigger peptides less likely to be detected by 
mass spectrometry. Cell surface proteomic studies have found limitations on the 
identification of proteins due to the steric hindrance of proteases. Strategies to 
overcome this include the removal of N-linked glycans from proteins prior to proteolysis 
to prevent missed cleavages [495, 496], the use of alternative enzymes to trypsin for 
protein digestion or adaptations to the trypsin digestion protocol [497]. 
 Taken together, the results obtained in this chapter showed that PAD enzymes 
induce a reduction in the T cell IL-2 response to activating stimuli. In addition, the 
analysis of gene expression suggested that the impairment in the IL-2 response is 
related to alterations in glucose and amino acid metabolism. Studies described in 
chapter 5 aim to validate whether metabolic differences are seen in T cells from PID 
patients compared to periodontally healthy controls. Furthermore, a down-regulation of 
the complement system is suggested by the data obtained by both MP identification by 
MS and the GO analysis of pathways on the microarray study. The activation of the 
complement system results in the opsonisation and lysis of pathogens and in the 
generation of pro-inflammatory molecules, having a crucial role in the innate immunity 
against pathogens. However, this system can also be linked to adaptive immunity 
through the modulation of T cell differentiation and effector functions [498]. T cells and 
APC have been shown to produce complement components and up-regulate the 
expression of complement receptors, promoting T cell differentiation, expansion and 
survival. Previous studies described that dysregulation of the complement system 
induces T cell-mediated autoimmunity [499]. In accordance with this, the data obtained 
here associates a down-regulation of the complement system, mediated by PAD 
enzymes, to an impaired IL-2 T cell response.   
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Chapter 5  Translating ex vivo 
studies of T cell modification by PAD 
to periodontitis clinical samples 
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5.1. Preface 
PID is a chronic inflammatory disease in which citrullination has been implicated. In 
this chapter plasma and GCF samples from PID patients and periodontally HC were 
compared for levels of pro-inflammatory cytokines (IL-6 and IL-8), PAD activity and 
GSH levels. The expression of genes that were found to be up- or down-regulated in 
the ex vivo PBMC activation experiments, with and without PAD as described in 
Chapter 4, have been investigated in CD4 and CD8 T cells from PID patients.  
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5.2. Introduction 
In 2012, the WHO reported that 15–20% of middle-aged (35–44 years) adults are 
affected by severe PID. PID is a chronic inflammatory disease characterised by 
localised infections and inflammatory conditions that affect one or more of the 
periodontal tissues (alveolar bone, periodontal ligament, cementum and gingiva) which 
support the teeth [500]. At the cellular level, PID involves accumulation of lymphocytes 
and monocytes, endothelial cell proliferation and matrix degradation [213]. PID can be 
categorised from gingivitis to aggressive periodontitis according to the composition of 
the subgingival microbial flora and also the factors that influence the host response to 
the microbial attack [161, 213]. Histologically, the lesion observed in gingivitis and PID 
can be divided into four stages: initial lesion, early lesion, established lesion and 
advanced lesion. Initial, early and established lesions are characteristic of gingivitis 
whereas an advanced lesion is a feature of periodontitis. In the initial lesion a response 
from resident leukocytes and endothelial cells to the bacterial biofilm can be observed. 
Furthermore, neurons are stimulated to produce neuropeptides responsible for 
triggering vasodilation of local blood vessels, which will allow the migration of 
neutrophils towards the periodontium in response to chemokines. In the early lesion, 
increased numbers of neutrophils are observed, complemented with the appearance of 
macrophages, lymphocytes, plasma and mast cells. The complement system is also 
activated, the epithelium proliferates and the gingival crevice fluid flow increases. The 
established lesion stage is when the immune response shifts from innate to adaptive, 
with a predominance of macrophages, plasma cells and T and B cells. Increased 
collagen degradation is also observed. The transition from gingivitis to PID is 
characterised by advanced lesions, where the inflammatory lesion extends to the 
alveolar bone and irreversible attachment and bone loss are observed [500, 501]. 
Amongst the bacterial species involved in PID, P. gingivalis appears to be the 
major infectious agent, being detected in higher abundance in patients with aggressive 
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forms of PID [227]. Furthermore, P. gingivalis was reported to produce a unique 
bacterial enzyme, PPAD, responsible for the conversion of peptidylarginine into 
peptidylcitrulline, a reaction known as citrullination [110, 228, 231]. Citrullination of host 
proteins by PPAD enzyme was described to induce production of ACPA, suggesting 
the triggering of an autoimmune response [254]. Furthermore, isoforms 2 and 4 of 
human PAD enzymes were also found in inflamed gingiva [443]. The autoimmune 
nature of PID suggests the involvement of T cells. Ivanyi and Lehner first suggested 
the contribution of T cells in PID in 1970 [232]. Since then, several studies have found 
evidence for the role of T cells in the homeostasis of periodontal tissues [233], 
modulation of the immune responses [234] and mediation of the bone loss 
characteristic from PID [235]. The association between different T cell subsets and PID 
progression has also been investigated. However, consensus on T cell subset 
involvement in PID has not been reached so far. Several studies reported decreased 
ratios of CD4/CD8 T cells in PID lesions compared with healthy controls [242, 244, 
246], whereas others reported increased CD4/CD8 ratios [249, 250]. Furthermore, 
CD4 Th1 cells have been associated with stable PID lesions while CD4 Th2 have been 
linked to progressive lesions [502-507]. On the contrary, others have shown that up-
regulation of Th1 and down-regulation of Th2 are associated with PID tissue 
destruction [508-510]. Several studies have also focused on Th17 subset. Gingival 
tissue and GCF from PID patients revealed high levels of IL-17 and other Th17-related 
cytokines when compared to healthy sites [511-518]. However, it is not clear if Th17 
cells have a protective or destructive role in PID. 
 Here, the gene expression changes observed after the activation of T cells pre-
treated with PAD enzymes in chapter 4 were studied in CD4 and CD8 T cell 
populations from PID patients and compared with HC, in order to explore the 
significance of previous in vitro findings to disease activity. Therefore, the aims of this 
chapter are as follows: 
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 To analyse the inflammatory status of plasma from PID patients, compared with 
HC; 
 To assess the PAD activity of GCF from PID and HC individuals; 
 To evaluate the redox status of plasma and GCF samples from PID and HC 
individuals; 
 To compare the expression of metabolic and inflammatory genes, which are 
regulated by hPAD pretreatment and were identified in Chapter 4, in CD4 and 
CD8 T cell subsets from PID and HC. 
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5.3. Methods 
5.3.1. Clinical samples 
Plasma and GCF samples from PID patients and age-matched periodontally healthy 
controls (HC) were obtained from the periodontal clinic at Birmingham Dental Hospital, 
as detailed in section 2.5. Demographics of patients and controls are described in table 
5.1. 
 
5.3.2. Quantification of interleukin-6 and interleukin-8 levels in the plasma of 
periodontitis patients 
IL-6 and IL-8 levels in the plasma of PID and HC individuals were quantified by 
sandwich ELISA, as described in section 2.16. 
 
5.3.3. Quantification of reduced glutathione in the plasma and gingival 
crevicular fluid of periodontitis patients 
The levels of GSH in the plasma and GCF of PID and HC individuals were assessed 
by the GSH recycling assay as outlined in section 2.18. 
 
5.3.4. Quantification of peptidylarginine deiminase activity in the gingival 
crevicular fluid of periodontitis patients 
ABAP kit assay was used to quantify the activity of PAD enzymes in the plasma and 
GCF of PID and HC individuals as detailed in section 2.19. 
 
5.3.5. Quantification of gene expression in peripheral CD4 and CD8 T cells from 
periodontitis patients 
Total RNA was isolated from CD4 and CD8 T cells extracted from the blood of PID and 
HC individuals, converted to cDNA and analysed by RT-QPCR as outlined in section 
2.21. The mean of ΔCT values relative to housekeeper from HC group was used as a 
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control condition for the comparison of gene expression between PID patients and HC 
individuals.  
 
5.3.6. Statistical analysis 
Data obtained was analysed according to section 2.23. 
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5.4. Results 
Samples from PID patients attending the periodontal clinic at Birmingham Dental 
Hospital were collected and a summary of the demographics and main plasma and 
GCF findings are outlined in table 5.1. 
 
Table 5.1 Demographics and results obtained for the two groups.  
Parameter HC group PID group 
N 6 6 
Gender (M/F) 1/5 3/3 
Age (years) 49.0 ± 10.1 49.5 ± 9.4 
IL-6 (pg/mL) 3.96 ± 1.18 4.16 ± 0.86 
IL-8 (pg/mL) 13.54 ± 2.46 15.82 ± 4.15 
PAD activity (mU) 0.088 ± 0.030 0.337 ± 0.157 
Plasma GSH (nmol/mg prot) 0.023 ± 0.005 0.029 ± 0.012 
GCF GSH (nmol/mg prot) 62.47 ± 12.36 34.65 ± 5.70 
Plasma GSH (µM) 1.51 ± 0.31 2.02 ± 0.92 
GCF GSH (µM) 2.40 ± 0.11 2.39 ± 0.08 
GCF – gingival crevicular fluid; GSH – reduced glutathione; HC – healthy controls; IL – interleukin; N – 
number of subjects in each group; PAD – peptidylarginine deiminase; PID – periodontitis patients. Age is 
expressed as mean ± SD and all the other variables are expressed in mean ± SEM. 
 
 
5.4.1. Plasma inflammatory status of periodontitis patients 
Pro-inflammatory plasma factors, such as cytokines, are elevated in PID patients [519], 
therefore, the first step of this chapter was to assess the inflammatory status of 
patients with PID in comparison with periodontally healthy individuals. No differences in 
the plasma levels of IL-6 and IL-8 were found when comparing PID and HC groups 
(Figure 5.1).  
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Figure 5.1 IL-6 and IL-8 plasma concentration in PID patients and age-matched periodontally 
healthy controls (HC). Plasma was collected from whole blood by centrifugation and the levels of IL-6 
and IL-8 determined using an IL-6 Quantikine ELISA kit (R&D systems, Abington, UK) (a) and an IL-8 
Quantikine ELISA kit (R&D systems, Abington, UK) (b), respectively. Data are presented as mean ± SEM. 
N = 5–6. Mann-Whitney test was performed using GraphPad Prism (v6.02) software and no statistical 
significance was found. 
 
5.4.2. Citrullination status of the gingival crevicular fluid of periodontitis 
patients  
The presence of PPAD enzyme, human PAD enzymes and citrullinated proteins in PID 
inflamed tissue constitutes a hallmark of this disease [443]. To evaluate the likelihood 
of citrullination in PID patients relative to HC individuals, PAD enzyme activity in the 
GCF was determined in both groups. The mean PAD activity was 0.337 mU (with a 
confidence interval of 75%) for PID patients and was 0.088 mU (with a confidence 
interval of 75%) for HC, i.e. PAD activity was more than three times higher in PID 
patients than in HC. The differences were not statistically significant but it is possible to 
observe that two out of the six PID patients had higher levels of PAD enzyme activity in 
GCF samples (Figure 5.2). This might indicate that with a larger number of PID 
samples, significant differences might be observed. 
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Figure 5.2 PAD enzyme activity in the GCF of PID patients and age-matched periodontally healthy 
controls (HC). GCF was collected on PeriopaperTM strips (Oraflow Inc., Plainview, NY, USA) and 
extracted from the strips by centrifugation. PAD activity was determined using an ABAP kit (Modiquest 
Research B. V., Oss, Netherlands). Data are presented as mean ± SEM. N = 6. Mann-Whitney test was 
performed using GraphPad Prism (v6.02) software and no statistical significance was found. 
 
5.4.3. Redox status of plasma and gingival crevicular fluid of periodontitis 
patients 
The levels of antioxidants, like GSH, are known to be lower in PID patients [520, 521]. 
Here, GSH was quantified in the plasma and GCF of PID patients and HC. No 
differences were observed between the raw values of GSH in the plasma (Figure 5.3a) 
and in the GCF (Figure 5.3b) of PID and HC groups. The normalisation of the GSH 
levels for the amount of total protein present per sample showed a trend to lower levels 
of GSH in the GSF of PID patients, when compared with HC individuals (Figure 5.3d). 
No statistical significance was observed, possibly due to the small sample number. No 
differences were observed between the plasma levels of GSH in PID and HC 
individuals (Figure 5.3c). 
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Figure 5.3 Reduced glutathione levels in the plasma (a, c) and GCF (b, d) of PID patients and age-
matched periodontally healthy controls (HC). Plasma was collected from whole blood by centrifugation. 
GCF was collected on PeriopaperTM strips (Oraflow Inc., Plainview, NY, USA) and extracted from the 
strips by centrifugation. GSH was determined by the recycling assay, as previously described (2.18). Data 
are presented as mean ± SEM, and was normalised to protein content on c and d. N = 6. Mann-Whitney 
test was performed using GraphPad Prism (v6.02) software and no statistical significance was found. 
 
5.4.4. Validation of CD4 and CD8 T cell extraction for the study of gene 
expression in periodontitis patients 
To evaluate the reproducibility of CD4 and CD8 T cells extraction and RT-QPCR 
analysis of selected genes, CD4 and CD8 T cells were extracted from whole blood of a 
healthy volunteer in triplicate. The purity of the CD4 and CD8 T cells obtained was 
assessed by flow cytometry as outlined in section 2.5.6.  
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Figure 5.4 Purity of CD4 and CD8 T cells isolated from whole blood. CD4 and CD8 T cells were 
positively isolated as previously described and stained with anti-CD4-PE or PE isotype control and anti-
CD8-PE-Cy5.5 or PE-Cy5.5 isotype control, respectively, and analysed by flow cytometry. Data acquisition 
was stopped when 25,000 events were obtained. a) FSC and SSC of the whole cell population stained for 
CD4. b) Overlay plot of isotype control (grey histogram) and anti-CD4-PE (blue histogram) stained T cell 
population. c) FSC and SSC of the whole cell population stained for CD8. d) Overlay plot of isotype control 
(grey histogram) and anti-CD8-PE-Cy5.5 (green histogram) stained T cell population. Positive cells were 
considered above 5% positive of isotype control staining. e) Percentage of CD4 and CD8 positive T cells 
calculated relative to 5% positive staining of the isotype control. Data are presented as mean ± SEM. 
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mRNA was extracted from CD4 and CD8 T cells, converted to cDNA and the 
expression of ASS1 and HK3 analysed by RT-QPCR. The amount of CD4 and CD8 T 
cells obtained from the same healthy donor in three replicate extractions showed high 
variability, however, the amount of mRNA obtained after lysis of the cells was similar. 
The analysis of ASS1 and HK3 genes and the housekeeper gene YWHAZ revealed CT 
values very similar for CD4 and CD8 T cells. The gene expression, investigated by the 
comparative CT method, also presented similar results of expression of ASS1 and HK3 
in CD4 and CD8 T cells from one healthy donor analysed in triplicate (Table 5.2).  
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Table 5.2 Reproducibility of CD4 and CD8 T cell isolation. CD4 and CD8 T cells were positively isolated from one healthy donor in triplicate to assess reproducibility.  
  
105 
cells/mL 
mRNA 
(ng/µL) 
raw CT 
(YWHAZ-ASS1) 
raw CT 
(YWHAZ-HK3) 
raw CT (ASS1) raw CT (HK3) 2-ΔΔCT (ASS1) 2-ΔΔCT (HK3) 
CD4 
Replicate 1 3.9 15.8 19.54 19.99 25.32 31.90 0.72 0.40 
Replicate 2 11.2 13.7 19.74 20.18 25.03 31.80 1.01 0.49 
Replicate 3 1.0 13.2 20.33 20.85 25.34 31.67 1.23 0.86 
CD8 
Replicate 1 3.2 9.9 19.59 20.15 25.75 32.20 0.63 0.33 
Replicate 2 0.3 8.6 19.74 20.13 26.75 32.33 0.35 0.29 
Replicate 3 0.2 6.9 19.70 20.20 25.33 32.03 0.90 0.38 
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5.4.5. Gene expression in peripheral CD4 and CD8 T cells from periodontitis 
patients 
In chapter 4, ex vivo studies on the effect of PAD enzymes on PBMC revealed 
expression alterations in some genes. Here, peripheral CD4 and CD8 T cells were 
isolated from blood of PID patients and HC individuals and analysed by RT-QPCR for 
the expression of the genes studied before (ASS1, HK3, CD163). Additionally, the 
expression of IL-2 and IFN-G was also analysed to provide information regarding T cell 
activation status. ENO was also selected for study here; ENO encodes for α-enolase, 
an enzyme involved in glycolytic metabolism and that is also known to be citrullinated 
in RA [254]. The expression of ULBP1 was also addressed. ULBP1 was one of the 
genes found to be up-regulated by both PAD enzymes on the PBMC microarray study 
(Figure 4.10). ULBP1 encodes for the cell surface UL16 binding protein 1, which is a 
ligand for the killer cell lectin-like receptor subfamily K, member 1 / natural killer group 
2D receptor (KLRK1/NKG2D receptor) and, consequently, is involved in immune 
responses.  
 Initially, the peripheral CD4 and CD8 T cells positively isolated from whole 
blood of six PID patients and six HC individuals were lysed and mRNA extracted. The 
number of cells and the amount of mRNA obtained were variable between the two cell 
subsets (Table 5.3). Note that samples with less than 2 ng/µL of mRNA (highlighted in 
grey in table 5.3) were not further analysed by RT-QPCR since this amount of mRNA 
is not sufficient to be converted to cDNA and subsequent RT-QPCR. 
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Table 5.3 Number of cells and amount of mRNA obtained from peripheral CD4 and CD8 T cells 
from PID and HC groups. The samples highlighted represent samples where the amount of RNA 
extracted was not sufficient for the RT-QPCR experiment. 
  
106 cells/mL mRNA (ng/µL) 
CD4 
PID 0.29 4.1 
PID 1.08 20.4 
PID 0.88 19.6 
PID 1.95 34 
PID 1.03 14.1 
PID 0.79 8.5 
HC 0.11 0.8 
HC 1.47 15.3 
HC 0.78 9 
HC 1.61 9.7 
HC 1.99 26.4 
HC 1.07 15.9 
CD8 
 
PID 0.27 1.5 
PID 1.03 8.3 
PID 0.68 9.8 
PID 1.12 20.9 
PID 0.8 11.7 
PID 0.9 11.6 
HC 0.05 0.7 
HC 0.61 6.4 
HC 0.33 4.1 
HC 1.62 5.1 
HC 0.89 11.1 
HC 5.37 8.2 
 
ASS1 and ULBP1 were found to be up-regulated in PBMC pre-treated with PAD 
enzymes and activated with anti-CD3/anti-CD28. This was found initially in the 
microarray studies and further confirmed by RT-QPCR for ASS1 (Figures 4.10 and 
4.14). However, the expression analysis for these genes by RT-QPCR on CD4 and 
CD8 T cells from PID and HC did not reveal statistically significant differences. ASS1 
and ULBP1 expression showed a trend towards an increase in both peripheral CD4 
and CD8 T cells from PID, when compared with HC (Figures 5.5a and 5.5c).  
 HK3 and CD163 were two of the genes found to be down-regulated in PAD pre-
treated and activated PBMC on the microarray studies (Figure 4.11). By RT-QPCR 
studies, the expression of CD163 was shown to be down-regulated by both PAD 
enzymes on activated PBMC but the expression of HK3 was only down-regulated by 
hPAD2 enzyme, while the hPAD4 enzyme induced an up-regulation of this gene after 
PBMC activation. In peripheral CD4 and CD8 T cells from PID and HC the expression 
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of CD163 was not detected and the average expression of HK3 was found to be down-
regulated in PID when compared with HC (Figure 5.5b). 
 IL-2 and IFN-Ȗ are markers of T cell activation. The expression of IL-2 and IFN-
G was also assessed here in order to provide information regarding the activation 
status of T cells. In HC individuals and PID patients and IL-2 and IFN-G expression did 
not show statistical significant alterations in PID when compared with controls, 
however, both the average expression and paired expression pointed towards 
increased levels of IL-2 and IFN-G expression in peripheral CD4 and CD8 T cells from 
PID, compared with HC (Figures 5.5d, 5.5e, 5.6d and 5.6e). 
 The expression of ENO in peripheral CD4 and CD8 T cells from PID patients 
revealed high inter-individual variability and no trend was seen (Figure 5.5f). 
 The paired analysis of the results corroborated the findings stated above 
(Figure 5.6); four out of five pairs showed higher expression of ASS1, IFN-G and IL-2 
in CD4 T cells from PID patients in comparison to HC individuals; four out of five pairs 
showed higher expression of ASS1 and IFN-G in CD8 T cells from PID patients in 
comparison to HC individuals; four out of five pairs showed lower expression of HK3 in 
CD4 and CD8 T cells from PID patients in comparison to HC individuals; ULBP1 and 
ENO showed variable expression in both CD4 and CD8 T cells from PID patients in 
comparison to HC individuals. 
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Table 5.4 Raw CT values of the housekeeper YWHAZ in the plate of each of the selected genes analysed by RT-QPCR. CD4 and CD8 T cells were positively isolated 
from six periodontitis patients (PID) and six periodontally healthy controls (HC) and the mRNA extracted, converted into cDNA and used to evaluate the levels of ASS1, HK3, 
ULBP1, IL-2, IFN-G and ENO transcripts by RT-QPCR in an Agilent Max3000P QPCR system (Agilent Technologies LDA UK Ltd, Stockport, UK). Raw CT values are 
presented. N = number of independent experiments (donors) performed. 
 
YWHAZ CT values for each primer plate 
 
ASS1 primer HK3 primer ULBP1 primer IL-2 primer IFN-G primer ENO primer 
 
Mean SEM N Mean SEM N Mean SEM N Mean SEM N Mean SEM N Mean SEM N 
CD4 
HC 20.58 0.15 5 21.10 0.16 5 20.60 0.09 5 20.26 0.13 5 20.63 0.07 5 20.60 0.23 5 
PID 20.36 0.14 6 20.92 0.15 6 20.53 0.09 6 20.23 0.09 6 20.48 0.06 6 20.56 0.38 6 
CD8 
HC 20.32 0.11 5 21.22 0.22 5 20.29 0.12 5 20.18 0.12 5 20.22 0.11 5 20.76 0.33 5 
PID 19.98 0.11 5 20.65 0.18 5 19.96 0.14 5 19.77 0.13 5 20.34 0.13 5 20.18 0.20 5 
 
Table 5.5 Raw CT values of selected genes analysed by RT-QPCR. CD4 and CD8 T cells were positively isolated from six periodontitis patients (PID) and six periodontally 
healthy controls (HC) and the mRNA extracted, converted into cDNA and used to evaluate the levels of ASS1, HK3, ULBP1, IL-2, IFN-G and ENO transcripts by RT-QPCR in 
an Agilent Max3000P QPCR system (Agilent Technologies LDA UK Ltd, Stockport, UK). Raw CT values are presented. N = number of independent experiments (donors) 
performed. 
 
CT values 
 
ASS1 primer HK3 primer ULBP1 primer IL-2 primer IFN-G primer ENO primer 
 
Mean SEM N Mean SEM N Mean SEM N Mean SEM N Mean SEM N Mean SEM N 
CD4 
HC 25.89 0.16 5 31.7 0.16 5 30.93 0.11 5 32.29 0.30 5 28.42 0.17 5 22.86 0.19 5 
PID 25.21 0.15 6 31.87 0.13 6 31.09 0.35 6 31.13 0.17 6 28.08 0.27 6 22.51 0.10 6 
CD8 
HC 25.81 0.18 5 31.65 0.09 5 29.34 0.18 5 33.12 0.23 5 26.25 0.33 5 22.29 0.09 5 
PID 25.13 0.20 5 31.66 0.11 5 28.83 0.36 5 31.95 0.55 5 25.22 0.12 5 22.10 0.10 5 
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Figure 5.5 Fold changes in the expression of selected genes relative to HC. CD4 and CD8 T cells 
were positively isolated from five PID patients and five HC and the mRNA extracted, converted into cDNA 
and used to evaluate the levels of ASS1 (a), HK3 (b), ULBP1 (c), IL-2 (d), IFN-G (e) and ENO (f) 
transcripts by RT-QPCR. Results were obtained with the comparative CT method and are expressed as 
fold change relative to HC. N = 5. Boxes represent 5–95 percentile range and the midline corresponds to 
the median. Mann-Whitney test was performed using GraphPad Prism (v6.02) software to compare PID 
and HC within CD4 and CD8 groups and no statistical significance was found. 
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Figure 5.6 Individual fold changes in the expression of selected genes relative to HC. CD4 and CD8 
T cells were positively isolated from six PID patients and six age-matched HC and the mRNA extracted, 
converted into cDNA and used to evaluate the levels of ASS1 (a), HK3 (b), ULBP1 (c), IL-2 (d), IFN-G (e) 
and ENO (f) transcripts by RT-QPCR. Results were obtained with the comparative CT method and are 
expressed as fold change relative to age-matched HC. N = 5–6. Mann-Whitney test was performed using 
GraphPad Prism (v6.02) software to compare PID and HC within CD4 and CD8 groups and no statistical 
significance was found. 
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5.5. Discussion 
PID is a chronic inflammatory disease that affects periodontal tissue. PID is 
characterised by the accumulation of lymphocytes [522, 523], the increase of pro-
inflammatory plasma factors, such as cytokines [519], the decrease in antioxidant 
levels [520] and the occurrence of citrullination by PAD enzymes [443]. 
 The parameters evaluated here in the plasma and GCF of PID patients and HC 
individuals did not show statistically significant differences. Only six individuals were 
included in each group which can be an explanation for the high individual variability on 
the results and the lack of statistical significance in the results. Gorska et al. have 
previously reported that cytokines profiles in serum samples from PID patients and 
healthy controls show high variability between individuals [524]. IL-6 and IL-8 were the 
selected cytokines to study since they were previously described as being involved in 
the activity of leukocytes, osteoblasts and osteoclasts in PID, both locally and 
systemically [525-527]. IL-6 is a multifunctional cytokine, involved in B cell 
differentiation, T cell proliferation and stimulation of Ig secretion by B cells [528]. IL-8 is 
particularly important in the mediation of chemotaxis and activation of neutrophils in the 
inflamed gingiva [529]. IL-6 and IL-8 levels were previously found to be increased in 
PID-associated tissues [527, 530-534]. 
PAD enzyme activity was found to be increased in some patients in the PID 
group relative to HC. This is in agreement with previous findings from Harvey et al., 
who described that the expression of hPAD2 and hPAD4 enzymes and citrullinated 
proteins increased with the severity of inflammation observed in PID [443]. 
 The control of redox balance is key for an efficient immune response. GSH is 
one of the most important regulators of this balance. Previous studies have shown that 
glutathione in its reduced form is decreased in GCF and plasma from PID patients 
[520, 521]. Here, we found no differences in the levels of GSH in the plasma of PID 
patients when compared with HC groups. Despite the fact that no statistical 
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significance was observed, the levels of GSH in the GCF of PID patients were lower 
when compared with HC individuals, in agreement with previous reported data [520, 
521]. 
 The results point towards an oxidation and citrullination-induced environment in 
PID patient plasma. The susceptibility for T cells to be modified by citrullination was 
shown with the experiments performed in chapter 4, where the effect of PAD enzymes 
on the activation of T cells within the PBMC population was studied. 
 Within PBMC, T cells are involved in immune regulation processes and are 
necessary for the specific antibody production and polyclonal B cell activation, 
observed in PID, being essential for the pathogenesis of periodontal inflammation [535-
540]. Cytokine secretion profile can be used to subdivide CD4 (Th) and CD8 (Tc) T 
cells into Th1, Th2, Tc1 and Tc2, respectively [541-543]. Th1 cells produce IL-2, IFNȖ 
and TNF-α and –ȕ and are involved in cell-mediated responses in the elimination of 
intracellular pathogens. Th2 cells secrete IL-4 and IL-5 and promote B cell growth and 
differentiation [543]. Tc1 release IFNȖ and TNF-α and are involved in cytotoxic events. 
Tc2 secrete IL-4 and provide help for Ig secretion by B cells [544]. An effective immune 
response is highly dependent on the balanced generation of the different subsets of T 
cells and secretion of the correspondent cytokines.  
In advanced PID, a suppression of adaptive immunity response has been 
reported [236-240]. Lymphocyte suppression by bacteria involved in PID was 
demonstrated in several studies [236-240]. T cells isolated from tissue of PID patients 
were shown to have a reduced IL-2 response [243, 440] but no differences in 
intracellular IFNȖ levels [545]. Additionally, T cells isolated from whole blood of PID 
patients revealed similar levels of T cells as healthy individuals but with reduced 
functional activities [545, 546]. Petit et al. showed that the proportion of peripheral CD4 
and CD8 T cells committed to Th1/Th2 or Tc1/Tc2, respectively, from PID patients 
does not differ from periodontally healthy individuals. Moreover, these authors reported 
no differences in intracellular IFNȖ and IL-4 levels on CD4 T cells from PID and HC but 
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they found an increase in the intracellular levels of IL-4 in CD8 T cells from PID when 
compared with controls, indicating a shift towards Tc2 functions in the CD8 T cell 
population. 
Here, peripheral CD4 and CD8 T cells were isolated from PID and HC 
individuals, in order to assess gene expression patterns in the two T cell subsets. The 
number of CD4 and CD8 T cells between PID and HC showed no differences. The 
expression of IL-2 and IFN-G was found to be increased in CD4 and CD8 T cells from 
PID patients when compared with HC individual, suggesting an increased T cell 
response. In this Chapter, gene expression levels of IL-2 and IFN-Ȗ cytokine mRNA 
were evaluated, whereas in the previous studies reported by others, protein levels 
were measured. The difference in the analysed samples (mRNA versus protein) might 
explain the unconsistency of these results with previous ones since mRNA and protein 
have different processing times.  
ASS1 and HK3 expressions in CD4 and CD8 T cells from PID patients were 
found to be up- and down-regulated, respectively, consistent with what was previously 
found in chapter 4. The levels of ASS1 are related with T cell differentiation and 
function. An up-regulation of the gene responsible for this protein suggests de novo 
synthesis of arginine via ASS1 by T cells, possibly to counteract a decrease in the 
levels of arginine, resultant from impaired T cell proliferation [464, 468, 469]. Lower 
levels of arginine are also involved in impaired aerobic glycolysis [468], which 
corresponds to the down-regulation of HK3 in T cells from PID patients that was 
identified in this Chapter. 
CD163 is a monocyte/macrophage-specific scavenger receptor and 
consequently, it is not surprising that its expression was not detected on CD4 and CD8 
T cells obtained here. 
ULBP1 and ENO were two additional genes studied here that were not 
analysed in the previous chapter. ULBP1 is a NKG2D receptor that is present in both 
NK and T cells and is involved in the immune system activation, through the activation 
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of signal transduction pathways. ENO is responsible for the conversion of 2-
phosphoglycerate to phosphoenolpyruvate in the final steps of glycolysis and is has 
also been identified as a citrullinated antigen in RA [254]. Additionally, ENO has been 
detected on the surface of vascular endothelium [547], monocytes, macrophages, B 
cells and T cells [548] and is recognised as a plasminogen receptor. In ageing studies, 
ENO was found to be lower on the surface of CD4 T cells in healthy older adults [549]. 
RT-QPCR data showed no differences in the expression of ULBP1 and ENO in 
peripheral CD4 and CD8 T cells from PID patients relative to HC. 
Taken together, the results from this chapter indicate that PID patients are 
characterised by lower levels of GSH and higher levels of citrullination activity by PAD 
enzymes in the GCF. Consistent with the previous chapter, which investigated the 
effect of citrullination on T cells, here PID patients presented T cell with metabolic 
changes that indicate decreased glycolysis and increased amino acid biosynthetic 
pathway. Since T cells rely on aerobic glycolysis and glutaminolysis to meet the 
energetic requirements of proliferation, an impairment of these metabolic pathways 
due to the effects of PAD enzymes can be associated with decreased T cell 
proliferation. Taking the data obtained in this chapter as a pilot and considering PAD 
activity as a critical readout for the observed effects of PAD enzymes it can be 
estimated that the inclusion of seven samples in each of the tested groups would lead 
to 80% probability of observing a significant difference (p-value < 0.05) in the levels of 
PAD activity between PID and HC individuals (G*power software calculation).  
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Chapter 6  Concluding remarks 
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6.1. General discussion 
Citrullination is defined as the PTM resulting from the conversion of peptidylarginine to 
peptidylcitrulline catalysed by PAD enzymes [109]. Five human isoforms of PAD 
enzymes (PAD1–4 and PAD6) have been described in the human genome and are 
differentially expressed in specific tissues. Except for PAD4 enzyme, which translocate 
to the nucleus, PAD enzymes are typically located in the cytoplasm of different cell 
types [336]. Of particular interest, PAD enzymes expressed in white blood cells 
recruited to inflammation sites, can be released to the extracellular environment when 
apoptosis occurs and act on extracellular proteins. Physiologically, citrulline is a non-
essential amino acid, but citrullination is a vital reaction, being involved in keratinization 
of epithelial cells [120-124], inflammation [133, 147-150] and apoptosis [133, 140]. 
However, this conversion or arginine residues into citrulline residues in the polypeptide 
chain of proteins results in the loss of positive charge, affecting the protein structure 
and can lead to the formation of new protein motifs [109, 335]. In susceptible 
individuals, this process can induce the formation of neoantigens and trigger an 
immune response through the production of ACPA. This mechanism of citrullination-
induced autoimmunity has been described in diseases such as RA [421] and PID 
[286]. RA and PID share similar pathological processes, including gene- and 
environmentally-associated disease susceptibility, soft and hard tissue destruction 
triggered by an exaggerated inflammatory response and the involvement of bacteria in 
the aetiology of the disease [284, 422]. Other key factors linking these two 
inflammatory diseases include the local and systemic production of autoantibodies 
[282, 355, 422-425] and the production of citrullinated peptides recognised by 
autoreactive T cells [285, 426]. It is recognised that citrullination is involved in the loss 
of immunological tolerance of the immune system in diseases such as RA and PID. 
However, to date, no studies have investigated the effects of PAD enzymes on the 
cells that mediate the autoimmune response. T cells have been shown to have 
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important roles in the development of the immune response observed in RA and PID, 
so this study focused on the effects of citrullination in the modulation of T cell response 
to activation. Initially, conditions were optimised for the detection and identification of 
citrullination, using modified FNG as a model, and a functional T cell activation model 
was established in order to address this hypothesis. Next, the effects of PAD enzymes 
on the activation of T cells were studied in PBMC, focusing on genes with altered 
expression and cell surface proteins modified by PAD enzymes. Finally, samples from 
PID patients were used to corroborate the findings on metabolic alterations observed 
on PBMC pre-treated with PAD enzymes. 
 From the five isoforms of PAD enzyme, PAD2 and PAD4 enzymes were 
identified by others in the synovium of RA patients [187-189, 361] and in inflamed 
gingiva of PID patients [443]. Consequently, these isoforms were selected for this 
study. Isoforms 2 and 4 of PAD enzyme share sequence homology, but are expressed 
by different cells in the synovial tissue, their intracellular localisation is different and 
their expression and activation are separately regulated at transcription, translation and 
enzyme activation [133]. Furthermore, PAD2 and PAD4 enzyme stability, calcium 
dependency, optimal pH range and substrate specificity are significantly different [377, 
378].  
In chapter 4, a model to study T cell activation was established and citrullination 
studies were performed using this model. T cell activation responses in Jurkat E6.1 T 
cells, an immortalised cell line, were compared with the T cell response in primary T 
cells within the PBMC population, where T cell activation is closer to physiological 
conditions. To activate T cells, the lectin PHA-L and antibodies against CD3 and CD28 
were compared. The levels of IL-2 secreted to the extracellular medium of the cells, 
measured by ELISA, and the expression of CD25 at the surface of the cells, analysed 
by flow cytometry, confirmed that PBMC stimulated with anti-CD3/anti-CD28 antibodies 
were the most suitable model to study T cell activation. After the establishment of the 
activation T cell model, PAD2 and PAD4 enzymes were incubated with the cells to 
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assess their effects on the stimulation of T cell responses with anti-CD3 and anti-CD28 
antibodies. PBMC pre-treated with PAD2 and PAD4 enzymes prior to activation 
revealed a trend to lower levels of CD4 T cells expressing CD25 at the surface. The 
levels of IL-2 secreted by the cells showed a significant increase when the cells were 
activated via CD3/CD28, but PBMC pre-treated with PAD2 and PAD4 enzymes and 
activated via CD3/CD28 showed a significant decrease of more than 50% in the levels 
of secreted IL-2 when compared with activated cells, suggesting alterations in the IL-2 
T cell response. IL-2 is essential for T cell activation and proliferation and homeostasis 
of the immune system [550]. Decreased IL-2 production was previously reported in 
patients with autoimmune disease SLE [449], in cultured lymphocytes from patients 
with SLE [450] and in murine SLE models [451]. The reduced IL-2 secretion in SLE 
was suggested to derive from dysregulation of transcription or suppression of IL-2 
production in SLE T cells [452]. The main consequences of the dysregulation of IL-2 
secretion in SLE are the reduction in the number of Tregs that are involved in the 
inhibition of autoimmunity, the impairment of AICD, necessary for the down-regulation 
of expanded T cell clones [453, 454], and defective CD8 T cell cytotoxic functions 
[455]. In vitro studies in T cells isolated from SLE patients and activated with PHA, 
revealed impaired IL-2 secretion but normal expression of IL-2R [456]. This suggests 
that the T cell dysfunction observed in PBMC treated with PAD enzymes, similar to 
what is reported in SLE, may be a driver for autoimmunity. Also, in PID models and T 
cells from PID patients impairments in T cell responses were also observed [232, 236-
240, 243, 439, 440]. In PID, reports on the IL-2 T cell response are contradictory. P. 
gingivalis, F. nucleatum and A. actinomycetemcomitans, bacterial species involved in 
PID, have been shown to impair human lymphocyte responsiveness to both mitogens 
and antigens by targeting IL-2 expression at DNA, RNA and protein levels [237, 238, 
439]. Andrukhov et al. reported decreased levels of IL-2 in the serum of PID patients 
[551]. On the other hand, T cells collected from PID inflamed tissue showed increased 
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production of IL-2 indicative of increased in vivo stimulation [440] and Gorska et al. 
reported increased levels of serum and tissue IL-2 from PID patients [524]. 
PAD enzymes used in this study were obtained through recombinant 
expression, according to the manufacturer and, consequently, endotoxin 
(lipopolysaccharide – LPS) was suspected to be present. To address the effects of 
contaminating LPS in the mediation of the effects observed on different cell functions 
after cells were pre-treated with PAD enzymes, a control with HI PAD enzymes was 
performed. The 1D SDS-PAGE separation profile of FNG incubated with HI PAD 
enzymes did not show any differences when compared with FNG citrullinated with 
PAD2 and PAD4 enzymes in the presence of EDTA (a calcium chelator), confirming 
that the PAD enzymes have been inactivated with heating and any effects observed in 
cells following HI-PAD exposure are not likely to be due to citrullination. In terms of 
cellular functions, no significant inhibition of IL-2 secretion by T cells pre-treated with HI 
PAD enzymes prior to activation was observed and therefore the effects of hPAD 
treatment could not be associated to a non-enzymatic contaminant, like endotoxin. 
Endotoxin activates cells of the immune system through TLR4 signalling. Despite the 
fact that TLR4 is present in T cells, previous studies have shown that no effect on T 
cell proliferation or cytokine secretion can be linked to this receptor [552-554].  
One of the aims here was to understand how PAD enzymes may modify the T 
cell responses; to identify the proteins at the cell surface that have been modified by 
PAD enzymes and, additionally, to identify the arginine residues that were citrullinated 
in the identified MP. To address this, in chapter 3, FNG was used as a model protein to 
optimise conditions for the detection of citrullination. FNG is an example of an 
extracellular protein that was found to be citrullinated in RA [184, 197, 198]. ACPA 
against citrullinated FNG were also found in the serum and synovial fluid of RA 
patients [170, 201] and constitute a well-known marker for RA with excellent sensitivity 
and specificity [363, 427]. Citrullination is responsible for 1 Da increase in the MW of 
the protein for each arginine residue that is converted to citrulline [335]; this makes the 
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detection of this modification difficult. However, differences in the separation of 
citrullinated FNG when compared with non-citrullinated FNG were found by 1D SDS-
PAGE, 2D IEF/SDS-PAGE and 2D BN/SDS-PAGE, possibly due to conformational 
changes induced by the loss of a positive charge. van Beers and colleagues have 
previously shown that in vitro FNG citrullinated sites could be mapped by combining 
high resolution tandem mass spectrometry with imaging surface plasmon resonance 
microarray using RA patient sera [379]. Creese and colleagues have also developed a 
method for the identification of citrullinated sites based on the occurrence of neutral 
loss of isocyanic acid (43 Da) from citrullinated peptides that enables differentiating 
citrullination from other 1 Da producing modifications. In this method, the occurrence of 
neutral loss of isocyanic acid in the CID mass spectrum, triggers saETD of the parent 
ion, improving the identification and localisation of the modification site [310]. The 
analysis of in vitro citrullinated FNG by this method allowed the identification of 
eighteen arginine residues citrullinated by hPAD2 or hPAD4 enzymes amongst the 
three polypeptide chains of FNG, constituting a total of 28% of all the arginine residues 
present in FNG. From these, seven arginine residues were only citrullinated by hPAD2, 
whereas five arginine residues were exclusively citrullinated by hPAD4, suggesting that 
hPAD2 has a broader range of action compared with hPAD4. In the results from 
chapter 4, no significant differences were found in the IL-2 response between the 
treatments with hPAD2 and hPAD4. However, in the gene expression study, the 
effects of citrullination on PBMC activation were more pronounced on PBMC treated 
with hPAD2 enzyme compared with hPAD4, which suggests that the number of 
citrullinated arginine residues might have an impact on the readout effects. The 
proteomics results suggest that PAD2 and PAD4 citrullinated FNG can be detected by 
1D and 2D electrophoretic techniques and that citrullinated sites can be identified by 
LC-CID-saETD-MS/MS. Furthermore, the separation of citrullinated FNG by 2D 
BN/SDS-PAGE enabled detection of native FNG in the first dimension and the three 
chains of the protein in the second dimension, confirming the potential to obtain more 
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information about protein aggregates. The separation of MP by this technique also 
allows information about protein-protein associations, as previously described for 
human protein complexes, to be obtained [382-388]. The application of 2D BN/SDS-
PAGE followed by LC-CID-saETD-MS/MS to PBMC citrullinated with PAD enzymes 
allowed the identification of MP that were only present in specific conditions, like after 
treatment with PAD2 or PAD4. Of particular interest, MS data and GO analysis of 
pathways on the microarray study revealed a down-regulation of the complement 
system, which is consistent with an induction of T cell-mediated autoimmunity [499]. 
Furthermore, CRT was one of the proteins identified exclusively associated with PAD 
enzymes in MP. Citrullinated-CRT was found in the synovial tissue of RA patients [555] 
and the binding of this modified protein to the SE was also found to potentiate the 
activation of the innate immune system, when compared with the non-modified form 
[555, 556]. However, it was not possible to identify citrullination sites on the protein 
sequence by this technique. Previous studies from van Beers et al. [379] and Creese 
et al. [310] successfully mapped citrullination sites, but these only focused on single 
proteins and synthetic peptides, respectively, and not in complex protein mixtures, like 
the MP used here. Limitations in cell surface proteomic studies are usually associated 
with the heterogeneity and the amphiphilic nature of MP, combined with overall low 
relative abundance [557-559]. Citrullination efficiency is also arguable since MP 
contain less arginine residues than intracellular proteins and modification of arginine 
residues result in a lower number of available trypsin-targeted sites. The use of 
combined proteolytic enzymes is a common approach to improve the sequence 
coverage and minimise the influence of citrullination on the proteolytic cleavage. In the 
FNG studies this approach revealed good results, however in the PBMC studies it was 
not possible to digest MP with different enzymes due to the low abundance of initial 
sample.  
To investigate the intracellular effects of PAD enzymes in the activation of T 
cells, in chapter 4 microarray studies were performed on PBMC pre-treated with PAD 
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enzymes followed by activation. Eight genes were found to be up-regulated and thirty-
five genes were found to be down-regulated simultaneously by PAD2 and PAD4 
enzymes. From these, five genes (ASS1, CTH, HK3, CD163 and SGMS2) were 
selected for validation by RT-QPCR. Further, in chapter 5, peripheral CD4 and CD8 T 
cells isolated from PID patient were used to study the expression levels of these genes 
and additional candidate genes that were selected because of their role in cytokine 
signalling and metabolism (IL-2, IFN-G, ULBP1 and ENO). 
The sphingomyelin biosynthetic pathway is associated with TCR signalling in 
activated T cells. Here, SGMS2 was one of the genes identified to be down-regulated 
by PAD enzyme pre-incubation prior to PBMC activation on the microarray results 
which, according with Tafesse et al. [560] can be associated with an impairment in T 
cell activation. However, the analysis of this gene by RT-QPCR was not possible in the 
majority of the PBMC studies and, consequently, it was not assessed in T cells isolated 
from PID patients and HC. 
The soluble form of CD163 has been shown to be up-regulated in the sera of 
RA patients [470] and was also associated with global inflammation and impairment of 
T cell activation in SpA patients’ synovium [471]. CD163 is a monocyte/macrophage-
specific scavenger receptor and, consequently, it is not surprising to have been 
detected in the PBMC studies on chapter 4. CD163 was found to be down-regulated in 
activated PBMC pre-treated with PAD enzymes in microarray studies but this was not 
confirmed by RT-QPCR due to high variation in the results. In CD4 and CD8 T cells 
from PID patients, CD163 expression was not detected, confirming that the presence 
of this gene in PBMC analysis was due to other immune cells.  
CTH expression was found to be up-regulated by PAD enzymes in the studies 
described in chapter 4. However, the levels of this gene were low, only obtained for 
one of the independent experiments performed and were possibly due to the presence 
of a mixed population of cells (PBMC). As a consequence, the expression of this gene 
was not further explored.  
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ASS1 and HK3 are two enzymes involved in metabolic processes, urea cycle 
and glycolysis respectively. Upon activation, T cells rely on glycolysis and glutamine 
oxidation, to produce biosynthetic precursors required for rapid cell growth and 
proliferation [72, 82, 84]. The results obtained here showed an up-regulation of ASS1 
in activated PBMC pre-treated with PAD enzymes, suggesting de novo synthesis of 
arginine possibly to overcome a decrease in the arginine supply that is related with 
impaired T cell proliferation. This situation would also imply impairment of aerobic 
glycolysis, which can be correlated with a down-regulation of HK3 expression, that was 
observed here when PBMC were pre-treated with PAD2 enzyme prior to activation. 
Consistent with these, in chapter 5, ASS1 and HK3 expression levels in peripheral 
CD4 and CD8 T cells from PID patients were found to be up- and down-regulated, 
respectively. 
The metabolic switch from OXPHOS to aerobic glycolysis and glutaminolysis 
following activation of T cells, reduces the up-regulation of glycolytic enzymes and 
glucose transporters and induces an increased production of lactate [458, 561]. The 
results obtained in the PBMC citrullination study show that the higher lactate levels are 
associated with lower IL-2 secretion and, consequently, a non-activated T cell profile. 
However, an increase in the extracellular levels of lactate following T cell activation 
was not observed. An explanation for this might be the intracellular consumption of 
lactate to produce energy equivalents via OXPHOS. Lactate can be converted to 
pyruvate in the cytosol and this can then be transported to the mitochondria via the 
monocarboxylate transporter 1 and converted into pyruvate [562].  
ENO was additionally selected for analysis in peripheral CD4 and CD8 T cells 
from PID patients since it is involved in glycolytic metabolism and it has also been 
identified as a citrullinated antigen in RA [254]. ENO was also detected on the surface 
of vascular endothelium [547], monocytes, macrophages, B cells and T cells [548] and 
is recognised as a plasminogen receptor. In ageing studies, ENO was found to be 
lower on the surface of CD4 T cells in healthy older adults [549]. However, RT-QPCR 
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data showed no differences in the expression of ENO in peripheral CD4 and CD8 T 
cells from PID patients relative to HC. 
ULBP1 was one of the genes that was found to be up-regulated by PAD 
enzymes on the PBMC microarray study. The cell surface ULBP1, encoded by ULBP1 
gene, is a ligand for the KLRK1/ NKG2D receptor and is present on NK and T cells, 
being involved in the activation of several signalling pathways, resulting in the 
production of cytokines and chemokines. Although this gene was found to be up-
regulated by PAD enzymes in PBMC, the analysis by RT-QPCR on peripheral CD4 
and CD8 T cells revealed no differences between PID patients and HC individuals. 
The cytokines IL-2 and IFNȖ are established markers of T cell activation. In 
advanced PID, contradictory results have been obtained regarding the T cell response. 
For example, in the serum of PID patients, Andrukhov et al. reported a decrease in the 
levels of IL-2 but an increase in the levels of IFNȖ [551], while Gorska et al. found 
higher concentrations of IL-2 and IFNȖ in the serum and gingival tissue from PID 
patients [524]. Here, the expression of IL-2 and IFN-G was found to be increased in 
peripheral CD4 and CD8 T cells from PID patients when compared with HC individuals, 
suggesting an increased T cell response. A possible explanation for the difference in 
the results obtained here is that expression of IL-2 and IFN-γ genes were evaluated, 
whereas the studies reported in the literature protein levels were measured suggesting 
impairments in secretory pathways and not in the signalling via TCR.  
In addition to peripheral CD4 and CD8 T cells, plasma and GCF from PID 
patients were assessed for inflammatory factors, like cytokines, antioxidants and 
occurrence of citrullination by PAD enzymes, all characteristic of PID [443, 519, 520, 
522, 523]. IL-6 is a multifunctional cytokine, involved in B cell differentiation, T cell 
proliferation and stimulation of Ig secretion by B cells [528]. IL-8, a prototypic human 
chemokine, is particularly important in the mediation of chemotaxis and activation of 
neutrophils in the inflamed gingiva [529]. IL-6 and IL-8 were previously described as 
being involved in the activity of leukocytes, osteoblasts and osteoclasts in PID, both 
248 
 
locally and systemically [525-527]. IL-6 and IL-8 levels were previously found to be 
increased in PID-associated tissues [527, 530-534]. Here, no differences in the plasma 
levels of IL-6 and IL-8 were found in PID patients compared with age-matched 
periodontally healthy controls, probably due to the low number of samples.  
The expression of hPAD2 and hPAD4 enzymes and citrullinated proteins were 
found to be increased with the severity of inflammation observed in PID [443]. 
Consistent with this, here, the PAD enzyme activity was found to be increased in the 
PID group relative to HC. 
GSH is one of the most important regulators of the redox balance required for 
an efficient immune response. Previous studies have shown that glutathione in its 
reduced form is decreased in GCF and plasma from PID patients [520, 521]. Here, we 
found no differences in the levels of GSH in the plasma of PID patients when 
compared with HC groups. Despite the fact that no statistical significance was 
observed, the levels of GSH in the GCF of PID patients were lower when compared 
with HC individuals, in agreement with previous reported data [520, 521].  
The parameters evaluated in the plasma and GCF of PID patients and HC 
individuals did not show statistically significant differences. Only six individuals were 
included in each group, which can be an explanation for the high individual variability 
on the results and the lack of statistical significance in the results. However, the use of 
G*Power software suggested that the inclusion of seven samples per group would 
result in 80% probability of observing a significant difference (p-value < 0.05) in the 
levels of PAD activity between the PID and HC groups.  
Generally, one of the main limitations of this study is the low number of 
samples in the clinical studies and replicates in the PBMC ex vivo studies. This is an 
important point that can be overcome by the repetition of the ex vivo experiments and 
the recruitment of more PID and HC individuals. Such additional work has the potential 
to raise the relevance and impact of this study. Despite this, a major strength of this 
work is the translational research performed from in vitro single protein model to ex 
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vivo PBMC studies and from there to clinical samples. The simple in vitro model was 
important for the methodological optimisation, whereas the ex vivo studies were crucial 
to perform broad screening approaches that allowed to identify targets to be studied on 
clinical samples. Using such a translational approach is extremely advantageous as 
each method can provide different and complementary information that together can 
contribute to the general knowledge about the effects of citrullination on the breakdown 
of the immune system in PID. 
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Figure 6.1 Schematic representation of glucose and glutamine metabolism in activated T cells (a) 
and activated T cells pre-treated with PAD enzymes (b). Green highlights up-regulated pathways and 
red highlights down-regulated pathways. 
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6.2. Future work  
Several studies can be suggested to complement the translational approach used 
here. In the in vitro model, the combination of 1D SDS-PAGE and LC-CID-saETD-
MS/MS showed to be valid for the detection of FNG chains and to identify the arginine 
residues modified by citrullination. The separation of MP from citrullinated PBMC by 2D 
BN/SDS-PAGE allowed identification of some proteins, however no specific PAD-
mediated citrullination sites were identified. Due to their hydrophobic nature, MP are a 
particularly difficult class of proteins to analyse by common electrophoretic methods. 
The use of a 2D method here was adopted as a way of obtaining more information 
about the protein structure, in particular, protein-protein interaction, and also to 
maximise the separation of different proteins in order to identify differences between 
different treatments. Further optimisation of this approach is required, namely in terms 
of protein solubilisation. The use of different detergents and also different 
detergent/MP ratios are suggestions to improve the solubilisation of MP. Also, other 
methods of MP isolation could be approached, as biotinylated-based methods that use 
a cell impermeable biotinylated reagent to label exposed primary amines of proteins on 
the surface of intact cells and are then purified with avidin-based resins. Another 
proposed strategy to identify MP modified by citrullination is to use a targeted approach 
as opposed to a broad screening approach as the one used here. As the targeted cells 
of this study were T cells, the TCR complex is a potential target for citrullination, so, the 
immunoprecipitation of CD3 or CD28, for example, would allow the purification of the 
TCR complex and any associated proteins; LC-CID-saETD-MS/MS could be applied to 
detect and identify arginine residues in the proteins of the complex that are modified by 
PAD enzymes. This approach would only focused on the effects of PAD on the TCR 
complex, but as an impairment of the IL-2 response was observed, this would be a 
possible method to identify proteins at the cell surface modified by PAD enzymes and 
to localise the citrullinated arginine residues within the protein sequence. With a refined 
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method for the identification of MP and citrullinated residues it would be possible to 
apply the strategy to MP from PID and RA patients’ peripheral CD4 and CD8 T cells or 
even other subsets, as Th17. 
 In order to understand the impairment of the IL-2 T cell response observed in 
chapter 4, some targeted studies could be performed. Obtaining information about the 
expression of IL-2 gene would be a good first indicator if the effects of PAD to 
decrease T cell proliferation were due to up- or down-stream regulation of IL-2 gene 
expression. According with the results of the IL-2 gene expression, intracellular 
signalling studies could be performed in terms of TCR signalling or IL-2 translation and 
secretion. Another interesting way to investigate the impairment on T cell activation 
would be to target transcription factors like t-bet, since this is crucial for the 
differentiation of T cells. These experiments would elucidate about PAD-induced 
anomalies in the IL-2 signalling pathway that could be used for further therapeutic 
applications. 
The results obtained in this study suggest that PAD enzymes induce an 
impairment of T cell response that is linked to alterations in glycolysis and amino acid 
metabolism. Further investigation of metabolic activity of the cells would be important 
to clarify this. The use of Seahorse XF technology (Agilent Technologies LDA UK Ltd., 
Stockport, UK) is a possible approach to obtain functional data from live cells, in real 
time, providing a greater understanding of cell metabolism. The Seahorse XF analyser 
combines an electro-optical instrument with plastic cartridges that provide real time 
measurement of the two major energy pathways of the cell (mitochondrial respiration 
and glycolysis) in a non-invasive, multi-well microplate format. Complementary to this 
information about the use of glycolysis of OXPHOS, it would also be interesting to 
target GLUT1 and MCT1, as this are vital transporters for the uptake of glucose and 
efflux of lactate, respectively, both outcomes of aerobic glycolysis. Another important 
complementary study to the RT-QPCR would be to match the results obtained with 
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protein and enzymatic activity data on ASS1 and HK3, since it is the protein form that 
is responsible for activity not the gene form.  
The results obtained in chapter 5, regarding the pilot comparison of T cell gene 
expression in PID patients with age-matched periodontally HC were not powered to 
show significant differences so, as previously suggested, it would be important to 
increase the number of samples and also to assess parameters, such as the secretion 
of IL-2 and IFNȖ to complement the results obtained from PBMC studies and RT-
QPCR. 
 In general, it would also be interesting to compare the effects of human PAD 
enzymes, studied here, with the effects of PPAD enzyme on the activation of T cells. 
Khalaf and Bengtsson have previously suggested that arginine gingipain proteinases 
from P. gingivalis are involved in the suppression of IL-2 accumulation attenuating T 
cell proliferation and cellular communication, consequently being involved in the 
evasion of the host adaptive immune system [439]. Understanding the mechanism of 
action of human and bacterial PAD enzymes and blocking the generation of 
autoantigens that trigger the autoimmune response observe in RA and PID may lead to 
new knowledge that can be applied to develop powerful novel therapies for these 
diseases. 
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6.3. Conclusion 
Taken together, the results obtained here suggest that PID patients are 
characterised by lower levels of GSH and higher levels of PAD enzymes in the GCF. 
Also, PAD enzyme modification of PBMC alters expression of genes involved with 
glucose and amino acid metabolism, which is associated with a reduction in the T cell 
IL-2 response. Consistent with this, PID patients presented with differences in T cell 
metabolism compared to HC that indicate decreased glycolysis and increased amino 
acid biosynthetic pathway and, consequently, impairment of T cell proliferation. Also, 
proteomic and genomic studies both revealed an involvement of the complement 
system in the impairment of the T cell response. 
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Appendix 1: LC-CID-saETD-MS/MS identification of citrullination sites in fibrinogen 
Table 8.1 Description of peptides where citrullinated sites were detected. Data from the MS experiment was analysed with Proteome Discoverer software (Thermo Fisher 
Scientific lnc., Loughborough, UK) and the protein identification determined by comparison with the IPI human database. Citrullination sites were identified using the neutral 
loss method and the data was validated by sequence analysis. High confidence interval corresponds to 1% false discovery rate. 
Band Sample Identification Peptide Citrullinated site(s) (high confidence) 
1 FNG ɑ-chain KPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPrPGSTGTWNPGSSERGSAGHW R353 
rPDSPGSGNARPNNPDWGTF R394 
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFr R510 
TNTKESSSHHPGIAEFPSrGKSSSY R573 
2 FNG ȕ-chain KAPDAGGCLHADPDLGVLCPTGCQLQEALLQQERPIr R121 
4 FNG+hPAD2 ɑ-chain GDFSSANNrDNTYNR R123 
ERPGGNEITrGGSTSY R263 
MELERPGGNEITrGGSTSYGTGSETESPR R271 
GTGSETESPrNPSSAGSW R287 
NSGSSGTGSTGNQNPGSPRPGSTGTWNPGSSErGSAGHW R367 
HSESGSFrPDSPGSGNARPNNPDWGTF R394 
HSESGSFrPDSPGSGNArPNNPDWGTF R394, R404 
EEVSGNVSPGTrREY R425 
EEVSGNVSPGTrrEY R425, R426 
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFr R510 
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFrHR R510 
rHRHPDEAAFF R510 
HrHPDEAAFFDTASTGK R512 
SPMLGEFVSETESrGSESGIF R547 
TNTKESSSHHPGIAEFPSrGKSSSY R573 
ESSSHHPGIAEFPSrGK R573 
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Table 8.1 Continuation. 
Band Sample Identification Peptide Citrullinated site(s) (high confidence) 
5 FNG+hPAD2 ȕ-chain KREEAPSLrPAPPPISGGGYR R60 
DKKREEAPSLrPAPPPISGGGY R60 
QQErPIRNSVDELNNNVEAVSQTSSSSF R121 
DNENVVNEYSSELEKHQLYIDETVNSNIPTNLr R196 
TMTIHNGMFFSTYDrDNDGWLTSDPRK R410 
7 FNG+hPAD4 ɑ-chain TDMPQMRMELERPGGNEITrGGSTSY R271 
KPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTWNPGSSErGSAGHW R367 
EEVSGNVSPGTrREY R425 
EEVSGNVSPGTrrEY R425, R426 
EEVSGNVSPGTrrEYHTEKL R425, R426 
SPMLGEFVSETESrGSESGIF R547 
TNTKESSSHHPGIAEFPSrGKSSSY R573 
ESSSHHPGIAEFPSrGK R573 
NrGDSTFESKSY R591 
TSSTSYNrGDSTFESKSY R591 
SKQFTSSTSYNrGDSTF  
8 FNG+hPAD4 ȕ-chain DKKREEAPSLrPAPPPISGGGY R53, R60 
DKKREEAPSLrPAPPPISGGGY R60 
AHYGGFTVQNEANKYQISVNKYr R376 
9 FNG+hPAD4 Ȗ-chain VATrDNCCILDERF R31 
VELEDWNGr R282 
NGrTSTADYAMF R282 
IHLISTQSAIPYALRVELEDWNGr R282 
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Appendix 2: Sequence homology between hPAD2 and hPAD4 
 
Figure 8.1 A CLUSTALW 2.0.5 alignment of hPAD2 and hPAD4 enzymes [563]. Black shading 
denotes identical residues and grey shading denotes physicochemical similar residues. 
.
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Appendix 3: Microarray expression profile of selected genes 
 
Figure 8.2 Expression profile of ASS1 gene. 1 – unactivated PBMC; 2 – Activated PBMC; 3 – PBMC + 
hPAD2 prior to activation; 4 – PBMC + hPAD4 prior to activation. 
 
 
Figure 8.3 Expression profile of CTH gene. 1 – unactivated PBMC; 2 – Activated PBMC; 3 – PBMC + 
hPAD2 prior to activation; 4 – PBMC + hPAD4 prior to activation. 
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Figure 8.4 Expression profile of HK3 gene. 1 – unactivated PBMC; 2 – Activated PBMC; 3 – PBMC + 
hPAD2 prior to activation; 4 – PBMC + hPAD4 prior to activation. 
 
 
Figure 8.5 Expression profile of CD163 gene. 1 – unactivated PBMC; 2 – Activated PBMC; 3 – PBMC + 
hPAD2 prior to activation; 4 – PBMC + hPAD4 prior to activation. 
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Figure 8.6 Expression profile of SGMS2 gene. 1 – unactivated PBMC; 2 – Activated PBMC; 3 – PBMC 
+ hPAD2 prior to activation; 4 – PBMC + hPAD4 prior to activation. 
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Appendix 4: LC-CID-saETD-MS/MS protein identification of spots 244 and 
245 
Table 8.2 Results of protein identification for spot number 244 in non-PAD enzyme treated PBMC. 
The accession number is the unique identifier used for the protein sequence. The number of unique 
peptides represents the number of peptides matching the protein identified. The coverage indicates the 
percentage of the protein sequence that has been covered by the identified protein. Citrullination displays 
the peptides where citrullination was detected in the highlighted arginine residues. 
Accession 
number 
Protein Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
Q5T7C4 High mobility group protein B1 7 18.3 48.1  
Q06323 Proteasome activator complex 
subunit 1 
8 28.7 41.77  
P38117 Electron transfer flavoprotein 
subunit beta 
7 27.8 33.73  
F5H6Q2 Polyubiquitin-C (Fragment) 2 13.7 33.61  
H0YGX7 Rho GDP-dissociation inhibitor 2 
(Fragment) 
4 22.4 33.33  
P31946-2 Isoform Short of 14-3-3 protein 
beta/alpha 
3 27.8 31.56  
P60709 Actin, cytoplasmic 1 6 41.7 25.87 TTGIVmDSGDGVTH
TVPIYEGYALPHAILr 
O15144 Actin-related protein 2/3 
complex subunit 2 
6 34.3 25,00  
P13804 Electron transfer flavoprotein 
subunit alpha, mitochondrial 
6 35.1 23.12  
P81605 Dermcidin 3 11.3 22.73  
P02647 Apolipoprotein A-I 4 30.8 19.1  
P26583 High mobility group protein B2 2 24.0 18.18  
P63104 14-3-3 protein zeta/delta 3 27.7 17.14  
Q96C19 EF-hand domain-containing 
protein D2 
3 26.7 15.83  
P07339 Cathepsin D 5 44.5 15.78  
O15173 Membrane-associated 
progesterone receptor 
component 2 
3 23.8 15.25  
H0YM70 Proteasome activator complex 
subunit 2 
2 26.0 14.91  
P07355 Annexin A2 4 38.6 14.75  
P62258-2 Isoform SV of 14-3-3 protein 
epsilon 
2 26.5 14.16  
F5H018 GTP-binding nuclear protein 
Ran (Fragment) 
2 22.4 14.14  
P30084 Enoyl-CoA hydratase, 
mitochondrial 
4 31.4 13.79  
P16403 Histone H1.2 4 21.4 13.62  
Q9H3N1 Thioredoxin-related 
transmembrane protein 1 
3 31.8 12.86  
M0R208 ATP-dependent Clp protease 
proteolytic subunit 
2 20.6 12.11  
P30040 Endoplasmic reticulum resident 
protein 29 
3 29.0 11.88  
K7ELS8 Synaptogyrin-2 (Fragment) 2 14.7 11.85  
P50897 Palmitoyl-protein thioesterase 1 2 34.2 10.78  
P05090 Apolipoprotein D 2 21.3 10.58  
Q15691 Microtubule-associated protein 
RP/EB family member 1 
2 30.0 10.45  
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Table 8.3 Results of protein identification for spot number 244 in hPAD2 enzyme treated PBMC. 
The accession number is the unique identifier used for the protein sequence. The number of unique 
peptides represents the number of peptides matching the protein identified. The coverage indicates the 
percentage of the protein sequence that has been covered by the identified protein. Citrullination displays 
the peptides where citrullination was detected. 
Accession 
number 
Protein 
Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
Q5T7C4 High mobility group protein B1 9 18.3 48.73  
B4DJF2 14-3-3 protein epsilon 2 10.9 31.91  
Q06323 Proteasome activator complex 
subunit 1 
6 28.7 31.73  
H0YKF0 Electron transfer flavoprotein 
subunit alpha, mitochondrial 
(Fragment) 
6 30.2 25.26  
P81605 Dermcidin 2 11.3 22.73  
O15144 Actin-related protein 2/3 
complex subunit 2 
5 34.3 21.33  
I3L3Q7 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial (Fragment) 
2 20.0 19.77  
P26583 High mobility group protein B2 2 24.0 18.18  
A8MW50 L-lactate dehydrogenase 
(Fragment) 
2 25.2 18.1  
P31946-2 Isoform Short of 14-3-3 protein 
beta/alpha 
2 27.8 16.8  
J3KTF8 Rho GDP-dissociation inhibitor 1 
(Fragment) 
2 21.5 16.06  
O15173 Membrane-associated 
progesterone receptor 
component 2 
3 23.8 15.25  
P38117 Electron transfer flavoprotein 
subunit beta 
3 27.8 14.12  
P63104 14-3-3 protein zeta/delta 3 27.7 13.88  
B7Z6B8 2,4-dienoyl-CoA reductase, 
mitochondrial 
3 35.0 13.8  
Q96C19 EF-hand domain-containing 
protein D2 
3 26.7 13.75  
P16403 Histone H1.2 3 21.4 13.62  
P60709 Actin, cytoplasmic 1 4 41.7 13.6  
O43760 Synaptogyrin-2 3 24.8 12.5  
Q15691 Microtubule-associated protein 
RP/EB family member 1 
2 30.0 10.45  
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Table 8.4 Results of protein identification for spot number 244 in hPAD4 enzyme treated PBMC. 
The accession number is the unique identifier used for the protein sequence. The number of unique 
peptides represents the number of peptides matching the protein identified. The coverage indicates the 
percentage of the protein sequence that has been covered by the identified protein. Citrullination displays 
the peptides where citrullination was detected in the highlighted arginine residues. 
Accession 
number 
Protein 
Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
P63104 14-3-3 protein zeta/delta 8 27.7 54.29  
P52566 Rho GDP-dissociation inhibitor 2 7 23.0 49.25  
Q5T7C4 High mobility group protein B1 8 18.3 48.1  
P31946-2 Isoform Short of 14-3-3 protein 
beta/alpha 
4 27.8 47.95  
H0YL12 Electron transfer flavoprotein 
subunit alpha, mitochondrial 
(Fragment) 
8 24.9 46.86  
Q06323 Proteasome activator complex 
subunit 1 
9 28.7 45.78  
P81605 Dermcidin 3 11.3 32.73  
P22626-2 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins 
A2/B1 
5 36.0 31.96  
Q9UL46 Proteasome activator complex 
subunit 2 
5 27.4 30.13  
H3BMH2 Ras-related protein Rab-11A 
(Fragment) 
5 17.7 29.68  
O15144 Actin-related protein 2/3 
complex subunit 2 
8 34.3 29.33  
P09651-3 Isoform 2 of Heterogeneous 
nuclear ribonucleoprotein A1 
4 29.4 27.72  
I3L3Q7 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial (Fragment) 
3 20.0 27.12 ATFmVGSYGPrPE
EYEFLTPVEEAPK 
P60709 Actin, cytoplasmic 1 7 41.7 26.93  
P18669 Phosphoglycerate mutase 1 5 28.8 25.59  
P38117 Electron transfer flavoprotein 
subunit beta 
5 27.8 24.31  
J3KTF8 Rho GDP-dissociation inhibitor 1 
(Fragment) 
4 21.5 23.83  
P62873 Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-1 
2 37.4 23.53  
P61981 14-3-3 protein gamma 3 28.3 23.08  
P27348 14-3-3 protein theta 3 27.7 20.82  
Q04917 14-3-3 protein eta 2 28.2 20.33  
D6R9A6 High mobility group protein B2 
(Fragment) 
2 15.4 20.15  
O15143 Actin-related protein 2/3 
complex subunit 1B 
5 40.9 19.89  
F8VV32 Lysozyme C 2 11.5 19.23  
P07195 L-lactate dehydrogenase B 
chain 
4 36.6 19.16  
P07355 Annexin A2 5 38.6 18.88  
P16403 Histone H1.2 5 21.4 17.84  
Q9NUQ9 Protein FAM49B 4 36.7 16.05  
Q9HC38 Glyoxalase domain-containing 
protein 4 
4 32.0 15.57  
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Table 8.4 Continuation. 
Accession 
number 
Protein 
Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
P30084 Enoyl-CoA hydratase, 
mitochondrial 
5 31.4 15.52  
P30040 Endoplasmic reticulum resident 
protein 29 
3 29.0 14.18  
P62258-2 Isoform SV of 14-3-3 protein 
epsilon 
2 36.0 14.16  
M0R0Y2 Alpha-soluble NSF attachment 
protein 
3 29.1 12.89  
J3KPE3 Guanine nucleotide-binding 
protein subunit beta-2-like 1 
3 30.1 12.82  
O43760 Synaptogyrin-2 3 24.8 12.5  
P53597 Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, 
mitochondrial 
3 36.2 12.14  
M0R208 ATP-dependent Clp protease 
proteolytic subunit 
2 20.6 12.11  
Q9NUJ1 Mycophenolic acid acyl-
glucuronide esterase, 
mitochondrial 
3 33.9 11.44  
Q9H3N1 Thioredoxin-related 
transmembrane protein 1 
3 31.8 11.07  
Q07955-3 Isoform ASF-3 of 
Serine/arginine-rich splicing 
factor 1 
2 22.4 10.95  
P00387-2 Isoform 2 of NADH-cytochrome 
b5 reductase 3 
2 31.7 10.75  
Q15691 Microtubule-associated protein 
RP/EB family member 1 
2 30.0 10.45  
 
Table 8.5 Results of protein identification for spot number 245 in non-PAD enzyme treated PBMC. 
The accession number is the unique identifier used for the protein sequence. The number of unique 
peptides represents the number of peptides matching the protein identified. The coverage indicates the 
percentage of the protein sequence that has been covered by the identified protein. Citrullination displays 
the peptides where citrullination was detected in the highlighted arginine residues. 
Accession 
number 
Protein 
Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
P60709 Actin, cytoplasmic 1 7 41.7 44,00  
P13796 Plastin-2 13 70.2 28.07  
F5H8J2 Uncharacterized protein 7 51.1 19.73  
F8VPV9 ATP synthase subunit beta 5 55.3 14.48  
P81605 Dermcidin 2 11.3 12.73  
 
Table 8.6 Results of protein identification for spot number 245 in hPAD2 enzyme treated PBMC. 
The accession number is the unique identifier used for the protein sequence. The number of unique 
peptides represents the number of peptides matching the protein identified. The coverage indicates the 
percentage of the protein sequence that has been covered by the identified protein. Citrullination displays 
the peptides where citrullination was detected in the highlighted arginine residues. 
Accession 
number 
Protein 
Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
P60709 Actin, cytoplasmic 1 3 41.7 28.53 TTGIVmDSGDGVTH
TVPIYEGYALPHAILr 
P81605 Dermcidin 3 11.3 22.73  
P13796 Plastin-2 6 70.2 14.83  
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Table 8.7 Results of protein identification for spot number 245 in hPAD4 enzyme treated PBMC. 
The accession number is the unique identifier used for the protein sequence. The number of unique 
peptides represents the number of peptides matching the protein identified. The coverage indicates the 
percentage of the protein sequence that has been covered by the identified protein. Citrullination displays 
the peptides where citrullination was detected. 
Accession 
number 
Protein 
Unique 
Peptides 
MW 
(kDa) 
Coverage 
(%) 
Citrullination 
P60709 Actin, cytoplasmic 1 7 41.7 46.93 TTGIVmDSGDGVTH
TVPIYEGYALPHAILr 
P81605 Dermcidin 2 11.3 20,00  
P06576 ATP synthase subunit beta, 
mitochondrial 
7 56.5 19.66  
P13796 Plastin-2 7 70.2 14.19  
P27797 Calreticulin 3 48.1 11.03  
 
 
 
